<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005228.pub4" GROUP_ID="NEUROMUSC" ID="799604120210035818" MERGED_FROM="" MODIFIED="2014-02-27 18:09:29 +0000" MODIFIED_BY="Ruth Brassington" REVIEW_NO="092" REVMAN_SUB_VERSION="5.2.8 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.2">
<COVER_SHEET MODIFIED="2014-02-27 18:08:09 +0000" MODIFIED_BY="Ruth Brassington">
<TITLE MODIFIED="2013-12-16 23:23:43 +0000" MODIFIED_BY="[Empty name]">Interventions for preventing neuropathy caused by cisplatin and related compounds</TITLE>
<CONTACT>
<PERSON ID="CB6734ED82E26AA2014E8D6709C7DE43" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>James</FIRST_NAME>
<MIDDLE_INITIALS>W</MIDDLE_INITIALS>
<LAST_NAME>Albers</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>jwalbers@umich.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>University of Michigan</ORGANISATION>
<ADDRESS_1>1C325/0032 University Hospital</ADDRESS_1>
<ADDRESS_2>1500 E. Medical Center Drive, Box 0316</ADDRESS_2>
<CITY>Ann Arbor</CITY>
<ZIP>MI 48109-0032</ZIP>
<REGION/>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+ 734 936 8586</PHONE_1>
<PHONE_2/>
<FAX_1>+ 734 936 5185</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-02-27 18:08:09 +0000" MODIFIED_BY="Ruth Brassington">
<PERSON ID="CB6734ED82E26AA2014E8D6709C7DE43" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>James</FIRST_NAME>
<MIDDLE_INITIALS>W</MIDDLE_INITIALS>
<LAST_NAME>Albers</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>jwalbers@umich.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>University of Michigan</ORGANISATION>
<ADDRESS_1>1C325/0032 University Hospital</ADDRESS_1>
<ADDRESS_2>1500 E. Medical Center Drive, Box 0316</ADDRESS_2>
<CITY>Ann Arbor</CITY>
<ZIP>MI 48109-0032</ZIP>
<REGION/>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+ 734 936 8586</PHONE_1>
<PHONE_2/>
<FAX_1>+ 734 936 5185</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="DE73F38382E26AA200BB9F5BC211E100" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Vinay</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chaudhry</LAST_NAME>
<SUFFIX/>
<POSITION>Professor, Vice Chair Clinical Affairs</POSITION>
<EMAIL_1>vchaudh@jhmi.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neurology</DEPARTMENT>
<ORGANISATION>Johns Hopkins Outpatient Center</ORGANISATION>
<ADDRESS_1>601 North Caroline Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Baltimore</CITY>
<ZIP>MD 21287</ZIP>
<REGION>Maryland</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 410 955 9167</PHONE_1>
<PHONE_2/>
<FAX_1>+1 410 614 8377</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="CB871CB682E26AA2014E8D670B2181E1" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Guido</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cavaletti</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>guido.cavaletti@unimib.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Dipartimento di Chirurgia e Medicina Interdisciplinare</DEPARTMENT>
<ORGANISATION>Università degli Studi di Milano-Bicocca</ORGANISATION>
<ADDRESS_1>Via Cadore 48</ADDRESS_1>
<ADDRESS_2/>
<CITY>Monza</CITY>
<ZIP>20900</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+ 39 02 6448 8039</PHONE_1>
<PHONE_2/>
<FAX_1>+ 39 02 6448 8250</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="CB83A05182E26AA2014E8D679B6E4829" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Ross</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Donehower</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>donehro@jhmi.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Medical Oncology</DEPARTMENT>
<ORGANISATION>Johns Hopkins University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Baltimore</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+ 410 955 0125</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-02-27 18:08:09 +0000" MODIFIED_BY="Ruth Brassington">
<UP_TO_DATE>
<DATE DAY="4" MONTH="3" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="3" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="4" MONTH="3" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-02-27 10:13:28 +0000" MODIFIED_BY="Ruth Brassington">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-02-27 10:13:28 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="27" MONTH="9" YEAR="2013"/>
<DESCRIPTION>
<P>Nine new included trials, one of a new intervention (retinoic acid)</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-01-17 15:57:44 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="8" YEAR="2013"/>
<DESCRIPTION>
<P>New search (4 March 2013) incorporated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-09-27 15:48:01 +0100" MODIFIED_BY="Ruth Brassington">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-09-27 15:48:01 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="12" MONTH="10" YEAR="2010"/>
<DESCRIPTION>
<P>Amended author name</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-09-27 15:47:57 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="7" MONTH="9" YEAR="2010"/>
<DESCRIPTION>
<P>Searches updated to August 2010.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-23 15:51:25 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="20" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="5" MONTH="10" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-10-05 20:51:49 +0100" MODIFIED_BY="Kate Jewitt">
<INTERNAL_SOURCES MODIFIED="2010-10-05 20:51:39 +0100" MODIFIED_BY="Kate Jewitt">
<SOURCE MODIFIED="2010-10-05 20:51:39 +0100" MODIFIED_BY="Kate Jewitt">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2010-10-05 20:51:49 +0100" MODIFIED_BY="Kate Jewitt">
<SOURCE MODIFIED="2010-10-05 20:51:49 +0100" MODIFIED_BY="Kate Jewitt">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-02-27 18:09:29 +0000" MODIFIED_BY="Ruth Brassington">
<SUMMARY MODIFIED="2014-02-19 12:26:17 +0000" MODIFIED_BY="Kate Jewitt">
<TITLE MODIFIED="2014-02-12 14:12:35 +0000" MODIFIED_BY="Kate Jewitt">Interventions for preventing nerve damage caused by cisplatin and other tumour-inhibiting platinum drugs</TITLE>
<SUMMARY_BODY MODIFIED="2014-02-19 12:14:53 +0000" MODIFIED_BY="Kate Jewitt">
<P>
<B>Review question</B>
</P>
<P>We reviewed the evidence about the effect of treatments to prevent or reduce damage to nerves from the anticancer (chemotherapy) drug cisplatin or other platinum-containing drugs.</P>
<P>
<B>Background</B>
</P>
<P>Cisplatin and other related platinum-containing drugs that are used to treat solid tumours are toxic to the peripheral nervous system. Most people who complete a full course of cisplatin chemotherapy develop a sensory neuropathy (damage to nerves that carry sensation). Symptoms can include tingling in the extremities and numbness. The neuropathy may only partially recover or not recover at all when the chemotherapy is stopped. To try to reduce the toxicity of platinum drugs, researchers have looked for therapies to protect the nerves.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We carried out a wide search for studies of treatments to prevent this type of nerve damage. We identified a total of 29 clinical trials, which involved almost 3000 participants who were receiving platinum-containing anticancer drugs (mostly cisplatin, oxaliplatin and carboplatin) for various types of cancer (mainly colon, ovary, and lung cancers). The nine treatments studied were: amifostine (seven trials), calcium and magnesium (four trials), glutathione (seven trials), Org 2766 (four trials) and vitamin E (three trials). There was one trial each of acetylcysteine, diethyldithiocarbamate (DDTC), oxcarbazepine, and retinoic acid. We chose an objective clinical test of sensation to report as our preferred measure of the effects of treatment. Only seven of the studies used this measure. Nine reported the results of nerve conduction studies which are another objective measure of nerve function. Most of the studies used a subjective assessment of neuropathy, such as the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) neuropathy grading scale.</P>
<P>
<B>Key results and quality of the evidence</B>
</P>
<P>Most of the included studies were fairly well performed, where it was possible to obtain this information.</P>
<P>Based on the combined results that generally described secondary and non-quantitative measures such as the NCI-CTC neuropathy grading scale, modest but promising (borderline statistically significant) results favoured the use of amifostine, calcium and magnesium, and glutathione to reduce the neurotoxicity of cisplatin and related chemotherapies. Three studies of vitamin E could only be studied individually but the results of each imply some mild subjective benefits. Nevertheless, given the limitations of the studies, such as small numbers of participants, lack of objective measures of neuropathy, and differing results among similar trials, the data remain insufficient to conclude that any of the neuroprotective agents tested prevent or limit the neurotoxicity of platinum drugs. Most of the treatments were not associated with adverse events. Amifostine infusions were associated with temporary low blood pressure in a significant number of cases, and retinoic acid with low levels of calcium in the blood. About one-fifth of people treated with DDTC stopped taking it because of harmful effects.</P>
<P>Amifostine, calcium and magnesium, vitamin E, and glutathione require further well designed trials to clarify if they are effective or not.</P>
<P>This is an updated review. The evidence is current to 4 March 2013.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-02-19 12:31:57 +0000" MODIFIED_BY="Kate Jewitt">
<ABS_BACKGROUND MODIFIED="2014-01-17 15:57:59 +0000" MODIFIED_BY="Kate Jewitt">
<P>Cisplatin and several related antineoplastic drugs used to treat many types of solid tumours are neurotoxic, and most patients completing a full course of cisplatin chemotherapy develop a clinically detectable sensory neuropathy. Effective neuroprotective therapies have been sought.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-01-17 15:58:03 +0000" MODIFIED_BY="Kate Jewitt">
<P>To examine the efficacy and safety of purported chemoprotective agents to prevent or limit the neurotoxicity of cisplatin and related drugs.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-02-12 09:55:49 +0000" MODIFIED_BY="Kate Jewitt">
<P>On 4 March 2013, we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE, EMBASE, LILACS, and CINAHL Plus for randomised trials designed to evaluate neuroprotective agents used to prevent or limit neurotoxicity of cisplatin and related drugs among human patients.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-02-19 12:31:54 +0000" MODIFIED_BY="Kate Jewitt">
<P>We included randomised controlled trials (RCTs) or quasi-RCTs in which the participants received chemotherapy with cisplatin or related compounds, with a potential chemoprotectant (acetylcysteine, amifostine, adrenocorticotrophic hormone (ACTH), BNP7787, calcium and magnesium (Ca/Mg), diethyldithiocarbamate (DDTC), glutathione, Org 2766, oxcarbazepine, or vitamin E) compared to placebo, no treatment, or other treatments. We considered trials in which participants underwent evaluation zero to six months after completing chemotherapy using quantitative sensory testing (the primary outcome) or other measures including nerve conduction studies or neurological impairment rating using validated scales (secondary outcomes).<BR/>
</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-01-17 15:59:45 +0000" MODIFIED_BY="Kate Jewitt">
<P>Two review authors assessed each study, extracted the data and reached consensus, according to standard Cochrane methodology.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-02-19 12:31:57 +0000" MODIFIED_BY="Kate Jewitt">
<P>As of 2013, the review includes 29 studies describing nine possible chemoprotective agents, as well as description of two published meta-analyses. Among these trials, there were sufficient data in some instances to combine the results from different studies, most often using data from secondary non-quantitative measures. Nine of the studies were newly included at this update. Few of the included studies were at a high risk of bias overall, although often there was too little information to make an assessment. At least two review authors performed a formal review of an additional 44 articles but we did not include them in the final review for a variety of reasons.</P>
<P>Of seven eligible amifostine trials (743 participants in total), one used quantitative sensory testing (vibration perception threshold) and demonstrated a favourable outcome in terms of amifostine neuroprotection, but the vibration perception threshold result was based on data from only 14 participants receiving amifostine who completed the post-treatment evaluation and should be regarded with caution. Furthermore the change measured was subclinical. None of the three eligible Ca/Mg trials (or four trials if a single retrospective study was included) described our primary outcome measures. The four Ca/Mg trials included a total of 886 participants. Of the seven eligible glutathione trials (387 participants), one used quantitative sensory testing but reported only qualitative analyses. Four eligible Org 2766 trials (311 participants) employed quantitative sensory testing but reported disparate results; meta-analyses of three of these trials using comparable measures showed no significant vibration perception threshold neuroprotection. The remaining trial reported only descriptive analyses. Similarly, none of the three eligible vitamin E trials (246 participants) reported quantitative sensory testing. The eligible single trials involving acetylcysteine (14 participants), diethyldithiocarbamate (195 participants), oxcarbazepine (32 participants), and retinoic acid (92 participants) did not perform quantitative sensory testing. In all, this review includes data from 2906 participants. However, only seven trials reported data for the primary outcome measure of this review, (quantitative sensory testing) and only nine trials reported our objective secondary measure, nerve conduction test results. Additionally, methodological heterogeneity precluded pooling of the results in most cases. Nonetheless, a larger number of trials reported the results of secondary (non-quantitative and subjective) measures such as the National Cancer Institute Common Toxicity Criteria (NCI-CTC) for neuropathy (15 trials), and these results we pooled and reported as meta-analysis. Amifostine showed a significantly reduced risk of developing neurotoxicity NCI-CTC (or equivalent) &#8805; 2 compared to placebo (RR 0.26, 95% CI 0.11 to 0.61). Glutathione was also efficacious with an RR of 0.29 (95% CI 0.10 to 0.85). In three vitamin E studies subjective measures not suitable for combination in meta analysis each favoured vitamin E. For other interventions the qualitative toxicity measures were either negative (N-acetyl cysteine, Ca/Mg, DDTC and retinoic acid) or not evaluated (oxcarbazepine and Org 2766).</P>
<P>Adverse events were infrequent or not reported for most interventions. Amifostine was associated with transient hypotension in 8% to 62% of participants, retinoic acid with hypocalcaemia in 11%, and approximately 20% of participantss withdrew from treatment with DDTC because of toxicity.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-01-17 16:05:29 +0000" MODIFIED_BY="Kate Jewitt">
<P>At present, the data are insufficient to conclude that any of the purported chemoprotective agents (acetylcysteine, amifostine, calcium and magnesium, diethyldithiocarbamate, glutathione, Org 2766, oxcarbazepine, retinoic acid, or vitamin E) prevent or limit the neurotoxicity of platin drugs among human patients, as determined using quantitative, objective measures of neuropathy. Amifostine, calcium and magnesium, glutathione, and vitamin E showed modest but promising (borderline statistically significant) results favouring their ability to reduce the neurotoxicity of cisplatin and related chemotherapies, as measured using secondary, non-quantitative and subjective measures such as the NCI-CTC neuropathy grading scale. Among these interventions, the efficacy of only vitamin E was evaluated using quantitative nerve conduction studies; the results were negative and did not support the positive findings based on the qualitative measures. In summary, the present studies are limited by the small number of participants receiving any particular agent, a lack of objective measures of neuropathy, and differing results among similar trials, which make it impossible to conclude that any of the neuroprotective agents tested prevent or limit the neurotoxicity of platinum drugs.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-02-27 11:56:58 +0000" MODIFIED_BY="Ruth Brassington">
<BACKGROUND MODIFIED="2014-02-19 12:15:00 +0000" MODIFIED_BY="Kate Jewitt">
<P>Cisplatin (cis-diaminodichloroplatinum) was the first heavy metal used as an antineoplastic agent. It has been used since the early 1970s to treat several kinds of solid tumours, including lung, ovary, testis, bladder, head and neck, and endometrium (<LINK REF="REF-Mollman-1990" TYPE="REFERENCE">Mollman 1990</LINK>; <LINK REF="REF-Prestayko-1979" TYPE="REFERENCE">Prestayko 1979</LINK>). Typical dosage regimes vary from 50 to 100 mg/m² given intravenously every three to four weeks, usually for about six cycles, based on clinical response and toxicity. Alternative schedules include 20 mg/m² daily for five days, or 20 mg/m² given weekly for about six weeks. Cisplatin is known to be toxic to the nervous system (<LINK REF="REF-Cavaletti-2004" TYPE="REFERENCE">Cavaletti 2004;</LINK> <LINK REF="REF-Mollman-1990" TYPE="REFERENCE">Mollman 1990</LINK>; <LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK>; <LINK REF="REF-Von-Hoff-1979" TYPE="REFERENCE">Von Hoff 1979</LINK>); it exhibits preferential uptake in the dorsal root ganglia and produces a dose-related large fibre sensory neuropathy (neuronopathy). The sensory neuropathy most often becomes evident after a cumulative cisplatin dose of at least 300 mg/m², but occasional patients, especially those with risk factors, those with pre-existing neuropathy, and those who are receiving combination chemotherapy, may develop symptoms after lower cumulative doses (<LINK REF="REF-Roelofs-1984" TYPE="REFERENCE">Roelofs 1984</LINK>; <LINK REF="REF-Windebank-1994" TYPE="REFERENCE">Windebank 1994</LINK>). Most people completing a full course of cisplatin chemotherapy develop a symptomatic and clinically detectable sensory neuropathy. Symptoms, including unpleasant distal paraesthesias (tingling in the extremities) and numbness, may appear as soon as one month after initiating treatment. Lhermitte's symptom (an electric shock-like sensation on bending the neck), likely caused by centripetal degeneration of posterior columns, has also been described. Associated signs include evidence of large fibre sensory loss (reduced vibration and joint position sensations) and diminished or absent muscle stretch reflexes (<LINK REF="REF-Roelofs-1984" TYPE="REFERENCE">Roelofs 1984</LINK>; <LINK REF="REF-Thompson-1984" TYPE="REFERENCE">Thompson 1984</LINK>). Sensory ataxia (inco-ordination) may be disabling in those who have severe neuropathy. Small fibre sensation is spared or mildly diminished (decreased pin-pain sensation). Strength is generally normal. Symptoms and signs are symmetric and usually worse distally. Despite the high frequency of neuropathy among people treated with cisplatin, relatively few people develop functional impairment sufficient to interfere with activities of daily living (ADL). Nevertheless, neurotoxicity is a major reason that cisplatin is discontinued and the cumulative dosage limited, potentially reducing its chemotherapeutic efficacy. In an attempt to reduce the toxicity of platinum drugs, second and third generation tumour-inhibiting platinum compounds including carboplatin, oxaliplatin, nedaplatin, and lobaplatin have emerged. Carboplatin lacks the nephrotoxicity of cisplatin, and neurotoxicity also is thought to be considerably less than that associated with cisplatin. Carboplatin is used to treat ovarian, small cell lung, and refractory testicular cancers. Oxaliplatin is now FDA and European Union approved for use in the treatment of metastatic colon cancer; neurotoxicity is the major dose-limiting adverse-event (<LINK REF="REF-Grothey-2003" TYPE="REFERENCE">Grothey 2003</LINK>; <LINK REF="REF-Grothey-2004" TYPE="REFERENCE">Grothey 2004</LINK>).</P>
<P>Quantitative measures of vibration perception threshold (VPT) and sensory nerve action potential (SNAP) amplitude are complementary means of evaluating large sensory fibres. Both measures have been used to document the development and progression of cisplatin-induced neuropathy (<LINK REF="REF-Wald-1994" TYPE="REFERENCE">Wald 1994</LINK>). Sequential nerve conduction studies among people receiving cisplatin chemotherapy demonstrate progressive reduction of SNAP amplitudes, with little or no change in motor nerve conduction studies and needle electromyography (EMG). Reduction of the SNAP amplitude is thought to be a relatively sensitive indication of early cisplatin-induced neurotoxicity. This objective change occurs early in the course of cisplatin neuropathy, often before development of symptoms or signs of sensory neuropathy. It is generally believed that most patients receiving cisplatin show a sequential decline in SNAP amplitude relative to baseline (<LINK REF="REF-Wald-1994" TYPE="REFERENCE">Wald 1994</LINK>; <LINK REF="REF-Wald-1995" TYPE="REFERENCE">Wald 1995</LINK>). A decline which exceeds 40% from baseline is used by some as the physiological criterion for sensory neuropathy associated with chemotherapy toxicity (<LINK REF="REF-Molloy-2001" TYPE="REFERENCE">Molloy 2001</LINK>). Sural nerve biopsy shows evidence of Wallerian-like axonal degeneration affecting the large myelinated fibres, with scant evidence of regeneration, consistent with damage at the level of the dorsal root ganglia. Unmyelinated fibres are spared (<LINK REF="REF-Krarup_x002d_Hansen-1993" TYPE="REFERENCE">Krarup-Hansen 1993</LINK>). Cisplatin-induced neuropathy stabilises or improves after discontinuing cisplatin (<LINK REF="REF-Elderson-1989" TYPE="REFERENCE">Elderson 1989</LINK>), but clinical and electrodiagnostic deterioration often progresses for a few weeks after completing cisplatin treatment (called 'coasting'). With higher cumulative dosages, however, residual nerve damage may persist for long periods of time.</P>
<P>Experimental models of cisplatin neurotoxicity confirm that the neuronal cell body within the dorsal root ganglion is the site of injury. Cultured rat embryo dorsal root ganglion models have been used to study the mechanisms of cisplatin neurotoxicity (<LINK REF="REF-Windebank-1994" TYPE="REFERENCE">Windebank 1994</LINK>). Cisplatin reproducibly inhibits axonal growth in a dose-dependent manner that includes concentrations similar to those known to produce human toxicity. The mechanism of action is thought to be related to platinum binding to DNA and interfering with DNA synthesis. Cisplatin produced abnormalities in the nucleoli of spinal root ganglion cells of large and small neurons (<LINK REF="REF-Tomiwa-1986" TYPE="REFERENCE">Tomiwa 1986</LINK>). The hypothesis that cisplatin-induced neuropathy may result from nuclear and nucleolar changes in the sensory ganglion cell body was confirmed in the rat (<LINK REF="REF-Cavaletti-1992" TYPE="REFERENCE">Cavaletti 1992</LINK>). After chronic cisplatin administration, the spinal ganglia and peripheral nerves showed severe damage of the spinal ganglia neurons with predominant involvement of the nucleus and nucleolus associated with a decrease in the cell size after chronic cisplatin administration. Changes also occurred in the sciatic and peroneal nerves with the features of axonopathy (<LINK REF="REF-Cavaletti-1992" TYPE="REFERENCE">Cavaletti 1992</LINK>). These changes described in rats also have been confirmed in mice (<LINK REF="REF-Carozzi-2010" TYPE="REFERENCE">Carozzi 2010</LINK>). In addition, <LINK REF="REF-Schmidt-1995" TYPE="REFERENCE">Schmidt 1995</LINK> showed in a mouse model that nerve growth factor (NGF) exerts a major effect on the metabolism of transmitters associated with nociception, pain and sensation in cervical dorsal root ganglia in various models of toxic neuropathy, including the neuropathy produced by cisplatin. Cisplatin specifically induced a significant decrease in the number of large- and medium-sized neurons in the dorsal root ganglia, indicating neuronal atrophy, a finding that correlated with a highly significant loss of neuropeptides in cervical dorsal root ganglia in mice (<LINK REF="REF-Schmidt-1995" TYPE="REFERENCE">Schmidt 1995</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="2">Prevention of cisplatin neurotoxicity</HEADING>
<P>In most instances of cisplatin-induced neuropathy, the nerves only partially recover or do not recover at all. For this reason, effective neuroprotective therapies have been sought. As therapeutic strategies were developed to maximise cisplatin effectiveness, such as minimising renal insufficiency, cumulative dose-related neuropathy emerged as a major dose-limiting toxicity (<LINK REF="REF-Gandara-1991" TYPE="REFERENCE">Gandara 1991</LINK>). Attempts to modulate cisplatin dose schedules did not influence the intensity of the resultant neurotoxicity (<LINK REF="STD-Hilkens-1995" TYPE="STUDY">Hilkens 1995</LINK>). Additional means of optimising the therapeutic index of cisplatin were sought, such as coadministration of chemoprotective or rescue therapies to reduce adverse side effects without reversing antitumour activity. An ACTH (4-9) analogue Org 2766, glutathione (GSH), amifostine, and various neurotrophic growth factors have all been tried in clinical and experimental models to prevent cisplatin-induced neurotoxicity, and reviews exist of the clinical pharmacology and therapeutic efficacy of several chemoprotectants (e.g. <LINK REF="REF-Links-1999" TYPE="REFERENCE">Links 1999</LINK>). Acetyl-L-carnitine has recently been reported to have a neuroprotective effect in cisplatin and paclitaxel models (<LINK REF="REF-Pisano-2003" TYPE="REFERENCE">Pisano 2003</LINK>). Both GSH and vitamin E have been tested in human trials with platinum drugs (<LINK REF="STD-Cascinu-1995" TYPE="STUDY">Cascinu 1995</LINK>; <LINK REF="STD-Cascinu-2002" TYPE="STUDY">Cascinu 2002</LINK>; <LINK REF="STD-Pace-2003" TYPE="STUDY">Pace 2003</LINK>; <LINK REF="STD-Smyth-1997" TYPE="STUDY">Smyth 1997</LINK>). Although the precise mechanism of cisplatin-induced neurotoxicity is unknown, various agents have been proposed to protect the peripheral nervous system from such neurotoxicity. For example, amifostine, an organic thiophosphate that acts as a scavenger of oxygen free-radicals, shows selective protection of normal tissues (cytoprotective) against toxicities induced by radiation, alkylating agents, and platinum compounds without influencing the antitumour effects of these treatments (<LINK REF="STD-Planting-1999" TYPE="STUDY">Planting 1999</LINK>). Diethyldithiocarbamate (DDTC) is a chelating agent thought to bind and remove tissue-bound platinum without interfering with the antitumour activity of cisplatin (<LINK REF="STD-Gandara-1995" TYPE="STUDY">Gandara 1995</LINK>). Glutathione (GSH) is a nucleophilic sulphur-containing tripeptide thiol thought to permit delivery of higher doses of cisplatin without producing the expected neurotoxicity, perhaps by preventing the initial accumulation of platinum adducts in the dorsal root ganglia (<LINK REF="STD-Cascinu-1995" TYPE="STUDY">Cascinu 1995</LINK>; <LINK REF="STD-Cascinu-2002" TYPE="STUDY">Cascinu 2002</LINK>). The neuropeptide Org 2766 is thought to potentially ameliorate cisplatin neuropathy by exerting trophic effects and enhancing endogenous nerve repair mechanisms (as opposed to directly protecting against cisplatin neurotoxicity) (<LINK REF="STD-van-Gerven-1994" TYPE="STUDY">van Gerven 1994</LINK>). Vitamin E is an antioxidant thought to protect against cisplatin-induced oto- and nephro-toxicities and potentially to protect against neurotoxicity (<LINK REF="STD-Pace-2003" TYPE="STUDY">Pace 2003</LINK>). Acetylcysteine (<I>N</I>-acetylcysteine, NAC) is a nutritional supplement thought to increase whole blood concentrations of glutathione, a useful agent for preventing the initial accumulation of platinum adducts and clinical oxaliplatin-induced neurotoxicity (<LINK REF="STD-Lin-2006" TYPE="STUDY">Lin 2006</LINK>). BNP7787 (disodium 2, 2' dithio-bisethane sulfonate) was developed as a putative chemoprotective agent (<LINK REF="STD-Miller-2008" TYPE="STUDY">Miller 2008</LINK>). Calcium and magnesium infusions were proposed to act as chelators of oxalate, thereby reducing the effect of oxalate on voltage-gated sodium channels (<LINK REF="STD-Gamelin-2004" TYPE="STUDY">Gamelin 2004</LINK>). Oxcarbazepine resembles the antiepileptic drug carbamazepine and also blocks voltage-sensitive sodium channels and certain calcium channels.  Oxcarbazepine was developed as a neuroprotective against oxaliplatin-induced neuropathy, which is thought to reflect the alteration of voltage-gated sodium channels by oxalate, a metabolite of oxaliplatin (<LINK REF="STD-Argyriou-2006a" TYPE="STUDY">Argyriou 2006a</LINK>).</P>
</SUBSECTION>
<INTERVENTION MODIFIED="2014-02-19 12:15:00 +0000" MODIFIED_BY="Michael Lunn">
<P>Several different interventions have been described as being effective in preventing platinum-induced neuropathy. A complex description of each intervention is beyond the scope of this review.</P>
<UL>
<LI>Acetylcysteine (NAC) is a nutritional supplement thought to increase whole blood concentrations of glutathione, a useful agent for preventing the initial accumulation of platinum adducts and clinical oxaliplatin-induced neurotoxicity (<LINK REF="STD-Lin-2006" TYPE="STUDY">Lin 2006</LINK>).</LI>
<LI>Amifostine is an organic thiophosphate described as a broad-spectrum cytoprotective agent potentially able to protect normal tissues from cytotoxic effects of chemotherapeutic agents (<LINK REF="STD-Kanat-2003" TYPE="STUDY">Kanat 2003</LINK>).</LI>
<LI>Calcium and magnesium infusions may chelate oxalate (a metabolite of oxaliplatin), thereby reducing the effect of oxalate on voltage-gated sodium channels (<LINK REF="STD-Ishibashi-2010" TYPE="STUDY">Ishibashi 2010</LINK>).</LI>
<LI>Diethyldithiocarbamate (DDTC) is a heavy metal chelating agent and has been reported to reduce the incidence and severity of cisplatin-induced neuropathy (<LINK REF="STD-Gandara-1995" TYPE="STUDY">Gandara 1995</LINK>).</LI>
<LI>Glutathione (GSH). The mechanism of neurotoxicity from platinum drugs is thought to be the accumulation of platinum within the dorsal root ganglia. The thio nucleophilic region of reduced GSH has high affinity for heavy metals and may be able to prevent the accumulation of platinum in the dorsal root ganglia.</LI>
<LI>Org 2766 is an ACTH (4-9) analogue which has been reported to reduce the incidence and severity of cisplatin-induced polyneuropathy (<LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK>).</LI>
<LI>Oxcarbazepine resembles the antiepileptic drug carbamazepine and also blocks voltage-sensitive sodium channels and certain calcium channels. It was developed as a neuroprotective against oxaliplatin-induced neuropathy, which is thought to reflect the alteration of voltage-gated sodium channels by oxalate, a metabolite of oxaliplatin (<LINK REF="STD-Argyriou-2006" TYPE="STUDY">Argyriou 2006</LINK>).</LI>
<LI>Retinoic acid. Retinoids play a role in a variety of biological functions; all-<I>trans</I> retinoic acid (ATRA) binds and activates subtypes of retinoid acid receptors and stimulates nerve growth factor (NGF) and the expression of its receptor. ATRA prevents and reverses neuropathy-associated morphological changes in diabetic animals (<LINK REF="STD-Arrieta-2011" TYPE="STUDY">Arrieta 2011</LINK>).</LI>
<LI>Vitamin E, an antioxidant protecting against free-radical injury, may be protective against cisplatin-induced polyneuropathy. Based on the observation that deficiency of vitamin E produces a pattern of peripheral neuropathy similar to cisplatin-induced toxic neuropathy and the fact that decreased plasma vitamin E levels are observed in patients with cisplatin neuropathy, trials of vitamin E for prevention of toxic neuropathy have been done (<LINK REF="STD-Pace-2003" TYPE="STUDY">Pace 2003</LINK>).</LI>
</UL>
</INTERVENTION>
<IMPORTANCE MODIFIED="2014-01-17 16:12:21 +0000" MODIFIED_BY="Ruth Brassington">
<P>Whilst platinum-containing chemotherapy can be highly effective for the treatment of a number of cancers, its use and dosing is not infrequently limited by neurotoxicity. As well as limiting choice and efficacy of chemotherapy agents the disability caused by the neuropathy can be devastating and irreversible. Agents that limit or prevent toxicity from platinum containing chemotherapy could be very important adjuncts to oncology regimens.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-01-17 16:12:36 +0000" MODIFIED_BY="Kate Jewitt">
<P>To examine the efficacy and safety of purported chemoprotective agents to prevent or limit the neurotoxicity of cisplatin and related drugs.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-02-19 12:15:04 +0000" MODIFIED_BY="Kate Jewitt">
<SELECTION_CRITERIA MODIFIED="2014-02-12 20:45:50 +0000" MODIFIED_BY="Kate Jewitt">
<CRIT_STUDIES MODIFIED="2014-01-17 16:13:01 +0000" MODIFIED_BY="Kate Jewitt">
<P>We included all randomised or quasi-randomised controlled human trials in which the efficacy of any form of chemoprotective treatment used to prevent or limit the neurotoxicity of cisplatin (or related oncologic platinum compounds including oxaliplatin or carboplatin) was compared with placebo, no treatment, or other treatments.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adult participants of either sex undergoing chemotherapy with cisplatin (or related oncologic platinum compounds including oxaliplatin or carboplatin) as an antineoplastic medication.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-01-17 16:13:07 +0000" MODIFIED_BY="Kate Jewitt">
<P>We included in the review any form of chemoprotective treatment, such as acetyl-L-carnitine, acetylcysteine (NAC), adrenocorticotrophic hormone (ACTH), amifostine, BNP7787, calcium and magnesium, Org 2766, glutathione, oxcarbazepine, vitamin E, and growth factors, used to prevent or limit cisplatin-induced neurotoxicity.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-02-12 20:45:50 +0000" MODIFIED_BY="Kate Jewitt">
<P>Primary and secondary outcomes were evaluated in the zero to six month period after completing or discontinuing chemotherapy. When more than one evaluation occurred during this interval, we selected the one closest to three months after completing chemotherapy treatment.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-02-12 20:45:50 +0000" MODIFIED_BY="[Empty name]">
<P>The primary outcome measure was the change in quantitative sensory testing (QST) results (e.g., vibration perception threshold (VPT). Measures of VPT have been used in several studies of cisplatin toxicity. Although VPT does not have the specificity of nerve conduction study results, the sensitivity of QST is likely similar to nerve conduction study results.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-02-12 13:47:04 +0000" MODIFIED_BY="Kate Jewitt">
<P>Secondary outcome measures included nerve conduction study results (SNAP amplitude) and measures of neurological impairment. Any other available measure of impairment was considered, but priority was given to those clinical, functional, or electrodiagnostic measures that used a validated scale. Examples of secondary outcome measures included the following.</P>
<OL>
<LI>SNAP amplitude.</LI>
<LI>Clinical impairment measured by neurological examination, using a validated scale.</LI>
<LI>Functional measures of activities of daily living (ADL).</LI>
<LI>Information from toxicity rating scales.</LI>
<LI>Serious adverse events of chemoprotective treatment, which were fatal, life threatening, or require prolonged hospital admission.</LI>
</OL>
<P>The National Cancer Institute-Common Toxicity Criteria for Peripheral Sensory Neuropathy (NCI-CTC for neuropathy) is an example of a neurotoxicity scale commonly used in clinical practice and frequently used in the studies we reviewed. Despite the wide use of the NCI-CTC, it is not a validated scale, which is a major limitation (<LINK REF="REF-Cavaletti-2010a" TYPE="REFERENCE">Cavaletti 2010a</LINK>; <LINK REF="REF-Cavaletti-2013" TYPE="REFERENCE">Cavaletti 2013</LINK>). The NCI-CTC as used in many of the studies we reviewed exists in slightly different forms. One form has the following grades: 1) Asymptomatic: loss of deep tendon reflexes or paraesthesias; 2) Moderate symptoms: limiting instrumental ADL; 3) Severe symptoms: limiting self care ADL; 4) Life-threatening consequences: urgent intervention indicated; and 5) Death. The second form uses grades as follows: 1) Asymptomatic: loss of deep tendon reflexes or paraesthesias (including tingling), but not interfering with function; 2) Sensory alteration or paraesthesias (including tingling) interfering with function, but not ADL; 3) Sensory alteration or paraesthesias interfering with ADL; and 4) Disabling. In the studies we reviewed, few participants developed grade 4 neuropathy, using either scale, and we elected to emphasise neuropathy based on participants showing grades &#8805;2 from either scale. In our opinion, such grading likely represents similar degrees of neuropathy, and separation based on which of the scales used limited the analyses we could perform (which was already severely limited by the few studies using our prespecified end points).</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-02-12 10:22:22 +0000" MODIFIED_BY="Kate Jewitt">
<ELECTRONIC_SEARCHES MODIFIED="2014-02-12 10:22:22 +0000" MODIFIED_BY="Kate Jewitt">
<P>On 4 March 2013, we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL (2013, Issue 2 in <I>The Cochrane Library</I>), MEDLINE (January 1966 to February 2013), EMBASE (January 1980 to February 2013), LILACS (January 1982 to February 2013), and CINAHL Plus (January 1937 to February 2013).</P>
<P>Our search strategy was not restricted by language. In the initial and updated review, we did not approach pharmaceutical companies, but, in a few instances, we did contact the authors of the trials for additional information. We did not formally screen the references of the selected papers.</P>
<P>The detailed search strategies are in the appendices: <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> (CENTRAL); <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> (MEDLINE); <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> (EMBASE); <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK> (CINAHL Plus); and <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> (LILACS).</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-02-19 12:15:04 +0000" MODIFIED_BY="Kate Jewitt">
<STUDY_SELECTION MODIFIED="2014-01-17 16:26:47 +0000" MODIFIED_BY="Kate Jewitt">
<P>Both for the original review and updates, two review authors (JA and VC or GC) independently screened the titles and abstracts of references to select potential studies for inclusion The review authors obtained the full text of all potentially relevant studies for independent assessment by two authors for each article (among JA, GC, VC, and RD). The authors decided which studies fitted the inclusion criteria and graded their risk of bias. The two authors assessing each article resolved any disagreements about inclusion by communication, resulting in consensus. </P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-01-17 16:27:34 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors performed data extraction for each article and a third author (JA) checked the data extraction to identify differences of opinion. We began by separating the studies into treatment categories: for example, amifostine, glutathione, Ca/Mg, DDTC (diethyldithiocarbamate), Org 2766, oxcarbazepine, ATRA and vitamin E. We assigned two authors to each of the categories (combining categories with few studies, such as DDTC and vitamin E). We next tabulated whether or not individual studies showed dose-response efficacy (if more than one dose was studied). We summarised the types of outcomes reported (QST, nerve conduction studies, clinical, functional measure). We included consideration of serious adverse events and determined if information on cost benefits was available.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-02-19 12:15:04 +0000" MODIFIED_BY="Kate Jewitt">
<P>We assessed risk of bias in included studies using the Cochrane Collaboration 'Risk of bias' tool, described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>, updated <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We considered the adequacy of studies in the following domains: sequence generation, allocation concealment, blinding (subject, observer and assessor), incomplete outcome data addressed, selective reporting, and other sources of bias. Assessments were 'low risk of bias', 'high risk of bias', and 'unclear risk of bias' (where there was insufficient information to make a judgment or when the criterion did not apply to the study). At least two review authors evaluated each study and consensus agreement was reached.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-02-07 15:16:50 +0000" MODIFIED_BY="[Empty name]">
<P>For studies using a common outcome measure, we calculated a treatment effect across trials and expressed the results as risk ratios (RR). For continuous outcomes, where meta-analysis was possible, we calculated a mean difference and expressed the results with confidence intervals.</P>
<P>When the results indicated unexplained heterogeneity, we undertook these tests using a random-effects model; if not, we used a fixed-effect model. When there was unexplained heterogeneity, we investigated its source by repeating the analysis after elimination of trials that were at high or unclear risk of bias on each of the risk of bias domains, paying particular attention to allocation concealment. We investigated heterogeneity beginning with visual inspection of forest plots to determine if the confidence intervals (CIs) were not overlapping or there were outliers to suggest statistical heterogeneity. As a general guideline, we used a Chi-squared statistic greater than the degrees of freedom to indicate heterogeneity, recognising that a non-significant result does not necessarily mean the absence of heterogeneity when the studies are small/few. As a rule of thumb, we used I<SUP>2</SUP>, describing heterogeneity as moderate for 30% to 60%, substantial for I<SUP>2 </SUP>of 50% to 90% and considerable for I<SUP>2 </SUP>of 75% to 100%. When there was unexplained heterogeneity, we repeated the analyses using a random-effects model to see whether the results differed. The possible outcomes were: 1. effect estimate is the same, 2. Effect estimate is similar, with different CIs (we used the random-effects model), or 3. Effect estimate is different, in which case we performed sensitivity analyses repeating the analyses excluding studies at high risk of bias (e.g. on allocation concealment), large studies, unpublished studies, or other studies, depending on any suspected source of heterogeneity.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-02-27 10:12:00 +0000" MODIFIED_BY="Ruth Brassington">
<STUDY_DESCRIPTION MODIFIED="2014-02-27 10:12:00 +0000" MODIFIED_BY="Ruth Brassington">
<P>The initial search identified 135 articles. From these, we selected 39 articles for complete review. We identified 15 articles fulfilling inclusion criteria. The 2010 search identified 275 articles (including many duplications and previously identified), from which we selected 11 new studies for complete review, of which we included five (a total of 20 included studies).</P>
<P>The 2013 search produced the following results: Cochrane Neuromuscular Disease Group Specialized Register 76 papers (19 new), CENTRAL 79 papers, MEDLINE 263 papers (34 new), EMBASE 193 papers (41 new), CINAHL Plus 50 papers (14 new), and LILACS 1 paper. The 2013 search resulted in selection of 21 articles for complete review, from which eight trials fulfilled inclusion criteria. One additional retrospective article was included (for reasons described below) and two articles describing the results of meta-analyses were excluded but selected for the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK>, for comparison to our interpretation of the data. We documented reasons for excluding studies (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). A total of 29 studies (2906 participants) are included in the review. The combined articles involved the following potential chemoprotectant treatments:</P>
<UL>
<LI>acetylcysteine (NAC) (one study);</LI>
<LI>amifostine (seven studies);</LI>
<LI>calcium and magnesium (four studies);</LI>
<LI>diethyldithiocarbamate (DDTC) (one study);</LI>
<LI>glutathione (GSH) (seven studies);</LI>
<LI>Org 2766 (four studies);</LI>
<LI>oxcarbazepine (one study);</LI>
<LI>retinoic acid (one study); and</LI>
<LI>vitamin E (three studies).</LI>
</UL>
<P>The characteristics of the individual studies, including the 'Risk of bias' assessments, are summarised in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Acetylcysteine (N-acetylcysteine, NAC)</HEADING>
<P>Our 2010 update identified one article fulfilling the selection criteria and reporting the results of a randomised controlled trial (RCT) designed to evaluate the protective effects of NAC against oxaliplatin-induced neurotoxicity (<LINK REF="STD-Lin-2006" TYPE="STUDY">Lin 2006</LINK>). This study, described as a "pilot study" involved only a small number of participants. Oxaliplatin dose was discontinued or dose reduced to 75% of previous dose if the participants developed NCI-CRC grade 3 or 4 neuropathy or had National Cancer Institute (NCI) grade 1 neuropathy respectively. Additionally, calculation of the score was arbitrarily modified (sum of worst neurological toxicity divided by number of assessable participants at each dose level). Trial participants received:   </P>
<UL>
<LI>oxaliplatin for colorectal cancer (five NAC-treated and nine placebo control participants) (<LINK REF="STD-Lin-2006" TYPE="STUDY">Lin 2006</LINK>).</LI>
</UL>
<P>Participants received oral NAC (1200 mg) one and one half hours before each oxaliplatin administration, occurring every two weeks for up to 12 treatment cycles.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Amifostine</HEADING>
<P>Our search identified nine articles describing a total of eight studies fulfilling the selection criteria and reporting the results of RCTs designed to evaluate the protective effects of amifostine against chemotherapy neurotoxicity. Two articles with different first authors (<LINK REF="STD-Kemp-1996" TYPE="STUDY">Kemp 1996</LINK>; <LINK REF="REF-Rose-1996" TYPE="REFERENCE">Rose 1996</LINK>), described the same trial and were considered together for this review (<LINK REF="STD-Kemp-1996" TYPE="STUDY">Kemp 1996</LINK>). One of the studies identified in the 2013 review (<LINK REF="STD-DeVos-2005" TYPE="STUDY">DeVos 2005</LINK>), described a meta-analysis of studies involving amifostine infusions for the prevention of neurotoxicity related to carboplatin (with paclitaxel); we included a review of that meta-analysis in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK>. The seven eligible trials included 372 amifostine-treated participants and 371 control participants. These trials included participants being treated with:</P>
<UL>
<LI>cisplatin for advanced head and neck cancer (37 amifostine-treated participants and 37 control participants) (<LINK REF="STD-Planting-1999" TYPE="STUDY">Planting 1999</LINK>);</LI>
<LI>paclitaxel and carboplatin for non-small cell lung cancer (19 amifostine-treated and 19 control participants) (<LINK REF="STD-Kanat-2003" TYPE="STUDY">Kanat 2003</LINK>);</LI>
<LI>paclitaxel and carboplatin for ovarian cancer (93 amifostine-treated and 94 control participants) (<LINK REF="STD-Lorusso-2003" TYPE="STUDY">Lorusso 2003</LINK>);</LI>
<LI>cisplatin and cyclophosphamide for advanced ovarian cancer (122 amifostine-treated and 120 control participants) (<LINK REF="STD-Kemp-1996" TYPE="STUDY">Kemp 1996</LINK>);</LI>
<LI>oxaliplatin (FOLFOX-4) for advanced or relapsed colorectal or gastric cancer with variable metastatic disease to liver, lung, and other sites (46 amifostine-treated and 46 control participants) <U>(</U>
<LINK REF="STD-Lu-2008" TYPE="STUDY">Lu 2008</LINK>);</LI>
<LI>carboplatin with paclitaxel for advanced ovarian carcinoma (45 amifostine-treated and 45 control participants (<LINK REF="STD-DeVos-2005" TYPE="STUDY">DeVos 2005</LINK>); and</LI>
<LI>radiotherapy and cisplatin for cervical cancer (10 amifostine-treated participants and 10 control participants) (<LINK REF="STD-Gallardo-1999" TYPE="STUDY">Gallardo 1999</LINK>)</LI>
</UL>
<P>The amifostine regimens varied only slightly among trials, and all participants randomised to the amifostine groups received intravenous amifostine immediately before chemotherapy at doses of 740 mg/m² (<LINK REF="STD-DeVos-2005" TYPE="STUDY">DeVos 2005</LINK>; <LINK REF="STD-Planting-1999" TYPE="STUDY">Planting 1999</LINK>), 910 mg/m²<SUP> </SUP>(<LINK REF="STD-Kanat-2003" TYPE="STUDY">Kanat 2003</LINK>; <LINK REF="STD-Kemp-1996" TYPE="STUDY">Kemp 1996</LINK>; <LINK REF="STD-Lorusso-2003" TYPE="STUDY">Lorusso 2003</LINK>), or 500 mg/m²<SUP> </SUP>
<U>(</U>
<LINK REF="STD-Lu-2008" TYPE="STUDY">Lu 2008</LINK>). All trials involved scheduled treatments of up to six cycles of chemotherapy, either weekly (<LINK REF="STD-Planting-1999" TYPE="STUDY">Planting 1999</LINK>), at three-week intervals (<LINK REF="STD-DeVos-2005" TYPE="STUDY">DeVos 2005</LINK>; <LINK REF="STD-Kanat-2003" TYPE="STUDY">Kanat 2003</LINK>; <LINK REF="STD-Kemp-1996" TYPE="STUDY">Kemp 1996</LINK>), or in two- or four-week cycles <U>(</U>
<LINK REF="STD-Lu-2008" TYPE="STUDY">Lu 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Calcium and magnesium (Ca/Mg)</HEADING>
<P>The 2010 and 2013 updates identified three articles fulfilling the selection criteria and reporting the results of an RCT to evaluate the protective effects of calcium and magnesium infusions against oxaliplatin neurotoxicity (<LINK REF="STD-Chay-2010" TYPE="STUDY">Chay 2010</LINK>; <LINK REF="STD-Grothey-2011" TYPE="STUDY">Grothey 2011</LINK>; <LINK REF="STD-Ishibashi-2010" TYPE="STUDY">Ishibashi 2010</LINK>). <LINK REF="STD-Grothey-2011" TYPE="STUDY">Grothey 2011</LINK> and <LINK REF="STD-Ishibashi-2010" TYPE="STUDY">Ishibashi 2010</LINK> included participants being treated with six cycles of FOLFOX, which includes oxaliplatin (85 mg/m²) every two weeks. The <LINK REF="STD-Chay-2010" TYPE="STUDY">Chay 2010</LINK> trial included participants being treated with up to eight cycles of either XELOX, which includes oxaliplatin 130 mg/m² on day one every three weeks (received by 22 or 27 participants) or FOLFOX-4, which includes oxaliplatin (85 mg/m²) every two weeks. This study was terminated prematurely because of negative results from the CONcePT trial. The initial three eligible trials included 76 Ca/Mg-treated participants and 78 control participants. One additional article describing a retrospective, non-randomised study of Ca/Mg used at the discretion of treating physicians (as part of a large multicentre RCT of different chemotherapy drugs) was included because neither the participants nor the investigators appeared aware that Ca/Mg was being (or was going to be) investigated (<LINK REF="STD-Knijn-2011" TYPE="STUDY">Knijn 2011</LINK>). When data from this retrospective study were included, there were 627 Ca/Mg-treated participants and 259 control participants. The 2013 review also identified two papers that described meta-analysis of studies involving Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity (<LINK REF="STD-Ao-2012" TYPE="STUDY">Ao 2012</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>); we included these studies in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK>.</P>
<UL>
<LI>oxaliplatin for colorectal cancer (9 Ca/Mg-treated and 10 control participants) (<LINK REF="STD-Chay-2010" TYPE="STUDY">Chay 2010</LINK>);</LI>
<LI>oxaliplatin for colon cancer (50 Ca/Mg-treated and 52 control participants) (<LINK REF="STD-Grothey-2011" TYPE="STUDY">Grothey 2011</LINK>);</LI>
<LI>oxaliplatin for metastatic colorectal cancer (17 Ca/Mg-treated and 16 control participants) (<LINK REF="STD-Ishibashi-2010" TYPE="STUDY">Ishibashi 2010</LINK>); and</LI>
<LI>oxaliplatin plus capecitabine, and bevacizumab with or without cetuximab for previously untreated colorectal cancer (551 Ca/Mg-treated and 181 control, at the discretion of the treating physician) (pseudo-random and retrospective) (<LINK REF="STD-Knijn-2011" TYPE="STUDY">Knijn 2011</LINK>).</LI>
</UL>
<P>In two studies, investigators administered calcium gluconate 1 g (10 mL of 10% calcium gluconate) + 15% magnesium sulfate 1 g diluted into 100 mL of normal saline infused over 15 minutes before and after oxaliplatin infusion (<LINK REF="STD-Chay-2010" TYPE="STUDY">Chay 2010</LINK>; <LINK REF="STD-Grothey-2011" TYPE="STUDY">Grothey 2011</LINK>). In addition to oxaliplatin FOLFOX chemotherapy includes administration of 5-fluorouracil and l-leucovorin with each of six, two-week treatment cycles. <LINK REF="STD-Knijn-2011" TYPE="STUDY">Knijn 2011</LINK> infused 2.25 mmol calcium glubionate plus 4 mmol magnesium chloride in 100 mL glucose over 15 minutes, before and after oxaliplatin infusion (retrospective analyses). <LINK REF="STD-Ishibashi-2010" TYPE="STUDY">Ishibashi 2010</LINK> administered Ca/Mg (850 mg/720 mg, respectively) before and after infusion of oxaliplatin or placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Diethyldithiocarbamate (DDTC)</HEADING>
<P>Our search identified only one article fulfilling the selection criteria and reporting the results of an RCT designed to evaluate the protective effects of DDTC against cisplatin neurotoxicity (<LINK REF="STD-Gandara-1995" TYPE="STUDY">Gandara 1995</LINK>). The trial included participants being treated with six courses of 100 mg/m² cisplatin every four weeks at 1.6 g/m²:</P>
<UL>
<LI>cisplatin for ovarian, small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC) (data available for 96 DDTC-treated participants and 99 control (placebo-treated) participants (<LINK REF="STD-Gandara-1995" TYPE="STUDY">Gandara 1995</LINK>).</LI>
</UL>
<P>DDTC, at 1.6 g/m², was administered 15 minutes before the start of cisplatin. In addition to cisplatin, other chemotherapies used were etoposide 100 mg/m² on days 1, 2, and 3 for SCLC and NSCLC, and cyclophosphamide 750 mg/m² for ovarian carcinoma as six courses every four weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Gluthathione (GSH)</HEADING>
<P>Our search identified seven articles fulfilling the selection criteria that reported the results of RCTs designed to evaluate the protective effects of GSH against platinum drugs (cisplatin and oxaliplatin) neurotoxicity. The seven prospective, randomised, and placebo-controlled studies included 193 GSH-treated participants and 194 control participants. The two platinum drugs used were cisplatin (153 and 155 respectively in each group and oxaliplatin (40 in the GSH group and 39 in the control group). The dose of cisplatin was variable (from 40 to 100 mg/m²) and oxaliplatin 100 mg/m² for every one to two weeks for three to nine weeks.</P>
<P>These trials included participants being treated with:</P>
<UL>
<LI>cisplatin for ovarian cancer (27 GSH-treated participants and 27 control participants) (<LINK REF="STD-Bogliun-1996" TYPE="STUDY">Bogliun 1996</LINK>);</LI>
<LI>cisplatin for ovarian cancer (25 GSH-treated participants and 25 control participants) (<LINK REF="STD-Cascinu-1995" TYPE="STUDY">Cascinu 1995</LINK>);</LI>
<LI>oxaliplatin for colorectal cancer (26 GSH-treated participants and 26 control participants) (<LINK REF="STD-Cascinu-2002" TYPE="STUDY">Cascinu 2002</LINK>);</LI>
<LI>cisplatin for relapsing ovarian cancer (16 GSH-treated participants and 17 control participants) (<LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK>);</LI>
<LI>oxaliplatin for colorectal cancer (14 GSH-treated participants and 13 control participants) (<LINK REF="STD-Milla-2009" TYPE="STUDY">Milla 2009</LINK>);</LI>
<LI>cisplatin for non-small cell lug cancer (NSCLC) and head and neck cancer (11 GSH-treated participants and 9 control participants) (<LINK REF="STD-Schmidinger-2000" TYPE="STUDY">Schmidinger 2000</LINK>); and</LI>
<LI>cisplatin for ovarian cancer (74 GSH-treated participants and 77 control participants) (<LINK REF="STD-Smyth-1997" TYPE="STUDY">Smyth 1997</LINK>).</LI>
</UL>
<P>The GSH dose was variable from 1.5 g/m² to 5 g before chemotherapy. The end points used were a toxicity score NCI/World Health Organization (WHO)) in all participants; functional scales (Hospital Anxiety and Depression (HAD) and Rotterdam scales) in 151 participants; Neuropathy Impairment Scale/Neuropathy Symptom Scale (NIS/NSS) in 54 participants; sensory nerve conduction studies (sural, median, or ulnar) in 156 participants; motor nerve conduction studies in 20 participants; and vibration perception threshold (VPT) testing in 54 participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Org 2766</HEADING>
<P>Our search identified four articles fulfilling the selection criteria and reporting the results of RCTs designed to evaluate the protective effects of Org 2766 against cisplatin neurotoxicity. The four trials included 188 Org 2766-treated participants and 123 control participants. These trials included participants being treated with:</P>
<UL>
<LI>cisplatin and cyclophosphamide for epithelial ovarian cancer (33 Org 2766-treated participants and 22 control participants) (<LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK>);</LI>
<LI>cisplatin and cyclophosphamide for epithelial ovarian cancer (7 Org 2766-treated and 11 control participants) (<LINK REF="STD-Hovestadt-1992" TYPE="STUDY">Hovestadt 1992</LINK>);</LI>
<LI>cisplatin and different combinations of etoposide, bleomicin and ifosphamide for testicular and adenocarcinoma of unknown primary (19 Org 2766-treated and 23 control participants) (<LINK REF="STD-van-Gerven-1994" TYPE="STUDY">van Gerven 1994</LINK>); and</LI>
<LI>cisplatin and cyclophosphamide for epithelial ovarian cancer (129 Org 2766-treated and 67 control participants) (<LINK REF="STD-Roberts-1997" TYPE="STUDY">Roberts 1997</LINK>).</LI>
</UL>
<P>The Org 2766 regimens largely varied among trials in the range 0.25 to 4.0 mg/kg. All participants randomised to the Org 2766 groups received subcutaneous Org 2766 before and one hour after cisplatin in one trial (<LINK REF="STD-Roberts-1997" TYPE="STUDY">Roberts 1997</LINK>), before and 24 hours after cisplatin in two trials (<LINK REF="STD-Hovestadt-1992" TYPE="STUDY">Hovestadt 1992</LINK>; <LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK>) and during the daily course of cisplatin administration in one trial (<LINK REF="STD-van-Gerven-1994" TYPE="STUDY">van Gerven 1994</LINK>). All trials involved scheduled treatments of up to nine cycles of chemotherapy, at three (<LINK REF="STD-Hovestadt-1992" TYPE="STUDY">Hovestadt 1992</LINK>; <LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK>; <LINK REF="STD-van-Gerven-1994" TYPE="STUDY">van Gerven 1994</LINK>) or three-to-four week intervals (<LINK REF="STD-Roberts-1997" TYPE="STUDY">Roberts 1997</LINK>). Cisplatin was administered at different doses/cycle: 75 mg/m² (<LINK REF="STD-Hovestadt-1992" TYPE="STUDY">Hovestadt 1992</LINK>; <LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK>), 75 to 100 mg/m² (<LINK REF="STD-Roberts-1997" TYPE="STUDY">Roberts 1997</LINK>) or 100 mg/m² (<LINK REF="STD-van-Gerven-1994" TYPE="STUDY">van Gerven 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oxcarbazepine (OXC)</HEADING>
<P>Our search identified one article fulfilling the selection criteria and designed to evaluate the protective effects of OXC against cisplatin neurotoxicity (<LINK REF="STD-Argyriou-2006a" TYPE="STUDY">Argyriou 2006a</LINK>). <LINK REF="STD-Argyriou-2006a" TYPE="STUDY">Argyriou 2006a</LINK> was prospective and randomised but without a placebo control arm (that is, control participants were untreated). The trial participants received:</P>
<UL>
<LI>cisplatin for colon cancer (1782 mg cumulative OXC-treated participants and 1750 mg cumulative control participants) (<LINK REF="STD-Argyriou-2006a" TYPE="STUDY">Argyriou 2006a</LINK>).</LI>
</UL>
<P>
<LINK REF="STD-Argyriou-2006a" TYPE="STUDY">Argyriou 2006a</LINK> included 40 patients being treated with cisplatin for colon cancer, of whom 20 were randomised to receive OXC, 600 mg twice a day, and 20 were randomised to receive no treatment. The cumulative oxaliplatin dose after 12 courses was similar in both groups (1782 mg OXC versus 1750 mg control). Ultimately, 16 participants in each group completed the trial, and data from the 32 participants were available for analysis. Neurological symptoms and neurophysiological testing (sural, superficial peroneal, and ulnar sensory nerve action potential (SNAP) and peroneal motor responses) were recorded at baseline and after 4, 8, and 12 courses of chemotherapy (that is, the last neurophysiological tests were performed at completion of 24 weeks of treatment).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Retinoic acid, all-<I>trans</I> (ATRA)</HEADING>
<P>Our search identified one article fulfilling the selection criteria and designed to evaluate the protective effects of ATRA against cisplatin neurotoxicity (<LINK REF="STD-Arrieta-2011" TYPE="STUDY">Arrieta 2011</LINK>). <LINK REF="STD-Arrieta-2011" TYPE="STUDY">Arrieta 2011</LINK> was a prospective, randomised, placebo-controlled study that included 92 participants being treated with cisplatin and paclitaxel for stage IIIB/IV NSCLC cancer, of whom 45 were randomised to receive ATRA, 20 mg/m²/day one week prior to chemotherapy until completion of two courses. The length of follow-up was only until immediately after the second course of therapy (three weeks). Motor and sensory response amplitudes were recorded, but the electrophysiological results were summarised as "grade of damage," ranked from zero to three for latency and amplitude measures. In addition, clinical examination results and NCI-CTC version 3.0 were recorded for each participant. The trial participants received:</P>
<UL>
<LI>cisplatin and paclitaxel for stage IIIB/IV NSCLC cancer (45 ATRA-treated participants and 47 control participants) (<LINK REF="STD-Arrieta-2011" TYPE="STUDY">Arrieta 2011</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Vitamin E</HEADING>
<P>Our original search identified only one article fulfilling the selection criteria of RCT to assess the protective effect of vitamin E against cisplatin neurotoxicity (<LINK REF="STD-Pace-2003" TYPE="STUDY">Pace 2003</LINK>). In that study, the cumulative cisplatin dose was &gt; 300 mg/m²<SUP> </SUP>(<LINK REF="STD-Pace-2003" TYPE="STUDY">Pace 2003</LINK>). Alpha tocopherol (vitamin E) was used at a dose of 300 mg/day starting before cisplatin and continuing up to three months after cisplatin treatment. Unmasked neurologists recorded neurological symptoms and signs and investigators performed neurophysiological testing (sural and median sensory nerves) at baseline, after three cycles, and after completion of chemotherapy. A cumulative toxicity score was assigned. The 2010 update identified a second trial of similar design (<LINK REF="STD-Argyriou-2006" TYPE="STUDY">Argyriou 2006</LINK>). <LINK REF="STD-Argyriou-2006" TYPE="STUDY">Argyriou 2006</LINK> included six courses of cisplatin chemotherapy in various doses. The treatment protocols in both studies were specific for the individual cancers, and all included chemotherapy drugs in addition to cisplatin. Of note, five participants with gastric cancer also received docetaxel, another potential neurotoxicant (two participants in the vitamin E group and three control participants). Thirty-five participants were enrolled; of whom 30 completed the trial. Of these, 14 participants received vitamin E (600 mg/day) starting before cisplatin and continuing up to three months after cisplatin treatment. Unmasked neurologists recorded neurological symptoms and signs and investigators performed neurophysiological testing (sural and median sensory nerves) at baseline, after three cycles, and after completion of chemotherapy. Both trials were prospective and randomised studies without a placebo control arm (control group participants were untreated). Both studies included participants being treated with cisplatin for various solid tumours (lung, ovarian, rhinopharynx, gastric, testicular, oesophagus, ethmoid, and tongue cancer). The 2010 update identified a third RCT involving the use of vitamin E (<LINK REF="STD-Pace-2010" TYPE="STUDY">Pace 2010</LINK>), but the substantial participant dropout rate prevented intention-to-treat analyses. The 2013 update identified one additional study, a randomised, double-blind, placebo-controlled trial investigating use of vitamin E among 189 evaluable participants with breast, lung, and other cancers being treated with cisplatin (8), carboplatin (2), oxaliplatin (50), taxanes (109), or combinations of each (20), with the inclusion of a large number of participants receiving taxanes confounding (<LINK REF="STD-Kottschade-2011" TYPE="STUDY">Kottschade 2011</LINK>). In this study, participants were randomly assigned to vitamin E (<I>d</I>l-alpha-tocopherol) 300 mg by mouth twice daily or matching placebo twice daily, initiated within four days of the first chemotherapy treatment and continued throughout and for one month beyond the last chemotherapy treatment (<LINK REF="STD-Kottschade-2011" TYPE="STUDY">Kottschade 2011</LINK>). The three trials included 130 vitamin E-treated participants and 134 control participants. These trials included participants being treated with:</P>
<UL>
<LI>cisplatin for various solid tumours (lung, ovarian, rhinopharyngeal, gastric, testicular, oesophagus, ethmoid, and tongue) (13 vitamin E-treated participants and 14 control participants) (<LINK REF="STD-Pace-2003" TYPE="STUDY">Pace 2003</LINK>);</LI>
<LI>cisplatin chemotherapy for various solid tumours (lung, ovarian, rhinopharyngeal, gastric, testicular, oesophagus, ethmoid, and tongue) (14 vitamin E-treated participants and 16 control participants) (<LINK REF="STD-Argyriou-2006" TYPE="STUDY">Argyriou 2006</LINK>); and</LI>
<LI>cisplatin (8), carboplatin (2), oxaliplatin (50), taxanes (109), or combinations of each (20) for the treatment of breast, lung, and other cancers (96 vitamin E-treated participants and 93 control participants) (<LINK REF="STD-Kottschade-2011" TYPE="STUDY">Kottschade 2011</LINK>).</LI>
</UL>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-02-19 12:18:00 +0000" MODIFIED_BY="Kate Jewitt">
<P>The 'Risk of bias' information for each study is summarised in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Acetylcysteine (N-acetylcysteine, NAC)</HEADING>
<P>The single trial of NAC had adequate baseline and follow-up NCI neurotoxicity assessment; although electrophysiological assessment, the nerve conduction study data, was only described qualitatively (<LINK REF="STD-Lin-2006" TYPE="STUDY">Lin 2006</LINK>), indicating no electrophysiological change in the NAC group without available data for the control group. The method of randomisation and of allocation concealment was unclear. It also was unclear whether the study was blinded to participants, investigators, or outcome assessors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Amifostine</HEADING>
<P>All seven trials had adequate baseline and follow-up assessments that occurred after completing chemotherapy within the intended zero to six-month window. All trials also included assessment following the last treatment cycle, with adequate follow-up to that point. Two trials included additional assessments up to three months after the last treatment cycle (<LINK REF="STD-Kemp-1996" TYPE="STUDY">Kemp 1996</LINK>; <LINK REF="STD-Planting-1999" TYPE="STUDY">Planting 1999</LINK>). The method of randomisation was deemed secure and allocation concealment at low risk of bias for two trials (<LINK REF="STD-Lorusso-2003" TYPE="STUDY">Lorusso 2003</LINK>; <LINK REF="STD-Lu-2008" TYPE="STUDY">Lu 2008</LINK>), but unclear for four trials. <LINK REF="STD-DeVos-2005" TYPE="STUDY">DeVos 2005</LINK> performed a phase II evaluation, with a control group that did not receive placebo, and participants received both carboplatin and taxanes. One additional trial was an open pilot study in which the participants were randomised and blinded but the control group did not receive placebo an the investigators were not blinded (<LINK REF="STD-Gallardo-1999" TYPE="STUDY">Gallardo 1999</LINK>). None of the trials clearly masked the participant or the observer, and only one study stated that the outcome assessor was blinded to the treatment group or to adverse events reported by the participant (<LINK REF="STD-Kemp-1996" TYPE="STUDY">Kemp 1996</LINK>). The adequacy of analyses was deemed at low risk of bias for four studies but unclear for one (<LINK REF="STD-Planting-1999" TYPE="STUDY">Planting 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Calcium and magnesium (Ca/Mg)</HEADING>
<P>The three trials had adequate baseline and follow-up assessments that occurred after completing chemotherapy within the intended zero to six month window, with assessment occurring immediately after the sixth treatment cycle (10 weeks). The method of randomisation was deemed secure, and allocation of concealment and subject, observer, and outcome assessor blinding appeared at low risk of bias. An unavoidable limitation of the <LINK REF="STD-Ishibashi-2010" TYPE="STUDY">Ishibashi 2010</LINK> study was that enrolment was discontinued after 33 participants were entered into the study because the interim analyses showed poorer results in the Ca/Mg group (early termination of enrolment). Similarly, the <LINK REF="STD-Chay-2010" TYPE="STUDY">Chay 2010</LINK> study was terminated prematurely because of reports of negative results from the CONcePT trial, and the <LINK REF="STD-Grothey-2011" TYPE="STUDY">Grothey 2011</LINK> study was terminated prematurely because of reports from another trial suggesting that Ca/Mg decreased treatment efficacy, data subsequently found to be incorrect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Diethyldithiocarabamate (DDTC)</HEADING>
<P>In the single DDTC study (<LINK REF="STD-Gandara-1995" TYPE="STUDY">Gandara 1995</LINK>), the methods of randomisation and allocation concealment were unclear, although we judged the participant blinding to be at low risk of bias. Observer and outcome assessor blinding were considered at low risk of bias. A large number of withdrawals for progressive disease or toxicity (40 in the intervention arm and 71 in the control arm) were noted.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Glutathione (GSH)</HEADING>
<P>All seven trials had adequate baseline and follow-up assessments that occurred after completing chemotherapy within the intended zero to six- month window. The method of randomisation was deemed secure, allocation concealment was also at low risk of bias, and blinding was done for participants and observers in three trials (<LINK REF="STD-Cascinu-1995" TYPE="STUDY">Cascinu 1995</LINK>; <LINK REF="STD-Cascinu-2002" TYPE="STUDY">Cascinu 2002</LINK>; <LINK REF="STD-Smyth-1997" TYPE="STUDY">Smyth 1997</LINK>), but not for the remaining three trials (<LINK REF="STD-Bogliun-1996" TYPE="STUDY">Bogliun 1996</LINK>; <LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK>; <LINK REF="STD-Milla-2009" TYPE="STUDY">Milla 2009</LINK>; <LINK REF="STD-Schmidinger-2000" TYPE="STUDY">Schmidinger 2000</LINK>). Outcome blinding was at low risk of bias for four trials (<LINK REF="STD-Bogliun-1996" TYPE="STUDY">Bogliun 1996</LINK>; <LINK REF="STD-Cascinu-1995" TYPE="STUDY">Cascinu 1995</LINK>; <LINK REF="STD-Cascinu-2002" TYPE="STUDY">Cascinu 2002</LINK>; <LINK REF="STD-Smyth-1997" TYPE="STUDY">Smyth 1997</LINK>), and unclear in the other three (<LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK>; <LINK REF="STD-Milla-2009" TYPE="STUDY">Milla 2009</LINK>; <LINK REF="STD-Schmidinger-2000" TYPE="STUDY">Schmidinger 2000</LINK>). The adequacy of analyses was deemed adequate for five studies (<LINK REF="STD-Bogliun-1996" TYPE="STUDY">Bogliun 1996</LINK>; <LINK REF="STD-Cascinu-1995" TYPE="STUDY">Cascinu 1995</LINK>; <LINK REF="STD-Cascinu-2002" TYPE="STUDY">Cascinu 2002</LINK>; <LINK REF="STD-Milla-2009" TYPE="STUDY">Milla 2009</LINK>; <LINK REF="STD-Smyth-1997" TYPE="STUDY">Smyth 1997</LINK>), and inadequate for two (<LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK>; <LINK REF="STD-Schmidinger-2000" TYPE="STUDY">Schmidinger 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Org 2766</HEADING>
<P>All four trials had adequate baseline and follow-up assessments that occurred after completing chemotherapy within the intended zero to six-month window. One trial (<LINK REF="STD-Hovestadt-1992" TYPE="STUDY">Hovestadt 1992</LINK>) included additional assessments up to 24 months after the last treatment cycle. The method of randomisation was deemed secure and allocation concealment at low risk of bias for one trial (<LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK>), but unclear for the remaining three trials. Participant and outcome assessor blinding was at low risk of bias in three trials (<LINK REF="STD-Hovestadt-1992" TYPE="STUDY">Hovestadt 1992</LINK>; <LINK REF="STD-Roberts-1997" TYPE="STUDY">Roberts 1997</LINK>; <LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK>), and unclear in one (<LINK REF="STD-van-Gerven-1994" TYPE="STUDY">van Gerven 1994</LINK>), while observer blinding was at low risk of bias in two trials (<LINK REF="STD-Roberts-1997" TYPE="STUDY">Roberts 1997</LINK>; <LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK>) and unclear in two (<LINK REF="STD-Hovestadt-1992" TYPE="STUDY">Hovestadt 1992</LINK>; <LINK REF="STD-van-Gerven-1994" TYPE="STUDY">van Gerven 1994</LINK>). The adequacy of analyses was deemed adequate for one study (<LINK REF="STD-Roberts-1997" TYPE="STUDY">Roberts 1997</LINK>), but unclear for two trials (<LINK REF="STD-Hovestadt-1992" TYPE="STUDY">Hovestadt 1992</LINK>; <LINK REF="STD-van-Gerven-1994" TYPE="STUDY">van Gerven 1994</LINK>), and inadequate for one (<LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oxcarbazepine (OXC)</HEADING>
<P>Out of 40 participants enrolled in the single OXC study (<LINK REF="STD-Argyriou-2006a" TYPE="STUDY">Argyriou 2006a</LINK>), eight dropped out (four in each arm), mainly for disease progression plus two for adverse symptoms related to OXC treatment. The specific method of randomisation was unclear, but the details were known only to the randomisation coordinator and concealed from the data analysts. Participants were not blinded, as this was an open label study. The dropout rate was not considered excessive, and the analyses were performed both on an intention-to-treat and completion-of-trial basis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Retinoic acid, all-<I>trans</I> (ATRA)</HEADING>
<P>There were no withdrawals and no participants were lost to follow-up. We deemed the risk for bias for all measures to be low.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Vitamin E</HEADING>
<P>Out of 47 participants enrolled in the initial vitamin E study (<LINK REF="STD-Pace-2003" TYPE="STUDY">Pace 2003</LINK>), 20 participants dropped out, mainly for disease progression. Twenty-seven participants, all of whom completed six cycles of cisplatin chemotherapy and received a cumulative dose of cisplatin greater than 300 mg/m², were available for analysis. Individual doses and combinations of chemotherapy varied. Methods of randomisation, allocation concealment, and blinding were unclear. Insufficient details were provided on withdrawals, dropouts, and losses to follow-up and we thought the analysis at unclear risk of bias in this respect. A modified total neuropathy scale was used, but this modified version is not a validated measure. In the second study (<LINK REF="STD-Argyriou-2006" TYPE="STUDY">Argyriou 2006</LINK>). Five of the 37 enrolled participants dropped out because of death or disease progression. Thirty participants completed the chemotherapy protocol; the mean total cisplatin dose was comparable in the vitamin E and control groups (120.6 ± 5.2 mg and 121.9 ± 3.4 mg, respectively). The precise randomisation method was not described but the allocation concealment appeared to be at low risk of bias, with details of the randomisations known only to the randomisation co-ordinator. In this open label study, the subjects were not blinded but those performing the evaluations were blinded, as were the outcome assessors. Out of 207 initial enrollees, there were 18 cancellations (7 ineligible and 11 withdrawals, mainly due to refusal of further treatment) (<LINK REF="STD-Kottschade-2011" TYPE="STUDY">Kottschade 2011</LINK>). One hundred and twenty-seven participants completed the study treatment protocol but a total of 189 participants completed a sufficient portion of the protocol to be available for the end point analyses. The study was a randomised, double-blind, placebo-controlled trial. Allocation concealment was not specifically described but there was no indication that it was inadequate. The inclusion of a large number of participants receiving taxanes was confounding.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-02-19 12:22:49 +0000" MODIFIED_BY="Kate Jewitt">
<P>The results of the review for each potential chemoprotective agent follow.</P>
<SUBSECTION>
<HEADING LEVEL="3">Acetylcysteine (N-acetylcysteine, NAC)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure</HEADING>
<P>No primary outcome measure was available in the single NAC study (<LINK REF="STD-Lin-2006" TYPE="STUDY">Lin 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(1) Nerve conduction measures of sensory response amplitudes</HEADING>
<P>Sensory (sural SNAP) amplitude, distal latency, and conduction velocity, and motor (median compound muscle action potential (CMAP)) amplitude, distal latency, conduction velocity, and F wave latency were measured at baseline and after 4, 8, and 12 cycles of chemotherapy. However, the data were only reported for the NAC group, indicating no significant deterioration over the full trial (something the authors attributed to NAC), without reporting similar data for the control group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(2) Clinical impairment on neurological examination using a validated scale</HEADING>
<P>A neurologist performed a complete neurological examination but the report does not provide the data, aside from noting (in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK>) that oxaliplatin-induced neurotoxicity is characterised by a rapid-onset acute sensory neuropathy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(3) Functional activities of daily living</HEADING>
<P>Not an outcome</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(4) Information from toxicity rating scales</HEADING>
<P>Toxicity due to possible sensory neuropathy was assessed every two weeks using the National Cancer Institute-Common Toxicity Criteria (NCI-CTC). After 12 cycles of treatment, the incidence of &#8805; Grade 1, 2, and 3 neurotoxicity was 80%, 20%, and 0% among the five participants in the NAC group, respectively, and 100%, 89%, and 33% in the nine participants in the control group (P = 0.01).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects attributed to the study intervention</HEADING>
<P>No adverse neurotoxicity was attributed to the NAC intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Details of other outcomes not specified in the protocol</HEADING>
<P>None described</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Amifostine</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure</HEADING>
<P>Quantitative sensory testing (QST) was used as an outcome measure in a single amifostine trial (<LINK REF="STD-Planting-1999" TYPE="STUDY">Planting 1999</LINK>), although only mean baseline and post-treatment values and non-parametric analyses were reported. This trial involved 74 participants with advanced neck cancer who were treated with six cycles of weekly cisplatin (70 mg/m²). Cisplatin neurotoxicity was measured by VPT recordings made from the second metatarsal bone of each hand (test of large sensory axons and receptors). An increased threshold indicates worsening sensory performance. Three measurements of the VPT (in &#956;m of skin displacement) were recorded for each hand and the mean taken as the VPT for each side. Participants receiving pretreatment with amifostine (740 mg/m²) prior to cisplatin administration (37 participants) showed significantly less subclinical neurotoxicity as measured by the VPT relative to control participants receiving cisplatin only (37 participants). Although the groups were similar in terms of most measures, a slightly smaller number of participants (borderline significant) in the amifostine group relative to the control group completed six cycles of cisplatin (20 versus 28; P = 0.07). The VPT analyses, which were based on participants in whom a three-month post-treatment VPT value was available, included 14 participants in the amifostine group and 20 participants in the control group. The mean VPT increased at three months compared to baseline values for both groups, but the increase was smaller for the amifostine group compared to the control group (left hand, 0.15 &#956;m versus 0.48 &#956;m, mean difference (MD) 0.33 &#956;m (95% CI -0.01 &#956;m to 0.67 &#956;m); right hand 0.18 &#956;m versus 0.40 &#956;m, MD 0.12 &#956;m (95% CI -0.03 &#956;m to 0.27 &#956;m). The authors explained that the borderline significant group difference for the right hand VPT reflected an imbalance at baseline for the groups and limited data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(1) Nerve conduction measures of sensory response amplitudes</HEADING>
<P>This secondary outcome measure was used in a single trial evaluating the protective effect of amifostine against neurotoxicity of carboplatin (area under the curve according to the Calvert formula) and paclitaxel (175 mg/m²) among participants with non-small cell lung cancer (<LINK REF="STD-Kanat-2003" TYPE="STUDY">Kanat 2003</LINK>). Chemotherapy-induced neurotoxicity was assessed by serial SNAPs recorded from the right sural, left ulnar, and right median sensory nerves. Evaluations were performed at baseline and immediately after the sixth cycle of treatment. Participants who received pretreatment with amifostine (910 mg/m²) prior to chemotherapy (19 participants) were compared to control participants who received chemotherapy only (19 participants). The mean SNAP amplitudes for both groups were comparable at baseline and also after six cycles of chemotherapy. There was no significant decline in the mean amplitudes for either group after treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(2) Clinical impairment on neurological examination using a validated scale</HEADING>
<P>There was no use of a uniform or standardised neurological examination scale among the studies, but several clinical scales were used that were based on descriptions of conventional neurological symptoms or signs. For example, in <LINK REF="STD-Planting-1999" TYPE="STUDY">Planting 1999</LINK>, clinical neurotoxicity "grade 1" developed in 4 of 37 participants in the cisplatin plus amifostine group and 5 of 37 participants in the cisplatin only group (risk ratio (RR) 0.80, 95% CI 0.23 to 2.75) (see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Conversely, paraesthesias "grade 2" (reflecting an adverse sensory symptom outcome) developed in 8 of 19 participants in the carboplatin and paclitaxel plus amifostine group compared to 18 of 19 in the carboplatin and paclitaxel only group (RR 0.59, 95% CI 0.36 to 0.98) in <LINK REF="STD-Kanat-2003" TYPE="STUDY">Kanat 2003</LINK>. Neurotoxicity as evaluated by a clinical examination and scored as "grade 3-4" (not further described) was reported among 93 participants receiving carboplatin and paclitaxel plus amifostine at any of the scheduled evaluations in 19 of 508 evaluations (3.7%) versus in 37 of 514 evaluations (7.2%) among participants receiving carboplatin and paclitaxel only (<LINK REF="STD-Lorusso-2003" TYPE="STUDY">Lorusso 2003</LINK>). Our review protocol was interested in results after treatment was completed. Data recorded after the last treatment cycle were not available in the Lorusso et al. article (<LINK REF="STD-Lorusso-2003" TYPE="STUDY">Lorusso 2003</LINK>), but, despite there being a similar proportion of subjects in each group who continued to show an adverse effect, the neurotoxicity comparisons for the last three cycles of chemotherapy no longer showed a substantial group difference (10 of 244 evaluations (4%) in the amifostine group and 23 of 245 evaluations (9%) in the control group). Furthermore, the paper reports the data as adverse neurotoxicity occurring during any of the treatment cycles and therefore includes multiple observations from individual participants, not independent observations, precluding further evaluation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(3) Functional activities of daily living</HEADING>
<P>Based on a sensorimotor neurotoxicity score, <LINK REF="STD-Kanat-2003" TYPE="STUDY">Kanat 2003</LINK> reported a minor ("grade 2") decrease in the activities of daily living (ADL) score in 2 of 19 participants in the carboplatin and paclitaxel plus amifostine group compared to 9 of 19 participants in the carboplatin and paclitaxel only group (RR of 0.22, 95% CI 0.06 to 0.90) (see <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(4) Information from toxicity rating scales</HEADING>
<P>
<LINK REF="STD-Kemp-1996" TYPE="STUDY">Kemp 1996</LINK> reported that the incidence of neurotoxicity, defined as symptoms of peripheral neuropathy or as a decrease in the neurological function daily activity score, was related to the cumulative dose of cisplatin among participants with ovarian cancer who were treated with cisplatin and cyclophosphamide. By treatment cycle five, there was a significant difference between the groups, favouring the amifostine group (P = 0.015). Following the last treatment cycle, the NCI-CTC neurologic toxicity rating (grades 0, 1, 2, or 3) was significantly reduced (P = 0.029) by pretreatment with amifostine (122 participants pre-treated with amifostine, 120 control participants). The risk of developing any level of neurotoxicity (grade 1, 2, or 3) was almost significantly reduced by pretreatment with amifostine relative to no treatment (RR of 0.81, 95% CI 0.66 to 1.00) (see data for Kemp 1996, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). None of the participants in the amifostine group but two of the participants in the control group discontinued cisplatin because of neurotoxicity. <LINK REF="STD-Lu-2008" TYPE="STUDY">Lu 2008</LINK> used the NCI-CTC (2.0) scale to evaluate neurotoxicity. The occurrence rate of an acute neurotoxicity during treatment was significantly lower in the amifostine group relative to the control (glutamine) group: 6.5% versus 95.7% (P &lt; 0.001). The occurrence rates of grade I&#8211;II and grade III&#8211;IV peripheral neurotoxicity after chemotherapy were significantly lower in amifostine group than in control group (10.9% versus 73.9%, P &lt; 0.001; 2.2% versus 19.6%, P = 0.007). The results at trial end were combined by grades 0, 1-2, and 3-4 and could not be evaluated using the more frequently used definition of neuropathy based on a &#8805; grade 2 rating. Nevertheless, after treatment cycle 6, the occurrence rates of all grades of neuropathy were significantly lower in the amifostine group relative to the control (glutamine) group: grade 0 (no neuropathy), 38 of 44 versus 6 of 43; grades 1-2, 6 of 44 versus 30 of 43; grade 3-4, 0 of 44 versus 7 of 43 (P &lt; 0.001) (See Lu 2008 data in <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). The incidence of acute cold paraesthesias was also lower in the intervention group than the control group. The frequency of regimen change because of chemotherapy-related neurotoxicity was significantly lower in the amifostine group than in the control group (4.3% versus 23.9%, P = 0.007). The overall response rates of evaluable participants were 44.4% in the amifostine group and 38.5% in the control group (P = 0.66). <LINK REF="STD-DeVos-2005" TYPE="STUDY">DeVos 2005</LINK> performed evaluations at the end of six cycles of chemotherapy using a subjective neuropathy-related symptom score (for which none of the items reached statistical significance) and the NCI-CTC neurotoxicity rating. Participants who experienced an NCI-CTC rating of &#8805; grade 2 at the end of six cycles (plus those terminated early because of neurotoxicity) included 7 of 45 participants in the amifostine group and 17 of 45 in the control group. Those who had a NCI-CTC grade 3 included 4 of 45 participants in the amifostine group and 5 of 45 control participants. <LINK REF="STD-Gallardo-1999" TYPE="STUDY">Gallardo 1999</LINK> used a neurotoxicity scale, presumably the NCI-CTC grading scale for neuropathy. That study included 20 participants with locally advanced, histologically diagnosed, cervical cancer to investigate the feasibility of five-day scheduling of amifostine with radiotherapy and cisplatin, randomised to receive amifostine (10 participants) or no amifostine (10 participants) before infusion of cisplatin.</P>
<P>A pooled analysis of the available data from four studies (<LINK REF="STD-DeVos-2005" TYPE="STUDY">DeVos 2005</LINK>; <LINK REF="STD-Kanat-2003" TYPE="STUDY">Kanat 2003</LINK>; <LINK REF="STD-Kemp-1996" TYPE="STUDY">Kemp 1996</LINK>; <LINK REF="STD-Lu-2008" TYPE="STUDY">Lu 2008</LINK>) was possible for the equivalent of NCI-CTC grades &#8805;1 (all grades of neuropathy). The pooled analysis showed a significantly reduced risk of developing any level of neurotoxicity favouring the amifostine group relative to the placebo group, with an RR of 0.66 (95% CI 0.57 to 0.76) (random-effects model because of substantial heterogeneity) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). A pooled analysis of the available data from three studies (<LINK REF="STD-DeVos-2005" TYPE="STUDY">DeVos 2005</LINK>; <LINK REF="STD-Gallardo-1999" TYPE="STUDY">Gallardo 1999</LINK>; <LINK REF="STD-Kanat-2003" TYPE="STUDY">Kanat 2003</LINK>) was possible for NCI-CTC grades &#8805;2. Despite use of slightly different versions of the NCI-CTC, inclusion of taxanes by <LINK REF="STD-DeVos-2005" TYPE="STUDY">DeVos 2005</LINK>, and slightly different evaluation times (e.g., end of the treatment cycle versus three months later), there was a significantly reduced risk favouring the amifostine group relative to the placebo group, showing an RR of 0.26 (95% CI 0.11 to 0.61) (random-effects model because of substantial heterogeneity) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). This analysis included a small number of participants (74 received amifostine) and included data from an open pilot study (<LINK REF="STD-Gallardo-1999" TYPE="STUDY">Gallardo 1999</LINK>), although similar results were found after exclusion of the Gallardo et al. study results. An additional pooled analysis of the available data from three studies was possible for the equivalent of NCI-CTC grades &#8805;3 (<LINK REF="STD-Kemp-1996" TYPE="STUDY">Kemp 1996</LINK>; <LINK REF="STD-Lu-2008" TYPE="STUDY">Lu 2008</LINK>; <LINK REF="STD-DeVos-2005" TYPE="STUDY">DeVos 2005</LINK>). Despite use of slightly different versions of the NCI-CTC and slightly different evaluation times (e.g., end of treatment cycle versus three months later), there was a non-significant reduced risk favouring the amifostine group relative to the placebo group, showing an RR of 0.54 (95% CI 0.2 to 1.29) (random-effects model because of substantial heterogeneity) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>, <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects attributed to the study intervention</HEADING>
<P>Hypotension occurred during 133 of 508 amifostine infusions (26%, 95% CI 23.5 to 23.8%) in <LINK REF="STD-Lorusso-2003" TYPE="STUDY">Lorusso 2003</LINK>. However, the degree of hypotension was generally mild and well tolerated and led to a reduction of the amifostine dose from 910 mg/m² to 740 mg/m² in subsequent cycles after only 18 of the 133 occurrences (14%). Similarly, <LINK REF="STD-Kanat-2003" TYPE="STUDY">Kanat 2003</LINK> reported that hypotension occurred in 5 of 19 participants (26%) during the first or second administration of amifostine; lowering the subsequent dose from 910 mg/m²<SUP> </SUP>to 740 mg/m² for these participants again eliminated the problem. In <LINK REF="STD-Planting-1999" TYPE="STUDY">Planting 1999</LINK>, hypotension was observed during amifostine infusion in 17 of 36 participants (47%) and in 45 out of 184 cycles (24%), despite use of a lower dose of amifostine (740 mg/m²) compared to the other three trials. The hypotension was described as grade 3 in two participants (three cycles) and grade 4 in three participants (four cycles), but considered to be of clinical relevance in only one participant. In <LINK REF="STD-Kemp-1996" TYPE="STUDY">Kemp 1996</LINK>, amifostine was well tolerated; the principal adverse side effect was a transient decrease in blood pressure observed in 75 of 122 (62%) of participants during amifostine administration. In addition, emesis occurred in 96% of participants in the amifostine group relative to 88% of participants in the control group. <LINK REF="STD-Lu-2008" TYPE="STUDY">Lu 2008</LINK> reported that the incidence of leucopenia, thrombocytopenia, and anaemia were all less in the amifostine group relative to the placebo group, but not significantly so. For grade 3-4 haemotoxicity, the occurrence rates of hypoleukaemia were 8.7% versus 17.4% in the amifostine versus placebo groups, respectively (P = 0.216). The incidence of transient hypotension was higher in the amifostine group (occurring in 4 of 46 participants during infusion). <LINK REF="STD-DeVos-2005" TYPE="STUDY">DeVos 2005</LINK> reported that nausea and vomiting occurred more frequently in participants receiving amifostine than in those not receiving amifostine (moderate nausea 21% versus 29%, and severe nausea 2% versus 6%, P = 0.007). Amifostine infusion was temporarily halted in five participants for 10 cycles due to hypotension (<LINK REF="STD-DeVos-2005" TYPE="STUDY">DeVos 2005</LINK>). Gallardo et al. reported that 1 of 10 amifostine-treated participants needed temporary interruption of amifostine due to hypotension, and 8 of 10 participants receiving amifostine developed hypocalcaemia during treatment (<LINK REF="STD-Gallardo-1999" TYPE="STUDY">Gallardo 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Details of other outcomes not specified in the protocol</HEADING>
<P>Progression of disease (ovarian cancer) was similar in the amifostine and control groups after an average of 24 months of follow-up (<LINK REF="STD-Lorusso-2003" TYPE="STUDY">Lorusso 2003</LINK>). Amifostine did not compromise the antitumour effect of cisplatin in the treatment of ovarian cancer (<LINK REF="STD-Kemp-1996" TYPE="STUDY">Kemp 1996</LINK>). However, amifostine also did not result in a higher dose intensity of cisplatin (<LINK REF="STD-Kemp-1996" TYPE="STUDY">Kemp 1996</LINK>; <LINK REF="STD-Planting-1999" TYPE="STUDY">Planting 1999</LINK>). Similarly, amifostine did not affect the response to oxaliplatin chemotherapy for digestive tract tumours (<LINK REF="STD-Lu-2008" TYPE="STUDY">Lu 2008</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Calcium and magnesium (Ca/Mg)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure</HEADING>
<P>No primary outcome measure was available in the any of the Ca/Mg studies (<LINK REF="STD-Chay-2010" TYPE="STUDY">Chay 2010</LINK>; <LINK REF="STD-Grothey-2011" TYPE="STUDY">Grothey 2011</LINK>; <LINK REF="STD-Ishibashi-2010" TYPE="STUDY">Ishibashi 2010</LINK>; <LINK REF="STD-Knijn-2011" TYPE="STUDY">Knijn 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(1) Nerve conduction measures of sensory response amplitudes</HEADING>
<P>SNAP amplitudes were measured in the <LINK REF="STD-Chay-2010" TYPE="STUDY">Chay 2010</LINK> study, but the results were reported as "abnormal" if each of the nerve conduction study measures was outside the normal values for their laboratory controls. At the end of treatment, six of seven participants receiving Ca/Mg compared to zero of nine participants receiving placebo experienced neuropathy, indicating that the treatment group had worse objective scores relative to the placebo group (RR 16.25, 95% CI 1.07 to 247.19) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(2) Clinical impairment on neurological examination using a validated scale</HEADING>
<P>Not reported, aside from mention by <LINK REF="STD-Grothey-2011" TYPE="STUDY">Grothey 2011</LINK> that acute muscle spasms associated with oxaliplatin were significantly reduced (P &lt; 0.01)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(3) Functional activities of daily living</HEADING>
<P>Not reported</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(4) Information from toxicity rating scales</HEADING>
<P>The NCI-CTC and Debiopharm Neurotoxicity Scale (DEB-NTS) were used to asses the development and severity of neurotoxicity in the <LINK REF="STD-Ishibashi-2010" TYPE="STUDY">Ishibashi 2010</LINK> study. According to the NCI-CTC criteria after six cycles of treatment, the incidence of &#8805; Grade 1, 2, and 3 neurotoxicity were 100%, 6%, and 6% in the Ca/Mg group, respectively, and 94%, 6%, and 0% in the control group, there being no significant difference between groups. Similarly, according to the DEB-NTS criteria after six cycles of treatment, the incidence of &#8805; Grade 1, 2, and 3 neurotoxicity was 100%, 71%, and 6% in the Ca/Mg group, respectively, and 94%, 56%, and 0% in the control group, there being no significant difference between groups. The authors did not comment on the acute neuropathy symptoms. <LINK REF="STD-Chay-2010" TYPE="STUDY">Chay 2010</LINK> included an acute subjective sensory neuropathy rating using the NCI-CTC (grades 0, 1, 2, or 3) during and at the end of treatment. Overall, the subjective neuropathy rate was 77% in the Ca/Mg group and 86% in the placebo group (P = 0.6). At the end of treatment, three participants receiving Ca/Mg and none receiving placebo reported grade 3 numbness (P = 0.02). Assessment of grade 3 toxicity favoured the placebo group but not significantly (P = 0.09), with no significant treatment group difference for dysaesthesias or time to onset of neuropathy. <LINK REF="STD-Grothey-2011" TYPE="STUDY">Grothey 2011</LINK> included a subjective cumulative sensory neurotoxicity (sNT) rating (grade &#8805;2 endpoint), the oxaliplatin-specific sNT. In the 102 participants available for analysis, Ca/Mg decreased the incidence of sNT &#8805; grade 2 on the oxaliplatin-specific sNT scale (RR 0.56, 95% CI 0.33 to 0.94) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>), representing a significant minor effect. No effect on acute, cold-induced sNT was found.</P>
<P>The pooled results from the three available studies reporting NCI-CTC neuropathy &#8805; grade 2 neurotoxicity at the end of chemotherapy showed no significant risk reduction associated with the use of Ca/Mg (<LINK REF="STD-Chay-2010" TYPE="STUDY">Chay 2010</LINK>; <LINK REF="STD-Grothey-2011" TYPE="STUDY">Grothey 2011</LINK>; <LINK REF="STD-Ishibashi-2010" TYPE="STUDY">Ishibashi 2010</LINK>), RR 0.84 (95% CI 0.44 to 1.60, random-effects model) (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>, <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects attributed to the study intervention</HEADING>
<P>No adverse neurotoxicity was attributed to the Ca/Mg intervention (<LINK REF="STD-Chay-2010" TYPE="STUDY">Chay 2010</LINK>; <LINK REF="STD-Grothey-2011" TYPE="STUDY">Grothey 2011</LINK>; <LINK REF="STD-Ishibashi-2010" TYPE="STUDY">Ishibashi 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Details of other outcomes not specified in the protocol</HEADING>
<P>The authors in <LINK REF="STD-Ishibashi-2010" TYPE="STUDY">Ishibashi 2010</LINK> reported in their final analyses that Ca/Mg infusions did not influence antitumour activity among participants. However, their interim analyses had indicated that "the results of treatment were poor" in the Ca/Mg group relative to the control group, resulting in discontinuation of subsequent enrolment. The authors of <LINK REF="STD-Chay-2010" TYPE="STUDY">Chay 2010</LINK> concluded that Ca/Mg infusions failed to reduce the rate of oxaliplatin-induced acute and cumulative sensory neuropathy, although there appeared to be a trend toward a benefit in the patient&#8217;s perception of numbness during chemotherapy, a perception that was not supported by the authors' nerve conduction findings.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Diethyldithiocarabamate (DDTC)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure</HEADING>
<P>No primary outcome measure was available in the single DDTC study (<LINK REF="STD-Gandara-1995" TYPE="STUDY">Gandara 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(1) Nerve conduction measures of sensory response amplitudes</HEADING>
<P>SNAP amplitudes were not measured.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(2) Clinical impairment on neurological examination using a validated scale</HEADING>
<P>Not reported</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(3) Functional activities of daily living</HEADING>
<P>Not reported</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(4) Information from toxicity rating scales</HEADING>
<P>NCI toxicity rating scale showed 13 of 96 participants (13%) in the DDTC arm and 12 of 99 participants (12%) in the control group developed neuropathy (RR 1.12, 95% CI 0.54 to 2.32) (see <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects attributed to the study intervention</HEADING>
<P>Adverse effects were reported in all study participants, with severe adverse events in 27 control group participants and 30 participants in the DDTC group. Twenty-two participants in the DDTC group and nine in control group withdrew because of toxicity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Details of other outcomes not specified in the protocol</HEADING>
<P>None described</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Glutathione (GSH)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure</HEADING>
<P>QST was used as an outcome measure in only one study (<LINK REF="STD-Bogliun-1996" TYPE="STUDY">Bogliun 1996</LINK>). Although the manuscript does not state the site of recording the VPT, a two- to three-fold increase in vibratory threshold occurred in the GSH group versus a seven- to 10-fold increase in the control group three months after chemotherapy. One of the Cochrane authors (GC) who is a co-author on this paper was able to retrieve the original information as follows. QST, measured at cisplatin doses of 50 mg/m²<SUP> </SUP>and 75 mg/m², changed from baseline to end of induction to end of consolidation from approximately 1.5 to 1.6 and 4.1 respectively in the GSH group, and changed from approximately 1.6 to 8.3 and 9.4 respectively in the control group. No additional information was available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(1) Nerve conduction measures of sensory response amplitudes</HEADING>
<P>Sural SNAP amplitude decreased by a greater amount in the control arm than in the GSH arm (58% to 68% controls versus 12% to 35% GSH) among participants receiving &lt; 150 mg/m² or &gt; 150 mg/m², respectively (<LINK REF="STD-Bogliun-1996" TYPE="STUDY">Bogliun 1996</LINK>). Similarly, <LINK REF="STD-Cascinu-1995" TYPE="STUDY">Cascinu 1995</LINK> documented a significant reduction of sural, median, and ulnar SNAP amplitudes in the control group versus the GSH arm. At week 15, the sural SNAP decreased from 13.3 ± 4.1 µv to 8.0 ± 1.68 µv in the control arm (n = 18) and from 10.8 ± 5.84 µv to 9.0 ± 6.48 µv in the GSH arm (n = 24). Median and ulnar SNAP amplitudes also reduced by significant amounts only in the control groups. In the oxaliplatin trial, the sural amplitude decreased in the placebo group (n = 8) from 11.0 ± 6.92 µv to 7.20 ± 5.05 µv in the placebo arm (P = 0.05) but did not change in the GSH group (n = 10) (9.1 ± 6.34 µv to 8.7 ± 5.50 µv; P = non-significant) after eight cycles of therapy (<LINK REF="STD-Cascinu-2002" TYPE="STUDY">Cascinu 2002</LINK>). <LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK> recorded sensory responses at baseline and at examination end, after nine weeks of weekly chemotherapy. The sural SNAP amplitude changed from 13.2 ± 8.5 µv to 7.6 ± 3.3 µv in the placebo group (n = 16) and from 13.1 ± 8.2 µv to 9.7 ± 5.9 µv in the GSH group (n = 15). A combined group analysis of post-treatment scores produced a MD in favour of GSH, with 95% CIs that allowed the possibility of no effect (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>).</P>
<P>No SNAP amplitudes were measures in the other studies (<LINK REF="STD-Bogliun-1996" TYPE="STUDY">Bogliun 1996</LINK>; <LINK REF="STD-Cascinu-2002" TYPE="STUDY">Cascinu 2002</LINK>; <LINK REF="STD-Milla-2009" TYPE="STUDY">Milla 2009</LINK>; <LINK REF="STD-Schmidinger-2000" TYPE="STUDY">Schmidinger 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(2) Clinical impairment on neurological examination using a validated scale</HEADING>
<P>At three months post chemotherapy, 5 of 19 participants in the GSH group and 8 of 16 in the control group changed in their neurological disability score (NDS) by more than 12 points (RR 0.53, 95% CI 0.21 to 1.29) (see <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>) (<LINK REF="STD-Bogliun-1996" TYPE="STUDY">Bogliun 1996</LINK>). In the same study, the neuropathy symptom score (NSS) developed in 14 of 19 participants in the GSH arm and all 16 participants in the control group (RR 0.75, 95% CI 0.56 to 0.99) (see <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>). After nine weeks of chemotherapy, at study end, <LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK> reported that 2 of 16 GSH participants and 4 of 15 placebo participants became symptomatic for sensory neuropathy (<LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>). The pooled results from the <LINK REF="STD-Bogliun-1996" TYPE="STUDY">Bogliun 1996</LINK> and <LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK> data showed a borderline significant decreased risk of developing neuropathy based on the NSS favouring the GSH group relative to the control group (RR 0.69, 95% CI 0.50 to 0.97) (<LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>). <LINK REF="STD-Colombo-1995" TYPE="STUDY">Colombo 1995</LINK> performed clinical neurological examinations but did not use a validated scale; <LINK REF="STD-Schmidinger-2000" TYPE="STUDY">Schmidinger 2000</LINK> also performed clinical neurological examinations and, although the investigators did not use a validated scale, they found no cases of peripheral neuropathy in either the GSH or the control group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(3) Functional activities of daily living</HEADING>
<P>Participants who received GSH reported an improvement in their quality of life. They also reported significantly less tingling in hands and feet and GSH allowed more cycles of cisplatin to be administered because of less toxicity (<LINK REF="STD-Smyth-1997" TYPE="STUDY">Smyth 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(4) Information from toxicity rating scales</HEADING>
<P>
<LINK REF="STD-Bogliun-1996" TYPE="STUDY">Bogliun 1996</LINK> assessed the NSS (symptoms) and NDS (signs) neuropathy scores, indicating a trend toward less severe neurotoxicity after cotreatment with GSH, although neuroprotection was not complete. Four of 24 participants in the GSH group developed neurotoxicity (3 grade I and 1 grade II by WHO criteria) and 16 of 18 in the control group (3 grade I; 10 grade II; 2 grade III and 1 grade IV) developed neuropathy by WHO neurotoxicity grade criteria (RR 0.19, 95% CI 0.08 to 0.47) (see <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>) (<LINK REF="STD-Cascinu-1995" TYPE="STUDY">Cascinu 1995</LINK>). Grade 3 or 4 neurotoxicity by NCI-CTC grading was seen in 0 of 21 participants at 8 weeks and 1 of 10 participants at 12 weeks in the GSH group and in 5 of 18 participants at 8 weeks and 6 of 8 participants at 12 weeks in the control group (RR 0.13, 95% CI 0.02 to 0.89) (see <LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>) (<LINK REF="STD-Cascinu-2002" TYPE="STUDY">Cascinu 2002</LINK>). In <LINK REF="STD-Schmidinger-2000" TYPE="STUDY">Schmidinger 2000</LINK>, no change in WHO toxicity was noted in either the GSH or the control group, although the authors noted that no finding of peripheral neuropathy was observed in any of their participants. In <LINK REF="STD-Smyth-1997" TYPE="STUDY">Smyth 1997</LINK> after six cycles, neuropathy (NCI-CTC) was seen in 39% of participants (24 grade 1, and 5 grade 2) in the GSH group and 49% of participants in the control group (32 grade 1, 4 grade 2, and 2 grade 3). Mean increase in Hospital Anxiety and Depression functional score was 0.8 in the GSH arm and 2.5 in the control arm. In addition, 45 of 47 had better Rotterdam scores in the GSH group. In <LINK REF="STD-Milla-2009" TYPE="STUDY">Milla 2009</LINK>, neurologic adverse effects were assessed using the neurosensory section of the NCI-CTC, version 3. At the end of treatment, only moderate neurotoxicity was reported in the GSH arm (50% grade 1 and 50% grade 2), whereas in the placebo arm the neurotoxicity was more severe (69% grade 2 and 31% grade 3), a difference considered statistically significant (Mann-Whitney test; P = 0.0037).</P>
<P>Three trials utilised WHO or NCI-CTC grade &#8805;2 neurotoxicity at end of treatment (the most frequently used subjective measure of neuropathy in available studies) after 12 cycles of oxaliplatin (<LINK REF="STD-Cascinu-1995" TYPE="STUDY">Cascinu 1995</LINK>; <LINK REF="STD-Cascinu-2002" TYPE="STUDY">Cascinu 2002</LINK>; <LINK REF="STD-Milla-2009" TYPE="STUDY">Milla 2009</LINK>). The pooled data significantly favoured the GSH group relative to the placebo group and showing a protective RR of 0.29 (95% CI 0.10 to 0.85, random-effects model) (see <LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>, <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). Although all three studies showed a favourable effect using this subjective rating, the data showed substantial heterogeneity (I<SUP>2</SUP> = 73%) and the studies that contributed data to the combined analysis involved a small number of participants (11 of 48 participants receiving GSH showing &#8805;2 neurotoxicity relative to 34 of 39 control participants showing a similar grade of neurotoxicity).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Details of other outcomes not specified in the protocol</HEADING>
<P>Oliguria occurred in 21 of 27 participants in cisplatin alone and 10 of 27 participants in the cisplatin with GSH group (RR 0.48, 95% CI 0.28 to 0.81) (see <LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>) (<LINK REF="STD-Bogliun-1996" TYPE="STUDY">Bogliun 1996</LINK>). Participants in the GSH group also required fewer haemotransfusions and showed fewer incidences of thrombocytopenia and anaemia than did participants in the control group (<LINK REF="STD-Cascinu-1995" TYPE="STUDY">Cascinu 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects attributed to the study intervention</HEADING>
<P>None described</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Details of other outcomes not specified in the protocol</HEADING>
<P>None described</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Org 2766</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure</HEADING>
<P>QST was used as an outcome measure in all four trials. Cisplatin neurotoxicity was measured by VPT recordings made from the second metacarpal bone of each hand (<LINK REF="STD-Hovestadt-1992" TYPE="STUDY">Hovestadt 1992</LINK>; <LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK>; <LINK REF="STD-van-Gerven-1994" TYPE="STUDY">van Gerven 1994</LINK>), or from the index finger and great toe (<LINK REF="STD-Roberts-1997" TYPE="STUDY">Roberts 1997</LINK>). An increased threshold indicates worsening sensory performance. Three measurements of the VPT (in &#956;m of skin displacement) were recorded for each hand and the mean taken as the VPT for each side in one study (<LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK>). Two trials (<LINK REF="STD-Hovestadt-1992" TYPE="STUDY">Hovestadt 1992</LINK>; <LINK REF="STD-van-Gerven-1994" TYPE="STUDY">van Gerven 1994</LINK>) referred to <LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK> in describing their methodology, but that study did not provide a clear description of the method actually used. The final study did not report details of the QST methodology used (<LINK REF="STD-Roberts-1997" TYPE="STUDY">Roberts 1997</LINK>).</P>
<P>Participants receiving treatment with Org 2766 1 mg/m² (n = 16) before and 24 hours after cisplatin administration showed significantly less increase in the VPT than did the 22 placebo-treated participants (mean value after 4th cycle 0.50 &#956;m versus 1.61 &#956;m, P &lt; 0.005; mean value after 6th cycle 0.88 &#956;m versus 5.87 &#956;m, P &lt; 0.005) in <LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK>. In the same study, the administration of Org 2766 at the dose of 0.25 mg/kg had no effect. In <LINK REF="STD-Hovestadt-1992" TYPE="STUDY">Hovestadt 1992</LINK>, only an exploratory, descriptive statistical analysis without formal tests for significance was performed, due to the low number of participants enrolled in the study (seven in the placebo group, five treated with Org 2766 at the dose of 0.25 mg/kg and six at the dose of 1 mg/kg). Mean values in placebo-treated participants were higher than in the low- and high-dose Org 2766-treated participants one month after cisplatin treatment (mean 3.7 versus 2.9 versus 1.1 &#956;m, respectively), intermediate one to four months after treatment (8.1 versus 14.6 versus 2.5 &#956;m), and higher again after 4 to 12 and 12 to 24 months (4.8 versus 3.6 versus 2.0 &#956;m, and 2.9 versus 0.6 versus 0.8 &#956;m). However, the number of evaluable participants decreased markedly during the study and the final evaluation included only nine participants (for whom no indication about treatment is available). <LINK REF="STD-van-Gerven-1994" TYPE="STUDY">van Gerven 1994</LINK> reported VPT changes after the fourth cycle and three to five months later. Mean values obtained after the fourth cycle (0.95 &#956;m in the placebo group versus 0.45 &#956;m in the Org 2766-treated group, number of participants nine versus six respectively) and three to five months later (4.03 versus 1.85 &#956;m, number of participants 12 versus eight) were statistically compared with two different methods: the difference in slopes between Org 2766 and placebo-treated groups was significant by ANOVA (P value = 0.04), but not by Wilcoxon's rank sum test (P = 0.06). In that study, VPTs became abnormal three to five months after treatment in nine out of 12 placebo-treated participants and in four of the eight participants treated with Org 2766 (RR 0.67, 95% CI 0.31 to 1.43) (see <LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK>). In <LINK REF="STD-Roberts-1997" TYPE="STUDY">Roberts 1997</LINK>, VPT was assessed separately for the index finger and for the great toe. After the blind was broken, 174 participants (59 in the placebo group, 52 in the 2 mg/kg Org 2766 group, and 57 in the 4 mg/kg Org 2766 group) were evaluable. At each time point (i.e., at each cisplatin cycle up to six courses and monthly for three months after treatment withdrawal) no difference was observed between groups. The four Org 2799 studies all performed QST and evaluated our primary outcome measure, VPT. Three of the trials (<LINK REF="STD-Roberts-1997" TYPE="STUDY">Roberts 1997</LINK>; <LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK>; <LINK REF="STD-van-Gerven-1994" TYPE="STUDY">van Gerven 1994</LINK>), measured VPT at the index finger or hand, and evaluated comparable doses of Org 2766 (1 mg or 2 mg). Based on comparison of the Org 2766 treatment and placebo groups at three to five months, the combined data from the three trials showed no significant group difference at the follow-up QST examination (MD -1.77 &#956;m, 95% CI -4.78 to 1.23 &#956;m, random-effects model) (see <LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(1) Nerve conduction measures of sensory response amplitudes</HEADING>
<P>This secondary outcome measure was not used in any of the selected trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(2) Clinical impairment on neurological examination using a validated scale</HEADING>
<P>There was no use of a uniform or standardised neurological examination scale among the studies, but clinical scales were used that were based on descriptions of conventional neurological symptoms or signs. In one trial (<LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK>) neurological examination was based on a series of signs and symptoms evaluated after four and six chemotherapy courses, resulting in a "sum score." Using this score a difference was observed only for the high dose Org 2766 treatment at the evaluation performed after the 6th course versus the placebo-treated participants (P = 0.03). Two other trials used non-validated neurological scales and the authors performed no statistical comparison (<LINK REF="STD-Hovestadt-1992" TYPE="STUDY">Hovestadt 1992</LINK>; <LINK REF="STD-van-Gerven-1994" TYPE="STUDY">van Gerven 1994</LINK>). <LINK REF="STD-Roberts-1997" TYPE="STUDY">Roberts 1997</LINK> stated that neurological evaluation was used to assess inclusion/exclusion criteria, but provided no data about the severity of the neuropathy. In this trial, repeated neurological examinations failed to demonstrate any significant difference between Org 2766- and placebo-treated participants up to three months after cisplatin treatment withdrawal.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(3) Functional activities of daily living</HEADING>
<P>This secondary outcome measure was not used in any of the selected trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(4) Information from toxicity rating scales</HEADING>
<P>In one study (<LINK REF="STD-van-Gerven-1994" TYPE="STUDY">van Gerven 1994</LINK>), authors reported that two participants in the placebo group and one in the Org 2766 group discontinued cisplatin treatment because of peripheral neurotoxicity (P = not significant). The other three trials reported no details about neurotoxicity-induced treatment withdrawal.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects attributed to the study intervention</HEADING>
<P>No adverse effects were attributed to Org 2766 in any trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Details of other outcomes not specified in the protocol</HEADING>
<P>Progression of disease (ovarian cancer) was similar in the Org 2766 and control groups after an average of 24 months of follow-up (<LINK REF="STD-Roberts-1997" TYPE="STUDY">Roberts 1997</LINK>). Org 2766 did not compromise the antitumour effect of cisplatin in the treatment of ovarian cancer (<LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oxcarbazepine (OXC)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure</HEADING>
<P>QST was not used as a primary outcome measure in the single OXC study available (<LINK REF="STD-Argyriou-2006a" TYPE="STUDY">Argyriou 2006a</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(1) Nerve conduction measures of sensory response amplitudes</HEADING>
<P>This secondary outcome measure was reported for sural, superficial peroneal, and ulnar SNAP amplitudes. A modest but significant decline in SNAP amplitude pre- to post- treatment was reported for the control group relative to the OXC group for the sural nerve (14.5 ± 6.1 to 8.3 ± 6.1 µv versus 13 ± 6.8 to 11.5 ± 7.1 µv) and superficial peroneal nerve (9.2 ± 3.2 to 6.8 ± 4.8 µv versus 9.3 ± 4.0 to 8.8 ± 4.4 µv) but not for the ulnar nerve (9.9 ± 3.4 to 7.0 ± 4.3 µv versus 9.5 ± 4.2 to 8.2 ± 4.3 µv ) (or for ulnar or peroneal motor amplitudes; motor nerves not thought to be affected by oxaliplatin) (<LINK REF="STD-Argyriou-2006a" TYPE="STUDY">Argyriou 2006a</LINK>). However, group comparisons of SNAP amplitudes at post-treatment (at six months, after 24 cycles) showed no significant differences (<LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>, <LINK REF="CMP-016.02" TYPE="ANALYSIS">Analysis 16.2</LINK>, <LINK REF="CMP-016.03" TYPE="ANALYSIS">Analysis 16.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(2) Clinical impairment on neurological examination using a validated scale</HEADING>
<P>Based on a NSS and the NDS, the incidence of oxaliplatin-induced neuropathy was decreased among those who completed the trial in the OXC group relative to the control group (five of 16 versus 12 of 16) (RR 0.42, 95% CI 0.19 to 0.91) (see <LINK REF="CMP-017.01" TYPE="ANALYSIS">Analysis 17.1</LINK>), and the between-group comparisons of the NSS (0.6 ± 0.9 versus 1.5 ± 1.3) and NDS (5 ± 8.2 versus 20.0 ± 23.1) differed significantly, both favouring the OXC group. Also, the severity of oxaliplatin-induced neuropathy was significantly lower in the OXC group versus controls, based on the total neuropathy scores (MD -7.10, 95% CI -11.98 to -2.22) (see <LINK REF="CMP-017.02" TYPE="ANALYSIS">Analysis 17.2</LINK>). None of the participants receiving OXC reported negative sensory symptoms versus three controls; five participants receiving OXC reported positive sensory symptoms versus 12 controls.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(3) Functional activities of daily living</HEADING>
<P>This secondary outcome measure was not used in the selected trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(4) Information from toxicity rating scales</HEADING>
<P>None described</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects attributed to the study intervention</HEADING>
<P>Adverse chemotherapy effects were described but none was attributed to OXC (there was a similar frequency in both groups).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Details of other outcomes not specified in the protocol</HEADING>
<P>None reported</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Retinoic acid</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure</HEADING>
<P>QST was not performed in <LINK REF="STD-Arrieta-2011" TYPE="STUDY">Arrieta 2011</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(1) Nerve conduction measures of sensory response amplitudes</HEADING>
<P>
<LINK REF="STD-Arrieta-2011" TYPE="STUDY">Arrieta 2011</LINK> utilised nerve conduction study results summarised by converting the quantitative results to a non-parametric zero to three ranking of "damage," summated for latency and amplitude measures. These electrophysiological results were not separated into their motor and sensory components, something physiologically nonsensical. Significant deterioration was reported for the summated sensory response amplitude only for the placebo group, but this group demonstrated worse function relative to the intervention group at baseline. Baseline differences between the intervention and control groups are troublesome and not explained. Also, the period of evaluation (i.e. six weeks to the end of the second course of chemotherapy) was likely to have been inadequate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(2) Clinical impairment on neurological examination using a validated scale</HEADING>
<P>No validated scale of clinical impairment on neurological examination was measured (<LINK REF="STD-Arrieta-2011" TYPE="STUDY">Arrieta 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(3) Functional activities of daily living</HEADING>
<P>
<LINK REF="STD-Arrieta-2011" TYPE="STUDY">Arrieta 2011</LINK> did not measure any functional ADL.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(4) Information from toxicity rating scales</HEADING>
<P>
<LINK REF="STD-Arrieta-2011" TYPE="STUDY">Arrieta 2011</LINK> utilised the NCI-CTC rating scale for assessment of neuropathy. NCI-CTC neuropathy grades &#8805;2 were present in 23 of 45 ATRA participants and in 37 of 47 placebo participants (RR 0.75, 95% CI 0.55 to 1.02) (<LINK REF="CMP-018.01" TYPE="ANALYSIS">Analysis 18.1</LINK>). As noted previously, the period of evaluation (i.e., six weeks to the end of second course of chemotherapy) was likely to have been inadequate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects attributed to the study intervention</HEADING>
<P>Five of 45 participants in the intervention group but no participants in the control group developed hypertriglyceridaemia grade 3 and 4 (<LINK REF="STD-Arrieta-2011" TYPE="STUDY">Arrieta 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Details of other outcomes not specified in the protocol</HEADING>
<P>None described</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Vitamin E</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure</HEADING>
<P>QST was not performed in any of the vitamin E studies (<LINK REF="STD-Argyriou-2006" TYPE="STUDY">Argyriou 2006</LINK>; <LINK REF="STD-Kottschade-2011" TYPE="STUDY">Kottschade 2011</LINK>; <LINK REF="STD-Pace-2003" TYPE="STUDY">Pace 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(1) Nerve conduction measures of sensory response amplitudes</HEADING>
<P>In <LINK REF="STD-Pace-2003" TYPE="STUDY">Pace 2003</LINK>, after six cycles of treatment, four of 13 participants in the vitamin E group had at least one abnormal finding among the median sensory or sural sensory amplitude, whereas 11 of 14 participants in the control group had at least one abnormal amplitude (RR 0.39, 95% CI 0.17 to 0.93) (see <LINK REF="CMP-019.01" TYPE="ANALYSIS">Analysis 19.1</LINK>). Nerve conduction measures of sensory response amplitudes showed that the median SNAP amplitudes were reduced by a lesser degree in those taking vitamin E relative to control participants (vitamin E group: baseline 15.1 ± 9.2 µv, six months later 12.0 ± 0.6 [sic] µv; control group: baseline 15.0 ± 9.2 µv, six months later 8.7 ± 5.3 µv (P &lt; 0.01)). By comparison, the sural amplitudes showed little effect of vitamin E (vitamin E group: baseline 15.5 ± 6.3 µv, six months later 13.7 ± 5.5 µv; control group: baseline 14.5 ± 8.5 µv, six months later 13.6 ± 9.2 µv, P = not significant). In the second vitamin E trial (<LINK REF="STD-Argyriou-2006" TYPE="STUDY">Argyriou 2006</LINK>), after six cycles of treatment and three months after treatment ended, all SNAP amplitudes (sural, superficial peroneal, and ulnar) had deteriorated, although the change from baseline was significantly less in the vitamin E group relative to controls. In contrast, the peroneal and ulnar motor amplitudes and conduction velocities showed no significant group differences in terms of change from baseline as reported in the trial report. However, group comparisons of the SNAP amplitudes at post-treatment (at end of treatment and three months later) showed no significant differences, although the comparison of the superficial peroneal SNAP amplitude for the vitamin E and control groups showed slightly better performance for the vitamin E group at the end of treatment (8.5 ± 6.6 versus 4.9 ± 3.6 µv; P = 0.07; MD 3.60 µv, 95% CI -0.35 to 7.55 µv), although the CIs just allowed the possibility of no effect (<LINK REF="CMP-020.01" TYPE="ANALYSIS">Analysis 20.1</LINK>). There was little difference between vitamin E and control groups in post-treatment ulnar SNAP amplitude (<LINK REF="CMP-020.02" TYPE="ANALYSIS">Analysis 20.2</LINK>). When the sural nerve results at end of treatment were combined for the two studies, no significant treatment effect existed (MD 2.01 µv, 95% CI -1.60 to 5.61 µv) (see <LINK REF="CMP-020.03" TYPE="ANALYSIS">Analysis 20.3</LINK>, <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). <LINK REF="STD-Kottschade-2011" TYPE="STUDY">Kottschade 2011</LINK> did not perform nerve conduction studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(2) Clinical impairment on neurological examination using a validated scale</HEADING>
<P>Although both selected trials measured clinical impairment on neurological examination (<LINK REF="STD-Argyriou-2006" TYPE="STUDY">Argyriou 2006</LINK>; <LINK REF="STD-Pace-2003" TYPE="STUDY">Pace 2003</LINK>), neither trial used a validated scale. <LINK REF="STD-Argyriou-2006" TYPE="STUDY">Argyriou 2006</LINK> reported that the incidence of clinical neuropathy was lower in the vitamin E group than in the control group among participants completing the study (3 of 14 versus 11 of 16, RR 0.31, 95% CI 0.11 to 0.90) (see <LINK REF="CMP-021.01" TYPE="ANALYSIS">Analysis 21.1</LINK>). Similar results were reported for the intention-to-treat analysis (5 of 16 versus 13 of 19, RR 0.46, 95% CI 0.21 to 1.00) (see <LINK REF="CMP-021.02" TYPE="ANALYSIS">Analysis 21.2</LINK>). The severity of clinical neuropathy, as judged by the mean score on a modified peripheral neuropathy scale at trial end, also showed a significant difference favouring the vitamin E group (4.99 ± 1.33 versus 10.47 ± 10.62, P = 0.04) (MD -5.48, 95% CI -10.73 to -0.23) (see <LINK REF="CMP-022.01" TYPE="ANALYSIS">Analysis 22.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(3) Functional activities of daily living</HEADING>
<P>The vitamin E studies (<LINK REF="STD-Argyriou-2006" TYPE="STUDY">Argyriou 2006</LINK>; <LINK REF="STD-Kottschade-2011" TYPE="STUDY">Kottschade 2011</LINK>; <LINK REF="STD-Pace-2003" TYPE="STUDY">Pace 2003</LINK>), did not measure any functional ADL and did not provide any information on standardised toxicity rating scales.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(4) Information from toxicity rating scales</HEADING>
<P>In <LINK REF="STD-Pace-2003" TYPE="STUDY">Pace 2003</LINK>, the incidence of neurotoxicity, measured by a modified version of the total neuropathy score, was significantly lower in the group with vitamin E supplementation (4 of 13 participants) compared to the group without vitamin E (12 of 14 participants; RR of developing symptoms or signs of neurotoxicity was 0.36, 95% CI 0.15 to 0.83) (see <LINK REF="CMP-023.01" TYPE="ANALYSIS">Analysis 23.1</LINK>). In addition, the severity of neuropathy, measured with neurotoxicity scores, was higher (worse) in participants without vitamin E supplementation compared to those who received vitamin E (4.7 versus 2.0, P &lt; 0.01).</P>
<P>
<LINK REF="STD-Argyriou-2006" TYPE="STUDY">Argyriou 2006</LINK>, using a measure presumably derived from a modified Peripheral Neuropathy (PNP) score, reported results similar to those of <LINK REF="STD-Pace-2003" TYPE="STUDY">Pace 2003</LINK>, including mean PNP scores in the vitamin E group versus the control group of 4.99 ± 1.33 and 10.47 ± 10.62, respectively (P = 0.023). The pooled results from these two studies identified neurotoxicity after completion of chemotherapy in 9 of 29 participants receiving vitamin E versus 25 of 33 controls (P = 0.002); with an RR of 0.41 (95% CI 0.23 to 0.73, fixed-effect model) (see <LINK REF="CMP-023.01" TYPE="ANALYSIS">Analysis 23.1</LINK>, <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>).</P>
<P>
<LINK REF="STD-Kottschade-2011" TYPE="STUDY">Kottschade 2011</LINK> reported the incidence of neuropathy using the NCI-CTC adverse event (NCI-CTCAE) score for neuropathy (a scale of one to four), as well as by a neuropathy-specific questionnaire developed by the North Central Cancer Treatment Group (NCCTG). The primary endpoint was a &#8805;2 grade sensory neuropathy using the NCI-CTC 3.0 criteria, with the percentage of grade 2+ sensory neuropathic toxicity. Although this endpoint produced a negative result, the inclusion of a large number of participants (109, 58% of the total) treated with taxanes versus those treated with cisplatin, oxaliplatin, or carboplatin made it impossible to combine the results of this study with other studies using similar measures because it was impossible to separate out those subjects who did not receive taxanes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects attributed to the study intervention</HEADING>
<P>No information was provided pertaining to the adverse effects attributed to the study interventions in <LINK REF="STD-Pace-2003" TYPE="STUDY">Pace 2003</LINK>. Overall adverse effects experienced were judged unlikely to be due to vitamin E supplementation in <LINK REF="STD-Argyriou-2006" TYPE="STUDY">Argyriou 2006</LINK>. Similar results were report for the <LINK REF="STD-Kottschade-2011" TYPE="STUDY">Kottschade 2011</LINK> study; namely, no adverse effects were attributed to vitamin E.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Details of other outcomes not specified in the protocol</HEADING>
<P>None described.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-02-19 14:58:50 +0000" MODIFIED_BY="Kate Jewitt">
<SUMMARY_OF_RESULTS MODIFIED="2014-02-19 14:58:50 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Acetylcysteine (N-acetylcysteine, NAC)</HEADING>
<P>The single eligible study evaluating the use of N-acetylcysteine (NAC) against the neurotoxicity of oxaliplatin was described as a pilot study and included only a small number of participants (five receiving NAC and nine controls) (<LINK REF="STD-Lin-2006" TYPE="STUDY">Lin 2006</LINK>). In addition, uncertainty about the randomisation methods and presence of blinding (participants or investigators), report only of subjective toxicity scales, and inclusion of nerve conduction results from the NAC group but not the control group are issues that limit interpretation of the preliminary study results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Amifostine</HEADING>
<P>The eligible studies evaluating the use of amifostine as a neuroprotective agent against the neurotoxicity of cisplatin and other chemotherapy agents are inconclusive in demonstrating efficacy, primarily because few studies utilised quantitative measures of neurotoxicity. Although the studies were generally well done, participant masking was unclear, perhaps because amifostine was given intravenously in conjunction with interval chemotherapy and felt to be of little interest to the recipient. The authors of one study acknowledged that the trial was not conceived as a double-blind study, but that the physicians assessing non-haematological toxicity usually were not the same physicians involved in administering treatment and they therefore could not be influenced by the evaluation of symptoms and signs associated with chemotherapy (<LINK REF="STD-Lorusso-2003" TYPE="STUDY">Lorusso 2003</LINK>). It is unknown whether this belief about the low likelihood of inadvertent influence on judgment is correct. Paclitaxel was used together with carboplatin in two of the amifostine trials that were included (<LINK REF="STD-Kanat-2003" TYPE="STUDY">Kanat 2003</LINK>; <LINK REF="STD-Lorusso-2003" TYPE="STUDY">Lorusso 2003</LINK>).</P>
<P>
<LINK REF="STD-Planting-1999" TYPE="STUDY">Planting 1999</LINK> was the single study that included quantitative sensory testing (QST), our primary outcome measure, among their assessment instruments. That trial showed a favourable outcome in terms of amifostine neuroprotection, but the subclinical result was based on only 14 participants in the amifostine group and 20 participants in the control group and the results were not particularly robust, showing statistical but unclear clinical significance. Among the secondary outcome measures we selected, the only other quantitative measure used in any of the four studies was related to evaluation of peripheral nerve electrophysiology. A single study utilised electrophysiological measures, recording sensory nerve action potential (SNAP) amplitudes from two upper extremity sensory nerves and one lower extremity sensory nerve at baseline and after completing chemotherapy (<LINK REF="STD-Kanat-2003" TYPE="STUDY">Kanat 2003</LINK>). This study, which also included a relatively small number of participants (19 participants in each study arm), found that the quantitative measures of large fibre sensory axons failed to identify evidence of significant amifostine neuroprotection. Unfortunately, the study also showed an unexpected and almost implausible low level of neurotoxicity among the control participants who received carboplatin and paclitaxel but not amifostine, rendering the amifostine efficacy result uninterpretable.</P>
<P>Despite the lack of quantitative measures showing amifostine efficacy, the authors of all seven trials concluded that pretreatment with amifostine reduced, prevented, or at least exerted some protection from the cumulative neurotoxicity associated with cisplatin or carboplatin and paclitaxel. This conclusion reflected the results obtained from the various neurological examination scales or neurotoxicity scales, most often the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) neuropathy rating. The neurotoxicity rating scale was not specified by <LINK REF="STD-Gallardo-1999" TYPE="STUDY">Gallardo 1999</LINK>, but presumably represented the NCI-CTC scale. For the most part, the other scales utilised were of unknown sensitivity or specificity, and the clinical relevance of the results uncertain. For example, it is unclear whether any of the sensory symptoms or signs resulted in substantial functional impairment or persisted. Some of the neurotoxicity results were reported in terms of each evaluation, rather than for each participant, suggesting fluctuation during the trial. Such fluctuation suggests inclusion of non-specific symptoms, as opposed to the persistent distal predominant and symmetrical sensory symptoms and signs characteristic of most toxic neuropathies. One exception is the functional activities of daily living (ADL) scale reported by <LINK REF="STD-Kanat-2003" TYPE="STUDY">Kanat 2003</LINK>. Although based on a small number of participants (19 participants in each study arm), the results of this sensorimotor neurotoxicity score suggested a small but statistically significant decrease in the ADL in 2 of 19 participants in the amifostine group compared to 9 of 19 participants in the control group (risk ratio (RR) 0.22, 95% confidence interval (CI) 0.6 to 0.90). Another exception reflected the use of the NCI neurological toxicity rating among 242 participants with ovarian cancer treated with cisplatin and cyclophosphamide (<LINK REF="STD-Kemp-1996" TYPE="STUDY">Kemp 1996</LINK>). The significant decrease in the NCI rating among participants pre-treated with amifostine compare to control participants was an impressive finding, despite the lack of QST or electrophysiological evaluations. The limited availability of clinical trials utilising conventional QST and nerve conduction study measures of peripheral nerve function is disappointing, at least in part because of the relative simplicity of the peripheral nervous system evaluation relative to other neurological functions, such as behavior. Similarly, <LINK REF="STD-De-Vos-2005" TYPE="STUDY">De Vos 2005</LINK> concluded that amifostine showed minor but significant activity in diminishing neurotoxicity (but not in preventing paclitaxel plus carboplatin-induced bone marrow toxicity) without interfering with chemotherapy efficacy.</P>
<P>The largely positive results based on subjective neuropathy ratings generally led to conclusions that amifostine could reduce the incidence and severity of peripheral neurotoxicity caused by cisplatin or oxaliplatin chemotherapy (e.g., <LINK REF="STD-Kemp-1996" TYPE="STUDY">Kemp 1996</LINK>; and <LINK REF="STD-Lu-2008" TYPE="STUDY">Lu 2008</LINK>). These conclusions were supported by the pooled data involving secondary neurotoxicity rating scales, most often based on the NCI-CTC neuropathy scale. Although the additional studies identified in the 2013 update permitted pooling of data, there still were only a small number of studies that could be included, and those studies involved a relatively small number of participants. For example, the pooled data from three studies involving the equivalent of NCI-CTC grades &#8805;2 neurotoxicity included only 148 participants, of which 10 of 74 receiving amifostine showed &#8805; grade 2 neurotoxicity relative to 39 of 74 control participants showed a similar grade of neurotoxicity (<LINK REF="STD-DeVos-2005" TYPE="STUDY">DeVos 2005</LINK>; <LINK REF="STD-Gallardo-1999" TYPE="STUDY">Gallardo 1999</LINK>; <LINK REF="STD-Kanat-2003" TYPE="STUDY">Kanat 2003</LINK>). In this analysis, the <LINK REF="STD-Kanat-2003" TYPE="STUDY">Kanat 2003</LINK> results represented outlying (positive) values relative to the other studies. That the pooled data showed substantial heterogeneity is perhaps not surprising considering the different cancers and primary treatment protocols described in these studies. Similar results were obtained from pooled analysis of the available data from three other studies using the equivalent of NCI-CTC grades &#8805;3 although the results were no longer statistically significant (<LINK REF="STD-De-Vos-2005" TYPE="STUDY">De Vos 2005</LINK>; <LINK REF="STD-Kemp-1996" TYPE="STUDY">Kemp 1996</LINK>; <LINK REF="STD-Lu-2008" TYPE="STUDY">Lu 2008</LINK>), demonstrating how sensitive the results are to inclusion of data from different trials. In this analysis, the <LINK REF="STD-Lu-2008" TYPE="STUDY">Lu 2008</LINK> results represent very outlying (positive) values relative to the other studies.</P>
<P>In terms of direct relevance to chemotherapy, the expectation that reduced neurotoxicity would result in increased dosing was not clearly realised in any of the trials reviewed, although <LINK REF="STD-Lu-2008" TYPE="STUDY">Lu 2008</LINK> reported that the proportion of chemotherapy schedule adjustment because of chemotherapy-induced neurotoxicity was significantly lower in the amifostine group relative to the placebo group (4.3% versus 23.9%, P = 0.007).The expectation of the beneficial result of increased dosing is based on recognition that neurotoxicity is the primary dose-limiting adverse effect attributed to cisplatin.</P>
<P>
<LINK REF="STD-De-Vos-2005" TYPE="STUDY">De Vos 2005</LINK> conducted a randomised phase II study of paclitaxel and carboplatin with and without amifostine and, as part of their discussion, pooled the results of three studies, all involving chemotherapy with paclitaxel and carboplatin (<LINK REF="STD-De-Vos-2005" TYPE="STUDY">De Vos 2005</LINK>; <LINK REF="STD-Kanat-2003" TYPE="STUDY">Kanat 2003</LINK>; <LINK REF="STD-Leong-2003" TYPE="STUDY">Leong 2003</LINK>). We had excluded from our review the data from the Leong et al. study because participants received only two doses of carboplatin. We included the data from the De Vos et al. study, but noted that we were unable to separate the effects of carboplatin versus paclitaxel. The pooled results reported by De Vos et al. identified an odds ratio (OR) for developing &#8805; grade 2 neurotoxicity of 0.30 (95% CI 0.15, 0.63; P &lt; 0.05, random-effects model. This compared to our pooled results (after change the RR to an OR), which showed an OR of 0.08 (95% CI 0.01to 0.79, random-effects model, P = 0.03) for developing &#8805; grade 2 neurotoxicity. Notwithstanding the different studies included, the two analyses based on pooled data (our analysis and the one reported by De Vos et al.) suggested potential amifostine protection against chemotherapy-induced neurotoxicity.</P>
<P>In conclusion, the results of the available trials suggest the possibility of potential amifostine neuroprotection against cisplatin and other chemotherapy drugs. However, data involved a relatively small number of trials and participants, did not include improvement of primary measures or objective quantitative secondary measures, and the neuroprotection appears to be of small magnitude. Given this, in our opinion the overall efficacy results, while promising, remain inconclusive.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Calcium and magnesium (Ca/Mg)</HEADING>
<P>The studies of Ca/Mg infusions as a chemoprotective agent against oxaliplatin neurotoxicity included subjective NCI-CTC grading for neuropathy and Debiopharm Neurotoxicity Scale (DEB-NTS) or similar neurotoxicity grading criteria (<LINK REF="STD-Chay-2010" TYPE="STUDY">Chay 2010</LINK>; <LINK REF="STD-Grothey-2011" TYPE="STUDY">Grothey 2011</LINK>; <LINK REF="STD-Ishibashi-2010" TYPE="STUDY">Ishibashi 2010</LINK>). Enrolment in all three studies was terminated prematurely, owing to reports that treatment results were poorer in the Ca/Mg group than in the control group. in This was according to the authors' interim analysis in the <LINK REF="STD-Ishibashi-2010" TYPE="STUDY">Ishibashi 2010</LINK> study, results not confirmed in the final analyses and, in the <LINK REF="STD-Chay-2010" TYPE="STUDY">Chay 2010</LINK> study, according to reports from other studies indicating negative results. <LINK REF="STD-Grothey-2011" TYPE="STUDY">Grothey 2011</LINK> was terminated early because of reports of treatment interference by the study medication (<LINK REF="STD-Grothey-2011" TYPE="STUDY">Grothey 2011</LINK>).The early discontinuations resulted in a small sample size and limited the data available to determine if Ca/Mg infusions had neuroprotective potential. The NCI-CTC rating of <LINK REF="STD-Grothey-2011" TYPE="STUDY">Grothey 2011</LINK>, the largest of the available studies, reported a borderline significant result favouring Ca/Mg infusions for preventing neuropathy, defined as an NCI-CTC grading &#8805;2 (OR 0.42; 95% CI 0.17 to 0.99). However, the combined available data using the same grading scale did not support a significant beneficial effect. In a non-randomised retrospective analyses, <LINK REF="STD-Knijn-2011" TYPE="STUDY">Knijn 2011</LINK> reported that early &#8805; NCI-CTC grade 2 neurotoxicity (occurring during six cycles of oxaliplatin chemotherapy) occurred in 218 of 551 (40%) Ca/Mg-treated participants versus 81 of 181 (45%) non-Ca/Mg-treated participants. Similarly, late &#8805; grade 2 neurotoxicity present at the last cycle before going off of study was present in 148 of 551 (27%) Ca/Mg-treated participants versus 62 of 181 (34%) non-Ca/Mg-treated participants. The retrospective <LINK REF="STD-Knijn-2011" TYPE="STUDY">Knijn 2011</LINK> described a decrease in the frequency of late &#8805; grade 2 neurotoxicity present at the last cycle before going off of study in Ca/Mg-treated participants relative to those who did not receive Ca/Mg. When we pooled these positive results with the other studies reporting &#8805; grade 2 neurotoxicity at the end of chemotherapy, we found a modest but statistically significant result favouring the use of Ca/Mg, OR 0.68 (95% CI 0.49 to 0.94) (<LINK REF="STD-Chay-2010" TYPE="STUDY">Chay 2010</LINK>; <LINK REF="STD-Grothey-2011" TYPE="STUDY">Grothey 2011</LINK>; <LINK REF="STD-Ishibashi-2010" TYPE="STUDY">Ishibashi 2010</LINK>; <LINK REF="STD-Knijn-2011" TYPE="STUDY">Knijn 2011</LINK>).</P>
<P>Our limited pooled results showed a non-significant reduced risk of developing a NCI-CTC &#8805; grade 2 favouring Ca/Mg (RR 0.84, 95% CI 0.62 to 1.05), results different from those two published meta-analysis involving the efficacy of Ca/Mg infusions (<LINK REF="STD-Ao-2012" TYPE="STUDY">Ao 2012</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>). <LINK REF="STD-Ao-2012" TYPE="STUDY">Ao 2012</LINK> analyses included one study requiring translation that we are waiting to review (<LINK REF="STD-Dong-2010" TYPE="STUDY">Dong 2010</LINK>), a double-blind study involving oxaliplatin-induced neuropathy in which 4 of 20 Ca/Mg-treated participants developed chronic neuropathy versus 11 of 27 control participants (a borderline significant difference). The pooled analyses performed in <LINK REF="STD-Ao-2012" TYPE="STUDY">Ao 2012</LINK> reported an OR of 0.44 (95% CI 0.23 to 0.85, fixed-effect model), indicating a significant result favouring treatment with Ca/Mg. After converting our analyses to an OR and using a fixed effects analyses, we showed a non-significant OR of 0.58 (95% CI 0.27 to 1.21), results still different from those reported by Ao et al. Similarly, <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK> reported the results of a second meta-analysis involving oxaliplatin-related neurotoxicity. Their analysis is potentially flawed because of the variability of the studies included, in which the study by Chay et al. was the only RCT included (it had a non-significant outcome for total cumulative subjective sensory neurotoxicity). Their analyses reached significance only after including the non-randomised trials of <LINK REF="STD-Knijn-2011" TYPE="STUDY">Knijn 2011</LINK> (discussed immediately above) and <LINK REF="STD-Gamelin-2004" TYPE="STUDY">Gamelin 2004</LINK>. We did not include data from either the Knijn et al. or the Gamelin et al. studies in our analyses because both represented retrospective non-randomised studies (and because it is a Cochrane Neuromuscular Disease Group policy to not include data from non-randomised studies in the results section). When we investigated the effect of pooling the retrospective data from Knijn et al. with the data we reported in the results section, we found a borderline significant RR of 0.80 (95% CI 0.62 to 1.05) favouring the use of Ca/Mg, a result qualitatively similar to the results of the two published meta-analyses. Regardless, the conclusion of Wen 2013a that Ca/Mg infusions tend to decrease the incidence of oxaliplatin-induced cumulative neurotoxicity and thus enhance patients' tolerance to oxaliplatin is based primarily on subjective data derived from retrospective studies, not RCTs.</P>
<P>In summary, the results of the best available trials selected for analyses are difficult to evaluate because of the small number of subjects, due primarily to early termination of several important studies (for reasons unrelated to the study intervention or treatment protocols). Based on the remaining data however, our results of the available RCT data do not show suggest statistically significant effect of Ca/Mg in preventing oxaliplatin-induced neurotoxicity. Inclusion of results from several retrospective non-randomised studies suggest more positive, borderline significant results favouring the use of Ca/Mg. At present, however, the limited data are not convincingly positive in favour of Ca/Mg neuroprotection and in our opinion, the overall efficacy results are promising but inconclusive.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Diethyldithiocarabamate (DDTC)</HEADING>
<P>The single study of DDTC as a neuroprotective agent suffers from having no measures of neurotoxicity other than subjective reporting (NCI). To gain full appreciation of the magnitude of the difference between the two arms (DDTC and placebo), one should probably add those withdrawn for toxicity, to patient request, and adverse experience (<LINK REF="STD-Gandara-1995" TYPE="STUDY">Gandara 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Glutathione (GSH)</HEADING>
<P>Overall, six out of seven studies reported a significant protective effect of GSH. All measures of peripheral neuropathy favoured the GSH group, including the measure of VPT (one study), sural SNAP amplitudes (four studies) and improvement in functional measures or various neurotoxicity rating scales (six studies). Even though the overall effect of GSH appears to be beneficial and protective, the variable dosages used with different malignancies and different combinations of chemotherapy, high drop out rate, predominant reliance on subjective measures, limited statistical analyses, and lack of long-term follow-up, make the overall effect of GSH difficult to judge.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Org 2766</HEADING>
<P>Overall, the few eligible studies evaluating the use of Org 2766 as a neuroprotective agent against the neurotoxicity of cisplatin are inconclusive in demonstrating efficacy. A major concern is that the total number of participants enrolled in the studies is rather low (188 Org 2766-treated and 123 control participants) and, moreover, participants are not homogenously distributed among the four trials, since one of them (<LINK REF="STD-Roberts-1997" TYPE="STUDY">Roberts 1997</LINK>) included 68% of the Org 2766-treated and 54% of the control participants. All the trials included QST, our primary outcome measure, among their assessment instruments, while none of the studies reported an evaluation of peripheral nerve electrophysiology or effects on ADL. Neurological examination was based on non-validated scales in all the four trials.</P>
<P>The first study suggesting a protective effect of Org 2766 (<LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK>) is based on an inadequate statistical analysis. In fact, analysis was performed after six cycles of cisplatin on only 28 participants out of the 55 admitted to the study, while the others were not eligible or had not yet received the planned chemotherapy cycles. Intermediate analysis (i.e. after four cycles of cisplatin) was performed on 39 participants. The authors of the second study (<LINK REF="STD-Hovestadt-1992" TYPE="STUDY">Hovestadt 1992</LINK>) admitted that the number of participants was too low to allow a reliable formal statistical analysis. The third study was the only one performed mostly on males (22 men versus 1 woman). The authors used two different methods of statistical analysis and the results were conflicting (<LINK REF="STD-van-Gerven-1994" TYPE="STUDY">van Gerven 1994</LINK>). The largest study had adequate subject, outcome assessor and observer blinding and also the statistical analysis was adequate (<LINK REF="STD-Roberts-1997" TYPE="STUDY">Roberts 1997</LINK>). Instead of providing evidence of protection induced by Org 2766, the authors suggested that high doses of the compound might even increase the rate of change and degree of neuropathy induced by cisplatin (P value &gt; 0.05).</P>
<P>In conclusion, although the results of the first trial (<LINK REF="STD-van-der-Hoop-1990" TYPE="STUDY">van der Hoop 1990</LINK>) suggested the possibility of potential Org 2766 neuroprotection, effects appear to be of small magnitude or not convincingly positive in favour of Org 2766 neuroprotection, particularly in view of the results reported in the most recent trial (<LINK REF="STD-Roberts-1997" TYPE="STUDY">Roberts 1997</LINK>). Furthermore, the combined data from the three trials using the same measure showed no significant group difference at the follow-up QST examination (mean difference -1.77 95% CI -4.78 to 1.23). The overall efficacy results are negative.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oxcarbazepine (OXC)</HEADING>
<P>The only study evaluating the efficacy of OXY for prophylaxis against oxaliplatin-induced neuropathy reported a favourable effect (<LINK REF="STD-Argyriou-2006a" TYPE="STUDY">Argyriou 2006a</LINK>). The results were based on an open label evaluation (randomised but not placebo-controlled), a small sample size, and without quantitative sensory testing as a primary outcome measure. However, validated clinical instruments (NSS and NDS) and appropriate neurophysiological measures were incorporated and showed several significant group differences, all favouring the OXC group. The significant nerve conduction results involved a change in the baseline to six month recordings for the lower extremity SNAP amplitude measures (sural and superficial peroneal), but not the ulnar sensory or peroneal motor measures, results consistent with those expected to represent the most sensitive indicators of an oxaliplatin-induced neuropathy. Comparisons of the mean SNAP amplitudes for the treatment versus control groups post treatment (six-month recordings after 24 cycles) showed no significant differences in any of the SNAP amplitudes, however. Although the significant neurophysiological group differences based on the change from baseline to six month records were modest and of uncertain clinical importance, the overall results support further investigation of OXC in a larger placebo-controlled randomised trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Retinoic acid</HEADING>
<P>The results from the single study involving retinoic acid as a neuroprotective agent are limited by methodological issues resulting in uninterpretable nerve conduction study results, unbalanced and unexplained baseline group differences, use of the NCI-CTC grading as the only measure of neuropathy, and an inadequate follow-up interval (<LINK REF="STD-Arrieta-2011" TYPE="STUDY">Arrieta 2011</LINK>). The NCI-CTC assessment of neuropathy grades &#8805;2 were present in 23 of 45 ATRA participants and in 37 of 47 placebo participants, showing a borderline significant difference favouring the ATRA treatment group over the placebo group (RR 0.75 95% CI 0.55 to 1.02) (<LINK REF="CMP-018.01" TYPE="ANALYSIS">Analysis 18.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Vitamin E</HEADING>
<P>Although the results involving vitamin E as a neuroprotective agent are encouraging, methodology issues, the small size of the study, the use of multiple chemotherapeutic regimens (including taxane in the largest available study), lack of blinding, and lack of primary outcome measures make the data less than convincing. This conclusion is despite the statistically significant results from the pooled data involving subjective measures of neuropathy (NCI-CTC neurotoxicity rating). The changes noted in median SNAP but not the in sural SNAP amplitudes and the use of a non-validated toxicity measure suggest that additional more definitive studies are needed. In our opinion the overall efficacy results, while promising, remain inconclusive.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Comment</HEADING>
<P>The quality and characteristics of the trials reviewed were quite variable, and included different measures of neuropathy (qualitative and subjective), different durations of follow-up, and different analyses. The duration of follow-up must be sufficient to identity cisplatin-induced sensory nerve deterioration, and therefore should extend beyond the last cisplatin treatment. How long after the last treatment is open to debate, as all toxic neuropathies demonstrate some progression after exposure ceases, and patients with cisplatin-induced neuropathy can show improvement (depending on the initial severity) after cisplatin is discontinued. We included all evaluations performed zero to six months after the last treatment, selecting the evaluation closest to three months after treatment to the extent possible. We believe that a two to three month interval after treatment is completed is biologically reasonable. In all, 15 trials were included in our initial review, a further five trials in our 2010 review, and an additional 9 trials in our 2013 update. The combined trials involved nine separate, unrelated potential neuroprotective agents and included many disparate measures of neuropathy, resulting in sufficient data to combine the results for only a few measures, most of which were secondary measures such as the NCI-CTC neurotoxicity rating. Based on our review, we feel that the evaluation of agents intended to prevent cisplatin-induced sensory neuropathy should include validated measures, and not necessarily be limited to the primary measures we initially identified (tests of QST at the index finger and great toe and nerve conduction study evaluation of SNAP amplitudes in the median sensory and sural nerves). Before performing our review, considerable consideration was given to two measures (QST or nerve conduction studies) competing for the primary endpoint. We selected QST as the primary endpoint, in part, because it had been used in several prominent trials. While QST is an excellent quantitative measure of the endpoint of interest (sensation), the SNAP amplitude has the advantage of providing information about the actual cisplatin target, the peripheral sensory nerve, independent of patient co-operation or motivation. Sufficient information exists about both measures to perform power calculations to determine the number of subjects required to detect a meaningful group difference. A difficulty we experienced in performing our review related to the limited data available, even when QST or SNAP amplitude recordings were performed. Most studies provided only descriptive statistics (e.g., mean, SD) reflecting the baseline examination and the follow-up examination for treatment and control groups, without information about change (mean, SD) between baseline and follow-up examinations. Inclusion of the latter facilitates comparisons with subsequent studies.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-02-19 12:23:42 +0000" MODIFIED_BY="Kate Jewitt">
<IMPLICATIONS_PRACTICE MODIFIED="2014-02-19 12:23:42 +0000" MODIFIED_BY="Michael Lunn">
<P>There is no high quality evidence that any agent has been demonstrated as neuroprotective against cisplatin-induced neuropathy, although the non-parametric available evidence, based primarily on grading of neurotoxicity using instruments such as the National Cancer Institute Common Toxicity Criteria neuropathy scale, suggests that amifostine, calcium and magnesium, glutathione, and vitamin E may have modest but potential use as neuroprotective agents.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-01-17 17:39:13 +0000" MODIFIED_BY="Kate Jewitt">
<P>There is a continued need for randomised controlled clinical trials, using objective measures of neuropathy, utilising appropriate masking of subjects and examiners, and including adequate numbers of participants to evaluated the efficacy of neuroprotective agents. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-01-17 15:49:06 +0000" MODIFIED_BY="Ruth Brassington">
<P>The authors acknowledge the helpful comments and assistance of RAC Hughes in preparing the protocol. The Cochrane Neuromuscular Disease Group Trials Search Co-ordinator ran the searches.</P>
<P>The editorial base of the Cochrane Neuromuscular Disease Group receives support from the MRC Centre for Neuromuscular Diseases.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-02-27 18:09:29 +0000" MODIFIED_BY="Ruth Brassington">
<P>Dr Albers has the following conflict of interest statement.</P>
<P>"None of the potential conflicts of interest noted below relates directly to any of the material discussed in the current review. In the interest of erring on the side of full disclosure, however, I include the following:</P>
<P>Within the time of this review, Dr. Albers has received personal compensation for activities with Amylin Pharmaceuticals, Dow Chemical Co., Dow AgroSciences, Eli Lilly &amp; Company, Lilly Research Laboratories, Periphagen (formerly Diamyd), Polymedix, Veristat, Wyeth Pharmaceuticals, or by firms representing companies in litigation. These activities have been as a consultant, advisory board member, data monitoring committee member, mortality and morbidity review committee member, participating study investigator, or expert witness. He also has received funding support for clinical research from government agencies, foundations, and private industry. Two immediate family members hold stock and/or stock options in companies whose products relate to the practice of medicine. These relationships are unrelated to the chemotherapy agents or chemo-neuroprotectants discussed in the review."</P>
<P>Dr Cavaletti has acted in the past as a paid consultant to Sigma-Tau IFR, Serono International SA, Rinat Neuroscience Co., Guilford Pharmaceuticals, and Eisai Pharmaceuticals, which manufacture different neuroprotective agents, and to Debiopharm SA which manufactures oxaliplatin. In the 36 months prior to submission of this updated review he has no known conflicts of interest.</P>
<P>Dr Chaudhry has served as a medical record reviewer and provided expert witness testimony for the Department of Justice Injury Compensation Program. Dr. Chaudhry has served as a consultant for clinical trials for Novartis. He receives compensation for serving on the editoria board of Neurologist. Dr. Chaudhry also receives royalities from Johns Hopkins University for use of Total Neuropathy Score (TNS).</P>
<P>Dr Donehower serves on the scientific advisory board of two companies involved in the development of new anticancer drugs.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-02-19 12:23:43 +0000" MODIFIED_BY="[Empty name]">
<P>All authors reviewed the selected literature. First drafts were prepared by Dr. Albers (amifostine), Dr. Cavaletti (Org 2766), and Drs. Chaudhry and Donehower (glutathione, diethyldithiocarbamate, and vitamin E). Dr. Albers prepared the first draft of the report, which was reviewed, edited, revised, and approved by the other authors. Evaluation of the studies identified in the 2010 and 2013 reviews were performed by all of the authors, after which Dr. Albers performed the pooled analyses and prepared the draft update to include the additional materials, which was reviewed, edited, revised, and approved by the other authors.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-02-19 12:23:47 +0000" MODIFIED_BY="[Empty name]">
<P>The protocol was published in 2005 (<LINK REF="REF-Albers-2005" TYPE="REFERENCE">Albers 2005</LINK>). Beginning with the 2010 update we revised the risk of bias methodology according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>, updated <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-02-27 10:15:03 +0000" MODIFIED_BY="Ruth Brassington">
<STUDIES MODIFIED="2014-02-27 10:15:03 +0000" MODIFIED_BY="Ruth Brassington">
<INCLUDED_STUDIES MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-Argyriou-2006" MODIFIED="2012-10-23 10:31:52 +0100" MODIFIED_BY="Kate Jewitt" NAME="Argyriou 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-10-23 10:31:52 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Argyriou AA, Chroni E, Koutras A, Iconomou G, Papapetropoulos S, Polychronopoulos P, et al</AU>
<TI>A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results</TI>
<SO>Support Care Cancer</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>11</NO>
<PG>1134-40</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:31:52 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:31:52 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="16622646"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Argyriou-2006a" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Argyriou 2006a" YEAR="">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Argyriou AA, Chroni E, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, et al</AU>
<TI>Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>12</NO>
<PG>2253-5</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:48:16 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:48:16 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="17190958"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arrieta-2011" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Arrieta 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arrieta Ó, Hernández-Pedro N, Fernández-González-Aragón MC, Saavedra-Pérez D, Campos-Parra AD, Ríos-Trejo MÁ, et al</AU>
<TI>Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer</TI>
<SO>Neurology</SO>
<YR>2011</YR>
<VL>77</VL>
<NO>10</NO>
<PG>987-95</PG>
<IDENTIFIERS MODIFIED="2014-02-05 15:19:23 +0000" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2014-02-05 15:19:23 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="21865574"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bogliun-1996" MODIFIED="2014-02-08 21:48:41 +0000" MODIFIED_BY="Angela A Gunn" NAME="Bogliun 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-02-08 21:48:41 +0000" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bogliun G, Marzorati L, Marzola M, Miceli MD, Cantu MG, Cavaletti G</AU>
<TI>Neurotoxicity of cisplatin +/- reduced glutathione in the first-line treatment of advanced ovarian cancer</TI>
<SO>International Journal of Gynecological Cancer</SO>
<YR>1996</YR>
<VL>6</VL>
<NO>5</NO>
<PG>415-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cascinu-1995" MODIFIED="2012-10-23 10:33:05 +0100" MODIFIED_BY="Angela A Gunn" NAME="Cascinu 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-10-23 10:33:05 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cascinu S, Cordella L, Del FE, Fronzoni M, Catalano G</AU>
<TI>Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>1</NO>
<PG>26-32</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:33:05 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:33:05 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="7799029"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cascinu-2002" MODIFIED="2012-10-23 10:47:03 +0100" MODIFIED_BY="Angela A Gunn" NAME="Cascinu 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-10-23 10:47:03 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, et al</AU>
<TI>Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>16</NO>
<PG>3478-83</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:47:03 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:47:03 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="12177109"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chay-2010" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Chay 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chay WY, Tan SH, Lo YL, Ong SY, Ng HC, Gao F, et al</AU>
<TI>Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy</TI>
<SO>Asia Pacific Journal of Clinical Oncology</SO>
<YR>2010</YR>
<VL>6</VL>
<NO>4</NO>
<PG>270-7</PG>
<IDENTIFIERS MODIFIED="2013-11-26 16:32:32 +0000" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2013-11-26 16:32:32 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="21114776"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colombo-1995" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Colombo 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colombo N, Bini S, Miceli D, Bogliun G, Marzorati L, Cavaletti G, et al</AU>
<TI>Weekly cisplatin +/- glutathione in relapsed ovarian carcinoma</TI>
<SO>International Journal of Gynecological Cancer</SO>
<YR>1995</YR>
<VL>5</VL>
<NO>2</NO>
<PG>81-6</PG>
<IDENTIFIERS MODIFIED="2013-10-31 19:07:47 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2013-10-31 19:07:47 +0000" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="11578459"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeVos-2005" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="DeVos 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Vos FY, Bos AM, Schaapveld M, Swart CA, Graaf H, et al</AU>
<TI>A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma</TI>
<SO>Gynecologic Oncology</SO>
<YR>2005</YR>
<VL>97</VL>
<NO>1</NO>
<PG>60-7</PG>
<IDENTIFIERS MODIFIED="2014-02-05 15:19:37 +0000" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2014-02-05 15:19:37 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="15790438"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallardo-1999" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Gallardo 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallardo D, Mohar A, Calderillo G, Mota A, Solorza G, Lozano A, et al</AU>
<TI>Cisplatin, radiation, and amifostine in carcinoma of the uterine cervix</TI>
<SO>International Journal of Gynecological Cancer</SO>
<YR>1999</YR>
<VL>9</VL>
<NO>3</NO>
<PG>225-30</PG>
<IDENTIFIERS MODIFIED="2013-11-26 16:39:29 +0000" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2013-11-26 16:39:29 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="11240771"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gandara-1995" MODIFIED="2012-10-23 10:33:57 +0100" MODIFIED_BY="Angela A Gunn" NAME="Gandara 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-10-23 10:33:57 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gandara DR, Nahhas WA, Adelson MD, Lichtman SM, Podczaski ES, Yanovich S, et al</AU>
<TI>Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>2</NO>
<PG>490-6</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:33:57 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:33:57 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="7844610"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grothey-2011" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Grothey 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, et al</AU>
<TI>Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>4</NO>
<PG>421-7</PG>
<IDENTIFIERS MODIFIED="2014-02-05 15:19:43 +0000" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2014-02-05 15:19:43 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="21189381"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hovestadt-1992" MODIFIED="2012-10-23 10:34:39 +0100" MODIFIED_BY="Angela A Gunn" NAME="Hovestadt 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-10-23 10:34:39 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hovestadt A, van der Burg ME, Verbiest HB, van Putten WL, Vecht CJ</AU>
<TI>The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo</TI>
<SO>Journal of Neurology</SO>
<YR>1992</YR>
<VL>239</VL>
<NO>3</NO>
<PG>143-6</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:34:39 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:34:39 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="1315383"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ishibashi-2010" MODIFIED="2012-10-23 10:46:10 +0100" MODIFIED_BY="Kate Jewitt" NAME="Ishibashi 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-10-23 10:46:10 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H</AU>
<TI>Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study</TI>
<SO>International Journal of Clinical Oncology</SO>
<YR>2010</YR>
<VL>15</VL>
<NO>1</NO>
<PG>82-7</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:46:10 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:46:10 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="20108160"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanat-2003" MODIFIED="2012-10-23 10:45:34 +0100" MODIFIED_BY="Angela A Gunn" NAME="Kanat 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-10-23 10:45:34 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanat O, Evrensel T, Baran I, Coskun H, Zarifoglu M, Turan OF, et al</AU>
<TI>Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study</TI>
<SO>Medical Oncology</SO>
<YR>2003</YR>
<VL>20</VL>
<NO>3</NO>
<PG>237-45</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:45:34 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:45:34 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="14514973"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kemp-1996" MODIFIED="2012-10-23 10:36:44 +0100" MODIFIED_BY="Kate Jewitt" NAME="Kemp 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-10-23 10:35:49 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, et al</AU>
<TI>Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1996</YR>
<VL>14</VL>
<NO>7</NO>
<PG>2101-12</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:35:49 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:35:49 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="8683243"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-23 10:36:44 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rose PG</AU>
<TI>Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma</TI>
<SO>Seminars in Oncology</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>4 Suppl 8</NO>
<PG>83-9</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:36:21 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:36:21 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="8783673"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knijn-2011" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Knijn 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knijn N, Tol J, Koopman M, Werter MJ, Imholz AL, Valster FA, et al</AU>
<TI>The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients</TI>
<SO>European Journal of Cancer</SO>
<YR>2011</YR>
<VL>47</VL>
<NO>3</NO>
<PG>369-74</PG>
<IDENTIFIERS MODIFIED="2014-02-05 15:12:13 +0000" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2014-02-05 15:12:13 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE=" 21067912"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kottschade-2011" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Kottschade 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, et al</AU>
<TI>The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2011</YR>
<VL>19</VL>
<NO>11</NO>
<PG>1769-77</PG>
<IDENTIFIERS MODIFIED="2014-02-04 16:32:11 +0000" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2014-02-04 16:32:11 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="20936417"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2006" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Lin 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin PC, Lee MY, Wang WS, Yen CC, Chao TC, Hsiao LT, et al</AU>
<TI>N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>5</NO>
<PG>484-7</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:44:47 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:44:47 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="16450089"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lorusso-2003" MODIFIED="2012-10-23 10:44:04 +0100" MODIFIED_BY="Angela A Gunn" NAME="Lorusso 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-10-23 10:44:04 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S, et al</AU>
<TI>Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients</TI>
<SO>Annals of Oncology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>7</NO>
<PG>1086-93</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:44:04 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:44:04 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="12853351"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2008" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Lu 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu P, Fan QX, Wang LX, Wang X, Zong H, Wang RL</AU>
<TI>Prophylactic effect of amifostine on oxaliplatin-related neurotoxicity in patients with digestive tract tumors</TI>
<SO>Ai Zheng [Chinese Journal of Cancer]</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>10</NO>
<PG>1117-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Milla-2009" MODIFIED="2012-10-23 10:43:29 +0100" MODIFIED_BY="Kate Jewitt" NAME="Milla 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-10-23 10:43:29 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattel L</AU>
<TI>Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity</TI>
<SO>Anticancer Drugs</SO>
<YR>2009</YR>
<VL>20</VL>
<NO>5</NO>
<PG>396-402</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:43:29 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:43:29 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="19287306"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pace-2003" MODIFIED="2012-10-23 10:39:20 +0100" MODIFIED_BY="Angela A Gunn" NAME="Pace 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-10-23 10:39:20 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del MG, et al</AU>
<TI>Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>5</NO>
<PG>927-31</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:39:20 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:39:20 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="12610195"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Planting-1999" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Planting 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Planting AS, Catimel G, de Mulder PH, de Graeff A, Höppener F, Verweij J, et al</AU>
<TI>Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group</TI>
<SO>Annals of Oncology</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>6</NO>
<PG>693-700</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:39:50 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:39:50 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="10442192"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roberts-1997" MODIFIED="2012-10-23 10:40:23 +0100" MODIFIED_BY="Angela A Gunn" NAME="Roberts 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-10-23 10:40:23 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberts JA, Jenison EL, Kim K, Clarke-Pearson D, Langleben A</AU>
<TI>A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer</TI>
<SO>Gynecologic Oncology</SO>
<YR>1997</YR>
<VL>67</VL>
<NO>2</NO>
<PG>172-7</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:40:23 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:40:23 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="9367703"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidinger-2000" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Schmidinger 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidinger M, Budinsky AC, Wenzel C, Piribauer M, Brix R, Kautzky M, et al</AU>
<TI>Glutathione in the prevention of cisplatin induced toxicities: a prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>2000</YR>
<VL>112</VL>
<NO>14</NO>
<PG>617-23</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:41:10 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:41:10 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="11008323"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smyth-1997" MODIFIED="2012-10-23 10:41:41 +0100" MODIFIED_BY="Angela A Gunn" NAME="Smyth 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-10-23 10:41:41 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smyth JF, Bowman A, Perren T, Wilkinson P, Prescott RJ, Quinn KJ, et al</AU>
<TI>Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial</TI>
<SO>Annals of Oncology</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>6</NO>
<PG>569-73</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:41:41 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:41:41 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="9261526"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Hoop-1990" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="van der Hoop 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerritsen van der Hoop R, Vecht CJ, van der Burg ME, Elderson A, Boogerd W, Heimans JJ, et al</AU>
<TI>Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>1990</YR>
<VL>322</VL>
<NO>2</NO>
<PG>89-94</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:42:11 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:42:11 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="2152972"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Gerven-1994" MODIFIED="2014-02-10 23:30:31 +0000" MODIFIED_BY="Angela A Gunn" NAME="van Gerven 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-02-10 23:30:31 +0000" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Gerven JMA, Hovestadt A, Moll JW, Rodenburg CJ, Splinter TA, van Oosterom AT, et al</AU>
<TI>The effects of an ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial</TI>
<SO>Journal of Neurology</SO>
<YR>1994</YR>
<VL>241</VL>
<NO>7</NO>
<PG>432-5</PG>
<IDENTIFIERS MODIFIED="2012-10-23 10:42:38 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-10-23 10:42:38 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="7931444"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-02-27 10:15:03 +0000" MODIFIED_BY="Ruth Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-Ali-2009" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Ali 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ali BH</AU>
<TI>Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals: a minireview of recent literature</TI>
<SO>Basic &amp; Clinical Pharmacology &amp; Toxicology</SO>
<YR>2009</YR>
<VL>106</VL>
<PG>272-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ao-2012" MODIFIED="2014-02-27 10:15:03 +0000" MODIFIED_BY="Ruth Brassington" NAME="Ao 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ao R, Wang Y-H, Li R-W, Wang Z-R</AU>
<TI>Effects of calcium and magnesium on acute and chronic neurotoxicity caused by oxaliplatin: a meta-analysis</TI>
<SO>Experimental and Therapeutic Medicine</SO>
<YR>2012</YR>
<VL>4</VL>
<NO>5</NO>
<PG>933-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Argyriou-2005" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Argyriou 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, et al</AU>
<TI>Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>1</NO>
<PG>26-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Block-2005" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Block 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Block KI, Gyllenhaal C</AU>
<TI>Commentary: the pharmacological antioxidant amifostine -- implications of recent research for integrative cancer care</TI>
<SO>Integrative Cancer Therapies</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>4</NO>
<PG>329-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bogliun-1992" NAME="Bogliun 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bogliun G, Marzorati L, Cavaletti G, Frattola L</AU>
<TI>Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione</TI>
<SO>Italian Journal of Neurological Sciences</SO>
<YR>1992</YR>
<VL>13</VL>
<NO>8</NO>
<PG>643-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cancer-Care-Ontario-2012" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Cancer Care Ontario 2012" YEAR="1998">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="OTHER">
<AU>Program in Evidence-based Care</AU>
<TI>Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer</TI>
<SO>Toronto (ON): Cancer Care Ontario; 2012 May 15 [Archived 2011 Sep]. Program in Evidence-based Care Evidence-based Series No.: 12-6 ARCHIVED 2011. https://www.cancercare.on.ca/toolbox/qualityguidelines/clin-program/systemic-ebs/</SO>
<YR>(accessed 12 September 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capizzi-1995" MODIFIED="2010-10-07 18:39:05 +0100" MODIFIED_BY="[Empty name]" NAME="Capizzi 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-10-07 18:39:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Capizzi RL, Oster W, Capizzi RL, Oster W</AU>
<TI>Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences</TI>
<SO>European Journal of Cancer</SO>
<YR>1995</YR>
<VL>31A</VL>
<NO>Suppl 1</NO>
<PG>S8-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cassidy-1998" MODIFIED="2011-01-10 12:29:26 +0000" MODIFIED_BY="Kate Jewitt" NAME="Cassidy 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-01-10 12:29:26 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cassidy J, Paul J, Soukop M, Habeshaw T, Reed NS, Parkin D, et al</AU>
<TI>Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin</TI>
<SO>Cancer Chemotherapy &amp; Pharmacology</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>2</NO>
<PG>161-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Catalano-1999" NAME="Catalano 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Catalano V</AU>
<TI>An evaluation of potential neuroprotective effect of reduced-glutathione (GSH) on oxaliplatin (OXA) based chemotherapy in advanced colorectal cancer patients [abstract no: 1529]</TI>
<SO>European Journal of Cancer</SO>
<YR>1999</YR>
<VL>35</VL>
<PG>S375</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2012" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Chen 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen XF, Wang R, Yin YM, Roe OD, Li J, Zhu LJ, et al</AU>
<TI>The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study</TI>
<SO>Biomedicine &amp; Pharmacotherapy</SO>
<YR>2012</YR>
<VL>66</VL>
<NO>4</NO>
<PG>279-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Culy-2001" NAME="Culy 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Culy CR, Spencer CM</AU>
<TI>Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome</TI>
<SO>Drugs</SO>
<YR>2001</YR>
<VL>61</VL>
<NO>5</NO>
<PG>641-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Grandis-2007" MODIFIED="2011-01-10 12:29:35 +0000" MODIFIED_BY="Kate Jewitt" NAME="De Grandis 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-01-10 12:29:35 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Grandis D</AU>
<TI>Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review</TI>
<SO>CNS Drugs</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>Suppl 1</NO>
<PG>39-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Vos-2005" MODIFIED="2011-01-10 12:29:54 +0000" MODIFIED_BY="Kate Jewitt" NAME="De Vos 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-01-10 12:29:54 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Vos FY, Bos AM, Schaapveld M, de Swart CA, de Graaf H, van der Zee AG, et al</AU>
<TI>A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma</TI>
<SO>Gynecologic Oncology</SO>
<YR>2005</YR>
<VL>97</VL>
<NO>1</NO>
<PG>60-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Durand-2003" MODIFIED="2011-01-10 12:30:06 +0000" MODIFIED_BY="Kate Jewitt" NAME="Durand 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-01-10 12:30:06 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Durand JP, Brezault C, Goldwasser F</AU>
<TI>Protection against oxaliplatin acute neurosensory toxicity by venlafaxine</TI>
<SO>Anticancer Drugs</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>6</NO>
<PG>423-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gamelin-2004" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Gamelin 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gamelin L, Boisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N, Morel A, et al</AU>
<TI>Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer</TI>
<SO>Clinical Cancer Research</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>12 Pt 1</NO>
<PG>4055-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gamelin-2008" MODIFIED="2011-01-10 12:30:57 +0000" MODIFIED_BY="Kate Jewitt" NAME="Gamelin 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-01-10 12:30:57 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gamelin L, Boisdron-Celle M, Morel A, Poirier AL, Berger V, Gamelin E, et al</AU>
<TI>Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy (letter)</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>7</NO>
<PG>1188-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gedlicka-2003" NAME="Gedlicka 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gedlicka C, Kornek GV, Schmid K, Scheithauer W</AU>
<TI>Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid (letter)</TI>
<SO>Annals of Oncology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>2</NO>
<PG>339-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gispen-1992" NAME="Gispen 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gispen WH, Hamers FP, Vecht CJ, Jennekens FG, Neyt JP</AU>
<TI>ACTH/MSH like peptides in the treatment of cisplatin neuropathy</TI>
<SO>Journal of Steroid Biochemistry &amp; Molecular Biology</SO>
<YR>1992</YR>
<VL>43</VL>
<NO>1-3</NO>
<PG>179-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glover-1987" NAME="Glover 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glover D, Glick JH, Weiler C</AU>
<TI>WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1987</YR>
<VL>5</VL>
<NO>4</NO>
<PG>574-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glover-1989" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Glover 1989" YEAR="1989">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glover D, Grabelsky S, Fox K, Weiler C, Cannon L, Glick J</AU>
<TI>Clinical trials of WR-2721 and cis-platinum</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1989</YR>
<VL>16</VL>
<NO>5</NO>
<PG>1201-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glover-2003" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Glover 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glover D, Ibrahim J, Kirkwood J, Glick J, Karp D, Stewart J, et al</AU>
<TI>Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: An Eastern Cooperative Oncology Group Study (E1686)</TI>
<SO>Melanoma Research</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>6</NO>
<PG>619-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gradishar-2001" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Gradishar 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gradishar WJ, Stephenson P, Glover DJ, Neuberg DS, Moore MR, Windschitl HE, et al</AU>
<TI>A phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188)</TI>
<SO>Cancer</SO>
<YR>2001</YR>
<VL>92</VL>
<NO>10</NO>
<PG>2517-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grothey-2005" MODIFIED="2011-01-10 12:31:09 +0000" MODIFIED_BY="Kate Jewitt" NAME="Grothey 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-01-10 12:31:09 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grothey A</AU>
<TI>Clinical management of oxaliplatin-associated neurotoxicity</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>S38-S46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haigentz-2003" NAME="Haigentz 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haigentz JM, Kim M, Sorich J, Lee J, Hochster H, Macapinlac M, et al</AU>
<TI>Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies</TI>
<SO>Anti-Cancer Drugs</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>4</NO>
<PG>321-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heidenreich-1999" NAME="Heidenreich 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heidenreich A, Marx FJ, Peters HJ, Engelmann UH, Hannappel J, Leusmann D</AU>
<TI>Amifostine as protective agent in cisplatin-based chemotherapy of advanced bladder cancer. [German]</TI>
<SO>Urologe</SO>
<YR>1999</YR>
<VL>38</VL>
<NO>6</NO>
<PG>586-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hensley-2009" MODIFIED="2011-01-10 12:31:30 +0000" MODIFIED_BY="Kate Jewitt" NAME="Hensley 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-01-10 12:31:30 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, et al</AU>
<TI>American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>1</NO>
<PG>127-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hilkens-1995" NAME="Hilkens 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hilkens PH, van-der-Burg ME, Moll JW, Planting AS, van-Putten WL, Vecht CJ, et al</AU>
<TI>Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration</TI>
<SO>European Journal of Cancer</SO>
<YR>1995</YR>
<VL>31A</VL>
<NO>5</NO>
<PG>678-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hilpert-2005" MODIFIED="2011-01-10 12:31:52 +0000" MODIFIED_BY="Kate Jewitt" NAME="Hilpert 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-01-10 12:31:52 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hilpert F, Stahle A, Tome O, Burges A, Rossner D, Spathe K, et al</AU>
<TI>Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>10</NO>
<PG>797-805</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hochster-2007" MODIFIED="2011-01-10 12:32:02 +0000" MODIFIED_BY="Kate Jewitt" NAME="Hochster 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-01-10 12:32:02 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hochster HS, Grothey A, Childs BH</AU>
<TI>Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>25</NO>
<PG>4028-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kesari-2005" NAME="Kesari 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kesari S, Wen PY</AU>
<TI>Neuroprotective effect of vitamin E supplementation (commentary)</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>1</NO>
<PG>1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leong-2003" NAME="Leong 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leong SS, Tan EH, Fong KW, Wilder-Smith E, Ong YK, Tai BC, et al</AU>
<TI>Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>9</NO>
<PG>1767-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lissoni-1997" NAME="Lissoni 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lissoni P, Tancini G, Barni S, Paolorossi F, Ardizzoia A, Conti A, et al</AU>
<TI>Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1997</YR>
<VL>5</VL>
<NO>2</NO>
<PG>126-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lissoni-1999" MODIFIED="2010-10-12 15:51:56 +0100" MODIFIED_BY="Kate Jewitt" NAME="Lissoni 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-10-12 15:51:56 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lissoni P, Barni S, Mandala M, Ardizzoia A, Paolorossi F, Vaghi M, et al</AU>
<TI>Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumor patients with poor clinical status</TI>
<SO>European Journal of Cancer</SO>
<YR>1999</YR>
<VL>35</VL>
<NO>12</NO>
<PG>1688-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lissoni-2002" NAME="Lissoni 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lissoni P, Vaghi M, Ardizzoia A, Malugani F, Fumagalli E, Bordin V, et al</AU>
<TI>A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha</TI>
<SO>In Vivo</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>2</NO>
<PG>93-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-2008" MODIFIED="2011-01-10 12:32:43 +0000" MODIFIED_BY="Kate Jewitt" NAME="Miller 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-01-10 12:32:43 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller AA, Wang XF, Gu L, Hoffman P, Khatri J, Dunphy F, et al</AU>
<TI>Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303)</TI>
<SO>Journal of Thoracic Oncology</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>10</NO>
<PG>1159-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mollman-1988" NAME="Mollman 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mollman JE, Glover DJ, Hogan WM, Furman RE</AU>
<TI>Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721</TI>
<SO>Cancer</SO>
<YR>1988</YR>
<VL>61</VL>
<NO>11</NO>
<PG>2192-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moore-2003" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Moore 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore DH, Donnelly J, McGuire WP, Almadrones L, Cella DF, Herzog TJ, et al</AU>
<TI>Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>22</NO>
<PG>4207-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="14615449"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pace-2005" MODIFIED="2011-01-10 12:32:54 +0000" MODIFIED_BY="Kate Jewitt" NAME="Pace 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-01-10 12:32:54 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pace A, Bove L, Jandolo B</AU>
<TI>Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>65</VL>
<NO>3</NO>
<PG>501-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pace-2010" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Pace 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pace A, Giannarelli D, Galie E, Savarese A, Carpano S, Della GM, et al</AU>
<TI>Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial</TI>
<SO>Neurology</SO>
<YR>2010</YR>
<VL>74</VL>
<NO>9</NO>
<PG>762-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Penz-2001" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Penz 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Scheithauer W</AU>
<TI>Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy</TI>
<SO>Annals of Oncology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>3</NO>
<PG>421-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rick-2001" NAME="Rick 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rick O, Beyer J, Schwella N, Schubart H, Schleicher J, Siegert W</AU>
<TI>Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor</TI>
<SO>Annals of Oncology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>8</NO>
<PG>1151-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2007" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Wang 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang WS, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, et al</AU>
<TI>Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients</TI>
<SO>Oncologist</SO>
<YR>2007</YR>
<VL>12</VL>
<NO>3</NO>
<PG>312-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-09-07 17:36:44 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wen-2013" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Wen 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wen F, Zhou Y, Wang W, Hu QC, Liu YT, Zhang PF, et al</AU>
<TI>Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis</TI>
<SO>Annals of Oncology</SO>
<YR>2013</YR>
<VL>24</VL>
<NO>1</NO>
<PG>171-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="22898039"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilkes-2007" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Wilkes 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilkes G</AU>
<TI>Peripheral neuropathy related to chemotherapy</TI>
<SO>Seminars in Oncology Nursing</SO>
<YR>2007</YR>
<VL>23</VL>
<NO>3</NO>
<PG>162-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-Dong-2010" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Dong 2010" YEAR="">
<REFERENCE MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dong M, Xing PY, Liu P, Feng FY, Shi YK</AU>
<TI>[Assessment of the protective effect of calcium-magnesium infusion and glutathione on oxaliplatin-induced neurotoxicity]</TI>
<SO>Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]</SO>
<YR>2010</YR>
<VL>32</VL>
<NO>3</NO>
<PG>208-11</PG>
<IDENTIFIERS MODIFIED="2014-02-10 22:06:28 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2014-02-10 22:06:28 +0000" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="20450590"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pang-2010" MODIFIED="2013-11-11 21:32:16 +0000" MODIFIED_BY="[Empty name]" NAME="Pang 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-11-11 21:32:16 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pang DM, Deng YM, Lan XS, Feng WN, Liang JM, Xu YH</AU>
<TI>Efficacy of reduced glutathione in preventing and reducing neurotoxicity of oxaliplatin [Chinese]</TI>
<SO>Chinese Journal of Cancer Prevention and Treatment</SO>
<YR>2010</YR>
<VL>17</VL>
<PG>2059</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romano-2011" MODIFIED="2013-11-11 21:30:30 +0000" MODIFIED_BY="[Empty name]" NAME="Romano 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-11-11 21:30:30 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Romano LM</AU>
<TI>Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. [Spanish]</TI>
<SO>Neurologia Argentina</SO>
<YR>2011</YR>
<VL>3</VL>
<PG>146</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington">
<ADDITIONAL_REFERENCES MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington">
<REFERENCE ID="REF-Carozzi-2010" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Carozzi 2010" TYPE="OTHER">
<AU>Carozzi VA, Canta A, Oggioni N, Sala B, Chiorazzi A, Meregalli C, et al</AU>
<TI>Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies</TI>
<SO>Experimental Neurology</SO>
<YR>2010</YR>
<VL>226</VL>
<NO>2</NO>
<PG>301-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cavaletti-1992" NAME="Cavaletti 1992" TYPE="JOURNAL_ARTICLE">
<AU>Cavaletti G, Tredici G, Marmiroli P, Petruccioli MG, Barajon I, Fabbrica D</AU>
<TI>Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats</TI>
<SO>Acta Neuropathologica</SO>
<YR>1992</YR>
<VL>84</VL>
<NO>4</NO>
<PG>364-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cavaletti-2004" MODIFIED="2011-01-10 12:34:12 +0000" MODIFIED_BY="Kate Jewitt" NAME="Cavaletti 2004" TYPE="JOURNAL_ARTICLE">
<AU>Cavaletti G, Marmiroli P, Cavaletti G, Marmiroli P</AU>
<TI>Chemotherapy-induced peripheral neurotoxicity</TI>
<SO>Expert Opinion on Drug Safety</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>6</NO>
<PG>535-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cavaletti-2010a" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Cavaletti 2010a" TYPE="JOURNAL_ARTICLE">
<AU>Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, et al</AU>
<TI>Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools</TI>
<SO>European Journal of Cancer</SO>
<YR>2010</YR>
<VL>46</VL>
<NO>3</NO>
<PG>479-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cavaletti-2013" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Cavaletti 2013" TYPE="JOURNAL_ARTICLE">
<AU>Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, et al</AU>
<TI>The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings</TI>
<SO>Annals of Oncology</SO>
<YR>2013</YR>
<VL>24</VL>
<NO>2</NO>
<PG>454-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elderson-1989" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Elderson 1989" TYPE="JOURNAL_ARTICLE">
<AU>Elderson A, Gerritsen van der Hoop R, Haanstra W, Neijt JP, Gispen WH, Jennekens FG</AU>
<TI>Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1989</YR>
<VL>93</VL>
<NO>2-3</NO>
<PG>167-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gandara-1991" NAME="Gandara 1991" TYPE="JOURNAL_ARTICLE">
<AU>Gandara DR, Perez EA, Weibe V, De Gregorio MW</AU>
<TI>Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity</TI>
<SO>Seminars in Oncology</SO>
<YR>1991</YR>
<VL>18</VL>
<NO>1 Suppl 3</NO>
<PG>49-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grothey-2003" NAME="Grothey 2003" TYPE="JOURNAL_ARTICLE">
<AU>Grothey A</AU>
<TI>Oxaliplatin-safety profile: Neurotoxicity</TI>
<SO>Seminars in Oncology</SO>
<YR>2003</YR>
<VL>30</VL>
<NO>4 Suppl 15</NO>
<PG>5-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grothey-2004" MODIFIED="2011-01-10 12:34:23 +0000" MODIFIED_BY="Kate Jewitt" NAME="Grothey 2004" TYPE="JOURNAL_ARTICLE">
<AU>Grothey A, Goldberg RM</AU>
<TI>A review of oxaliplatin and its clinical use in colorectal cancer</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>10</NO>
<PG>2159-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-10-05 20:32:59 +0100" MODIFIED_BY="Kate Jewitt" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green SE (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]</TI>
<SO>The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krarup_x002d_Hansen-1993" NAME="Krarup-Hansen 1993" TYPE="JOURNAL_ARTICLE">
<AU>Krarup-Hansen A, Fugleholm K, Helweg-Larsen S, Hauge EN, Schmalbruch H, Trojaborg W, et al</AU>
<TI>Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function</TI>
<SO>Brain</SO>
<YR>1993</YR>
<VL>116</VL>
<NO>Pt 5</NO>
<PG>1017-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Links-1999" MODIFIED="2010-10-05 20:32:44 +0100" MODIFIED_BY="Kate Jewitt" NAME="Links 1999" TYPE="JOURNAL_ARTICLE">
<AU>Links M, Lewis C, Links M, Lewis C</AU>
<TI>Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy</TI>
<SO>Drugs</SO>
<YR>1999</YR>
<VL>57</VL>
<NO>3</NO>
<PG>293-308</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mollman-1990" NAME="Mollman 1990" TYPE="JOURNAL_ARTICLE">
<AU>Mollman JE</AU>
<TI>Cisplatin neurotoxicity</TI>
<SO>New England Journal of Medicine</SO>
<YR>1990</YR>
<VL>322</VL>
<NO>2</NO>
<PG>126-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Molloy-2001" NAME="Molloy 2001" TYPE="JOURNAL_ARTICLE">
<AU>Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, et al</AU>
<TI>Thalidomide neuropathy in patients treated for metastatic prostate cancer</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2001</YR>
<VL>24</VL>
<PG>1050-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pisano-2003" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Pisano 2003" TYPE="JOURNAL_ARTICLE">
<AU>Pisano C, Pratesi G, Laccabue D, Zunino F, Giudice PL, Bellucci A, et al</AU>
<TI>Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine</TI>
<SO>Clinical Cancer Research</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>15</NO>
<PG>5756-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prestayko-1979" NAME="Prestayko 1979" TYPE="JOURNAL_ARTICLE">
<AU>Prestayko AW, D'Aoust JC, Issell BF, Crooke ST</AU>
<TI>Cisplatin (cis-diamminedichloroplatinum II)</TI>
<SO>Cancer Treatment Reviews</SO>
<YR>1979</YR>
<VL>6</VL>
<PG>17-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roelofs-1984" NAME="Roelofs 1984" TYPE="JOURNAL_ARTICLE">
<AU>Roelofs RI, Hrushesky W, Rogin J, Rosenberg L</AU>
<TI>Peripheral sensory neuropathy and cisplatin chemotherapy</TI>
<SO>Neurology (Minneap)</SO>
<YR>1984</YR>
<VL>34</VL>
<PG>934-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rose-1996" MODIFIED="2010-09-19 14:00:48 +0100" MODIFIED_BY="[Empty name]" NAME="Rose 1996" TYPE="JOURNAL_ARTICLE">
<AU>Rose PG</AU>
<TI>Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma</TI>
<SO>Seminars in Oncology</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>4 Suppl 8</NO>
<PG>83-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmidt-1995" NAME="Schmidt 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt Y, Unger JW, Bartke I, Reiter R</AU>
<TI>Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (db/db) mice</TI>
<SO>Experimental Neurology</SO>
<YR>1995</YR>
<VL>132</VL>
<NO>1</NO>
<PG>16-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1984" MODIFIED="2010-10-13 11:24:52 +0100" MODIFIED_BY="Kate Jewitt" NAME="Thompson 1984" TYPE="JOURNAL_ARTICLE">
<AU>Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC</AU>
<TI>Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies</TI>
<SO>Cancer</SO>
<YR>1984</YR>
<VL>54</VL>
<NO>7</NO>
<PG>1269-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tomiwa-1986" NAME="Tomiwa 1986" TYPE="JOURNAL_ARTICLE">
<AU>Tomiwa K, Nolan C, Cavanagh JB</AU>
<TI>The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry</TI>
<SO>Acta Neuropathologica</SO>
<YR>1986</YR>
<VL>69</VL>
<NO>3-4</NO>
<PG>295-308</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Von-Hoff-1979" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Von Hoff 1979" TYPE="JOURNAL_ARTICLE">
<AU>Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, et al</AU>
<TI>Toxic effects of cis-dichlorodiammineplatinum(II) in man</TI>
<SO>Cancer Treatment Report</SO>
<YR>1979</YR>
<VL>63</VL>
<NO>9-10</NO>
<PG>1527-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wald-1994" NAME="Wald 1994" TYPE="JOURNAL_ARTICLE">
<AU>Wald JJ, Albers JW, Simmons Z, Roberts JA, Capo B</AU>
<TI>Cisplatin neuropathy: clinical and nerve conduction correlation (abstr)</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1994</YR>
<VL>17</VL>
<PG>1116-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wald-1995" MODIFIED="2014-02-10 23:50:36 +0000" MODIFIED_BY="Ruth Brassington" NAME="Wald 1995" TYPE="JOURNAL_ARTICLE">
<AU>Wald JJ, Albers JW, Simmons Z, Roberts JA, Capo B</AU>
<TI>Cisplatin neuropathy not prevented by ACTH(4-9) analog (abstr)</TI>
<SO>Neurology</SO>
<YR>1995</YR>
<VL>45 (Suppl 4)</VL>
<PG>A170</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Windebank-1994" NAME="Windebank 1994" TYPE="JOURNAL_ARTICLE">
<AU>Windebank AJ, Smith AG, Russell JW</AU>
<TI>The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro</TI>
<SO>Neurology</SO>
<YR>1994</YR>
<VL>44</VL>
<NO>3 Pt 1</NO>
<PG>488-94</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-02-11 09:52:17 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Albers-2005" MODIFIED="2014-02-11 09:51:52 +0000" MODIFIED_BY="[Empty name]" NAME="Albers 2005" TYPE="COCHRANE_PROTOCOL">
<AU>Albers J, Chaudhry V, Donehower R, Cavaletti G</AU>
<TI>Interventions for preventing neuropathy caused by cisplatin and related compounds</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-02-07 13:58:36 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-07 13:58:36 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005228"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Albers-2007" MODIFIED="2014-02-11 09:52:08 +0000" MODIFIED_BY="[Empty name]" NAME="Albers 2007" TYPE="COCHRANE_REVIEW">
<AU>Albers J, Chaudhry V, Cavaletti G, Donehower R</AU>
<TI>Interventions for preventing neuropathy caused by cisplatin and related compounds</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-02-07 13:59:57 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-07 13:59:57 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005228.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Albers-2011" MODIFIED="2014-02-11 09:52:17 +0000" MODIFIED_BY="[Empty name]" NAME="Albers 2011" TYPE="COCHRANE_REVIEW">
<AU>Albers JW, Chaudhry V, Cavaletti G, Donehower RC</AU>
<TI>Interventions for preventing neuropathy caused by cisplatin and related compounds</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-02-07 14:02:00 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-07 14:02:00 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005228.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2010-09-07 18:13:43 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-New-Reference" MODIFIED="2010-09-07 18:13:43 +0100" MODIFIED_BY="[Empty name]" NAME="New Reference" TYPE="JOURNAL_ARTICLE">
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-02-27 17:59:22 +0000" MODIFIED_BY="Ruth Brassington">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-02-27 17:59:22 +0000" MODIFIED_BY="Ruth Brassington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-02-19 12:23:52 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Argyriou-2006">
<CHAR_METHODS MODIFIED="2013-12-12 17:22:02 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised, open label with blind assessment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-19 12:23:48 +0000" MODIFIED_BY="Kate Jewitt">
<P>30 participants with variety of cancers scheduled to receive cisplatin-based regimens plus other chemotherapy drugs (including 5 who received docetaxel)</P>
<P>14 participants received vitamin E (vit E) supplementation and 16 participants served as controls (no vit E)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-19 12:23:50 +0000" MODIFIED_BY="[Empty name]">
<P>Vit E 600 mg/day during chemotherapy and for 3 months after completion of treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-08 21:25:34 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Sural SNAP amplitude showed a significant decline in the control group relative to the vit E group</LI>
<LI>Superficial peroneal SNAP amplitude showed a significant decline in the control group relative to the vit E group</LI>
<LI>Ulnar SNAP amplitude showed a significant decline in control group relative to the vit E group</LI>
<LI>The overall incidence of peripheral neuropathy differed significantly (5/16 vit E vs 13/19 no vit E)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-19 12:23:52 +0000" MODIFIED_BY="Kate Jewitt">
<P>The trial authors concluded that 1. vit E was well tolerated and effectively protected against cisplatin neurotoxicity, a result supported by electrophysiology, although 2. due to the lack of a placebo group, they were unable to rule out the possibility that bias contaminated participant self reported information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-19 12:23:59 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Argyriou-2006a">
<CHAR_METHODS MODIFIED="2013-12-12 17:21:55 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised, open label with blind assessment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-19 12:23:57 +0000" MODIFIED_BY="Kate Jewitt">
<P>Initially participants with colon cancer scheduled to receive FOLFOX-4, which included oxaliplatin 85 mg/m² every 2 weeks for 12 courses. 20 participants were randomised to treatment with oxcarbazepine and 20 to no treatment (16 participants in each group completed the study for n = 32 total)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-17 15:47:33 +0000" MODIFIED_BY="Kate Jewitt">
<P>Oxcarbazepine, initiated at 150 mg/day and titrated over 4 weeks to 600 mg twice daily and maintained for 20 weeks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-19 12:23:58 +0000" MODIFIED_BY="Kate Jewitt">
<OL>
<LI>Sural SNAP amplitude showed a significant decline in the control group relative to the oxcarbazepine group</LI>
<LI>Superficial peroneal SNAP amplitude showed a significant decline in the control group relative to the oxcarbazepine group</LI>
<LI>Ulnar SNAP amplitude showed no significant group difference</LI>
<LI>The overall incidence of peripheral neuropathy differed significantly (9/20 oxcarbazepine vs 16/20 no treatment).</LI>
<LI>The severity of neuropathy (total neuropathy score) significantly favoured the oxcarbazepine group</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-19 12:23:59 +0000" MODIFIED_BY="Kate Jewitt">
<P>The trial authors concluded that oxcarbazepine might be able to protect against oxaliplatin-induced neuropathy. They acknowledged that the small sample size and the lack of a placebo group were limitations of the study design, but that larger placebo-controlled trials were warranted</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-27 09:59:55 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Arrieta-2011">
<CHAR_METHODS MODIFIED="2014-02-11 10:10:30 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective, randomised, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-08 23:37:29 +0000" MODIFIED_BY="[Empty name]">
<P>Histologically-confirmed stage IIIB/IV NSCLC treated with cisplatin 80 mg/m² AND paclitaxil 175 mg/m²</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-08 23:37:30 +0000" MODIFIED_BY="[Empty name]">
<P>Retinoic acid (ATRA), 20 mg/m²/day beginning 1 week prior to chemotherapy initiation and continuing until completion of two courses</P>
<P>45 intervention and 47 control participants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-19 12:24:03 +0000" MODIFIED_BY="[Empty name]">
<P>NCSs including sural, median, and ulnar sensory response (and peroneal motor) amplitude and latency measures, with quantitative results converted to a non-parametric "grade of damage," ranked from zero to three for latency and amplitude measures</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-19 12:24:05 +0000" MODIFIED_BY="[Empty name]">
<P>Period of evaluation (ie. 6 weeks to the end of second course of chemotherapy) was very likely inadequate. Also, the investigators did not separate motor and sensory electrophysiology, which is physiologically nonsensical</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-27 10:00:37 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Bogliun-1996">
<CHAR_METHODS MODIFIED="2014-02-11 10:10:24 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-08 23:37:33 +0000" MODIFIED_BY="[Empty name]">
<P>54 participants with ovarian cancer treated with cisplatin (50 mg/m² and 75 mg/m² x 3 weeks); 27 participants received GSH and 27 participants served as controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-19 12:24:11 +0000" MODIFIED_BY="[Empty name]">
<P>GSH 2.5 g before cisplatin<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-19 12:24:34 +0000" MODIFIED_BY="[Empty name]">
<P>For GSH vs control group:</P>
<OL>
<LI>VPT: 2- to 3-fold increase vs 7- to 10-fold increase</LI>
<LI>Sural amplitude decreases of 12% and 35% for low and high dose CDDP (GSH) and of 58% and 68% for high and low dose CDDP (control)</LI>
<LI>NIS changed &gt; 12 points in 5/19 vs 8/16</LI>
<LI>NSS symptoms of neuropathy 14/19 vs 16/16</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-12 14:02:48 +0000" MODIFIED_BY="Ruth Brassington">
<P>1. No statistics used because of small numbers<BR/>2. Trend towards less peripheral neuropathy with GSH in all measures. The authors concluded that, despite the small numbers and lack of statistical analyses, neuroprotection was not complete but there was a trend toward less severe toxicity after cotreatment with GSH<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-19 12:24:46 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Cascinu-1995">
<CHAR_METHODS MODIFIED="2014-02-11 10:10:18 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-08 23:37:35 +0000" MODIFIED_BY="[Empty name]">
<P>50 participants with ovarian cancer treated with cisplatin (40 mg/m² every week x 9 weeks); 25 participants received GSH and 25 participants served as controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-19 12:24:36 +0000" MODIFIED_BY="[Empty name]">
<P>GSH 1.5 g/m² or placebo before cisplatin<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-19 12:24:46 +0000" MODIFIED_BY="Kate Jewitt">
<P>1. Sural SNAP: significant change in control group only </P>
<P>2. Ulnar SNAP: significant change in control group only</P>
<P>3. Median SNAP: significant change in control group only</P>
<P>4. At 9 weeks, 0 participants in the GSH group developed neurotoxicity by WHO criteria vs 16/18 in the control group and at 15 weeks, the figures were 4/24 in the GSH group vs 16/18 in the control group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-19 12:24:46 +0000" MODIFIED_BY="Kate Jewitt">
<P>Long-term follow-up unclear. The trial authors believed that the results established GSH as a promising and partially effective agent for the prevention of cisplatin-induced and oxaliplatin-induced neurotoxicity</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-27 17:59:22 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Cascinu-2002">
<CHAR_METHODS MODIFIED="2014-02-11 10:10:12 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-08 23:37:37 +0000" MODIFIED_BY="[Empty name]">
<P>52 participants with colorectal cancer treated with oxaliplatin (100 mg/m² x 2 every 2 weeks); 26 participants received GSH and 26 placebo-treated participants served as controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-19 12:24:54 +0000" MODIFIED_BY="[Empty name]">
<P>GSH 1.5 g/m²<SUP> </SUP>or normal saline as placebo before administration of oxaliplatin</P>
<P>Oxaliplatin 100 mg/m² x 2 every 2 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-27 17:59:22 +0000" MODIFIED_BY="Ruth Brassington">
<P>Neurotoxicity (NCI CTC)</P>
<P>Neurophysiology (sural sensory nerve conduction)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-19 12:24:58 +0000" MODIFIED_BY="Kate Jewitt">
<P>GSH reduced symptoms and signs of neuropathy significantly. GSH was partially protective on measures of sural amplitude and latency. The trial authors believed that the results established GSH as a promising and partially effective agent for the prevention of cisplatin-induced and oxaliplatin-induced neurotoxicity</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-27 10:00:46 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Chay-2010">
<CHAR_METHODS MODIFIED="2014-02-11 10:10:06 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective, randomised, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-19 12:25:02 +0000" MODIFIED_BY="[Empty name]">
<P>27 participants (19 intervention and 8 control) with histologically verified colorectal cancer receiving oxaliplatin and either XELOX (including oxaliplatin 130 mg/m² on day 1 every 21 days, received by 22 of 27 participants) or FOLFOX (including oxaliplatin um 85 mg/m² on day 1 every 2 weeks, received by 5 of 22 participants) for 12 cycles of chemotherapy; 78% of participants received &gt; 600 mg/m² of oxaliplatin-based chemotherapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-19 12:25:02 +0000" MODIFIED_BY="[Empty name]">
<P>Calcium gluconate 1 g (10 mL of 10% calcium gluconate) + 15% magnesium sulfate 1 g diluted into 100 mL of normal saline infused over 15 minutes before and after oxaliplatin infusion (Arm A) or placebo (Arm B)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-19 12:25:04 +0000" MODIFIED_BY="[Empty name]">
<P>Neuropathy was measured by clinical assessment and NCS</P>
<P>NCS included secondary outcomes of sural, superficial peroneal, median, ulnar, and radial sensory nerves, plus median, ulnar, radial, posterior tibial, and peroneal motor nerves.<B> </B>The results were considered abnormal if each of the studies was outside the normal values of the laboratory controls.</P>
<P>Incidence of subjective neuropathy and grade 3 numbness in both groups were compared, as were differences in all objective neuropathy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-08 23:13:21 +0000" MODIFIED_BY="[Empty name]">
<P>The planned follow-up was for a total of 3 years<B>,</B> with review every 3 months for the first year, then every 4 months the second year, and then every 6 months in subsequent years</P>
<P>Due to the trial termination, only 19 participants reached the end of the treatment for study. A total of 13 participants completed the planned 6 months of adjuvant chemotherapy. No participants in the treatment arm terminated chemotherapy prematurely while 3 participants in the placebo arm terminated treatment because of grade 3 neurotoxicity</P>
<P>Overall 22 out of 27 participants experienced neuropathy. The subjective neuropathy rate was 77% in Arm A and 86% in Arm B (P = 0.6). At the end of treatment, three participants in Arm A and 0 in Arm B had grade 3 numbness (P = 0.09). There was no significant difference in neuropathy between arms, whether during or at the end of treatment. The median objective neuropathy score was 6 in Arm A and 0 in Arm B (P = 0.02), indicating that the Ca/Mg treatment group had worse objective neuropathy scores than the placebo group<BR/>Conclusion: premature closure of this study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-27 10:01:55 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Colombo-1995">
<CHAR_METHODS MODIFIED="2014-02-11 10:10:00 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective, randomised, placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-17 15:53:09 +0000" MODIFIED_BY="[Empty name]">
<P>Women with relapsed ovarian carcinoma treated with weekly cisplatin</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-17 15:53:18 +0000" MODIFIED_BY="[Empty name]">
<P>16 receiving glutathione (GSH) and 17 controls</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-17 15:53:21 +0000" MODIFIED_BY="[Empty name]">
<P>Provided results of sural sensory NCS amplitudes (mean), and used the NCI-CTC neurotoxicity scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-27 10:01:55 +0000" MODIFIED_BY="Ruth Brassington">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-19 12:25:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DeVos-2005">
<CHAR_METHODS MODIFIED="2014-01-17 15:53:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised phase II study </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-19 12:25:06 +0000" MODIFIED_BY="[Empty name]">
<P>A randomised phase II study of paclitaxel with carboplatin with/without amifostine, as first line treatment of 90 women with advanced ovarian carcinoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-08 23:37:51 +0000" MODIFIED_BY="[Empty name]">
<P>Amifostine, 740 mg/m² preceding chemotherapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-17 17:23:10 +0000" MODIFIED_BY="[Empty name]">
<P>Symptoms of neurotoxicity and standard NCI-CTC rating</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-08 23:30:25 +0000" MODIFIED_BY="[Empty name]">
<P>There are several problems with the study:</P>
<OL>
<LI>The two groups are not the same. The ones with worse tumour type are in control group. More participants in the intervention arm had treatment delays</LI>
<LI>It is not clear if the authors are making a case for a positive effect of amifostine in this study. They are assuming that it works for cisplatin and using pooled data to show that it works.</LI>
<LI>Too many subgroups tested. In over all there is no difference, for grade 1, intervention group is worse, for grade 2 to 3 the control group is worse</LI>
<LI>Toxicity is worse in the intervention group.</LI>
<LI>Clearly no subjective change or even QOL change but no clear data provided to see if CTC of neurotoxicity was based on objective criteria.</LI>
<LI>This is more about taxanes given the modest neurotoxicity of carboplatin in most patients</LI>
</OL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-19 12:25:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gallardo-1999">
<CHAR_METHODS MODIFIED="2014-02-11 10:09:46 +0000" MODIFIED_BY="[Empty name]">
<P>An open, single-blinded pilot study to investigate the feasibility of 5-day scheduling of amifostine with radiotherapy and cisplatin (total dose 400 mg/m²)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-19 12:25:07 +0000" MODIFIED_BY="[Empty name]">
<P>20 women with locally advanced, histologically diagnosed cervical cancer, treated with radiotherapy randomised to receive cisplatin at 20 mg/m² for 5 days in 2 cycles (beginning day 1 and day 22) and 100 mg/m² for 2 cycles with amifostine before cisplatin infusion (Group A) or cisplatin in the same dose without amifostine (Group B)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-08 23:34:56 +0000" MODIFIED_BY="[Empty name]">
<P>Amifostine 825 mg/m² before cisplatin infusion</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-19 12:25:08 +0000" MODIFIED_BY="[Empty name]">
<P>Neurotoxicity grade (presumably NCI-CTC neurotoxicity)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-12 14:53:41 +0100" MODIFIED_BY="[Empty name]">
<P>Neurotoxicity scale not specified, but from NCI</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-19 12:25:09 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Gandara-1995">
<CHAR_METHODS MODIFIED="2014-02-11 09:43:56 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-19 12:25:09 +0000" MODIFIED_BY="Kate Jewitt">
<P>214 participants with ovarian cancer, SCLC, or NSCLC treated with cisplatin (100 mg/m² every 4 weeks x 6); 106 participants received DDTC and 108 participants received placebo. Data were available for<B> </B>n = 195 participants from the combined lung and ovarian cancer populations (placebo, 99 participants; DDTC, 96 participants)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-08 23:36:02 +0000" MODIFIED_BY="[Empty name]">
<P>DDTC 1.6 g/m² 15 min before cisplatin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-17 17:18:38 +0000" MODIFIED_BY="Kate Jewitt">
<P>NCI toxicity rating scale showed 13 of 96 (13%) in the DDTC group and 12 of 99 (12%) in the placebo group developed neuropathy (P = not significant)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-19 12:25:09 +0000" MODIFIED_BY="Kate Jewitt">
<P>Adverse effects were reported in all study participants with severe adverse events in 27 control group and 30 of DDTC arm. The authors concluded that DDTC is not effective against protecting cisplatin-induced peripheral neuropathy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-19 12:25:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grothey-2011">
<CHAR_METHODS MODIFIED="2014-02-19 12:25:11 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective, randomised, placebo-controlled, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-12 14:53:58 +0100" MODIFIED_BY="[Empty name]">
<P>102 participants with colon cancer; 50 received Ca/Mg and 52 received placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-12 14:53:58 +0100" MODIFIED_BY="[Empty name]">
<P>Ca/Mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-19 12:25:12 +0000" MODIFIED_BY="[Empty name]">
<P>NCI-CTC adverse event score for neuropathy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-11 10:00:52 +0000" MODIFIED_BY="[Empty name]">
<P>Data appear to support the hypothesis that Ca/Mg infusions (marginally) decrease oxaliplatin-induced chronic sensory motor neuropathy but not acute cold-induced paraesthesias and cramps. However, the study was not completed for 6 months and had early closure (due to reports of treatment interference)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-19 12:25:15 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Hovestadt-1992">
<CHAR_METHODS MODIFIED="2014-02-11 10:09:33 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-08 23:37:54 +0000" MODIFIED_BY="[Empty name]">
<P>18 women with epithelial ovarian cancer treated with cisplatin (75 mg/m²) and cyclophosphamide (750 mg/m²) every 3 weeks up to 9 cycles; 7 participants received Org 2766 and 11 participants served as controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-08 23:37:56 +0000" MODIFIED_BY="[Empty name]">
<P>Org 2766 low dose (0.25 mg/m²) and high dose (1 mg/m²), immediately before cisplatin and 24 hours later</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-19 12:25:15 +0000" MODIFIED_BY="Kate Jewitt">
<P>Mean VPT in placebo-treated participants was higher than in the low- and high-dose Org 2766-treated participants at 1 month, intermediate 1 to 4 months after treatment, and higher again after 4 to 12 and 12 to 24 months)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-11 09:45:34 +0000" MODIFIED_BY="Kate Jewitt">
<P>Descriptive analysis only without formal statistical tests; the number of evaluable participants decreased during the study. The authors suggested that treatment with Org 2766 to prevent a cisplatin-induced neuropathy should possibly be continued up to 4 months after the last cycle of cisplatin</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-19 12:25:18 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Ishibashi-2010">
<CHAR_METHODS MODIFIED="2014-02-11 10:09:27 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-19 12:25:18 +0000" MODIFIED_BY="[Empty name]">
<P>33 participants with metastatic colorectal cancer treated with FOLFOX, which included oxaliplatin, 85 mg/m² every 2 weeks for 6 cycles; 17 Ca/Mg-treated and 16 control participants</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-16 17:13:37 +0100" MODIFIED_BY="[Empty name]">
<P>Ca (850 mg) and Mg (720 mg) infusions, before and after infusion of oxaliplatin or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-17 17:19:11 +0000" MODIFIED_BY="[Empty name]">
<P>NCI-CTC and Debiopharm Neurotoxicity Scale (DEB-NTS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-11 10:01:25 +0000" MODIFIED_BY="[Empty name]">
<P>FOLFOX chemotherapy includes administration of 5-fluorouracil and l-leucovorin with each of 6, 2-week treatment cycles</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-19 12:25:20 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Kanat-2003">
<CHAR_METHODS MODIFIED="2013-12-12 17:20:59 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-19 12:25:19 +0000" MODIFIED_BY="Kate Jewitt">
<P>38 participants with NSCLC treated with paclitaxel (175 mg/m²) and carboplatin (AUC = 6) were randomised; 19 participants received amifostine and 19 participants served as controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-08 23:38:00 +0000" MODIFIED_BY="[Empty name]">
<P>Amifostine 910 mg/m² every 3 weeks x 6</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-11 09:45:59 +0000" MODIFIED_BY="Kate Jewitt">
<P>The mean SNAP amplitudes for both groups were comparable at baseline and also after 6 cycles of chemotherapy, there being no decline (clinically or statistically apparent) in the mean amplitudes for either group after treatment. Paraesthesias "grade 2" (reflecting an adverse sensory symptom outcome) developed in 8 of 19 participants in the carboplatin and paclitaxel plus amifostine group compared to 18 of 19 in the carboplatin and paclitaxel only group (P = 0.018)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-19 12:25:20 +0000" MODIFIED_BY="Kate Jewitt">
<P>The trial authors concluded that the addition of amifostine to carboplatin and paclitaxel may prevent or reduce the incidence of neurotoxicity in the treatment of NSCLC, but they cautioned in the text that the data from their trial were insufficient to support use of amifostine as a neuroprotective agent for paclitaxel and carboplatin chemotherapy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-19 12:25:20 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Kemp-1996">
<CHAR_METHODS MODIFIED="2013-12-12 17:20:59 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-08 23:38:03 +0000" MODIFIED_BY="[Empty name]">
<P>242 participants with advanced ovarian cancer treated with cisplatin (100 mg/m²) and cyclophosphamide (1000 mg/m²) every 3 weeks x 6 cycles; 122 participants received amifostine, 120 participants served as controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-12 14:26:18 +0000" MODIFIED_BY="[Empty name]">
<P>Amifostine 910 mg/m² pretreatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-19 12:25:20 +0000" MODIFIED_BY="Kate Jewitt">
<P>Neurotoxicity, defined as symptoms of peripheral neuropathy or a decrease in the neurological function daily activity score was related to the cumulative dose of cisplatin among participants with ovarian cancer who were treated with cisplatin and cyclophosphamide (<LINK REF="STD-Kemp-1996" TYPE="STUDY">Kemp 1996</LINK>). By treatment cycle 5, there was a significant difference (P = 0.015) between the groups, favouring the amifostine group. Following the last treatment cycle, the NCI neurological toxicity rating (grades 0, 1, 2, or 3) was significantly reduced (P = 0.029) by pretreatment with amifostine (122 participants pre-treated with amifostine, 120 control participants)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-12 14:26:35 +0000" MODIFIED_BY="Kate Jewitt">
<P>The authors concluded that pretreatment with amifostine reduced the neurotoxicity associated with cisplatin chemotherapy, based on reduction of the NCI toxicity rating scale</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-19 12:25:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Knijn-2011">
<CHAR_METHODS MODIFIED="2013-08-14 14:19:13 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective analyses without randomisation (intervention at discretion of treating physicians)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-19 12:25:21 +0000" MODIFIED_BY="[Empty name]">
<P>755 previously untreated colorectal cancer patients who had been randomised to received capecitabine, oxaliplatin and bevacizumab or the same with the addition of cetuximab (CBC). 6 cycles over 6 months. 732 participants were evaluable</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-19 12:25:21 +0000" MODIFIED_BY="[Empty name]">
<P>Ca/Mg, IV 2.25 mmol calcium glubionate plus MgCl 4 mMol in 100 mL glucose over 15 minutes, before and after oxaliplatin infusion<B> </B>retrospectively given at the discretion of the treating physician</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-12 14:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>NCI-CTC v 3.0</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-12 14:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Very confusing retrospective dosing. Only reduced grade 1 neurotoxicity but not grade &#8805; 2; and only early not late?</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-19 12:25:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kottschade-2011">
<CHAR_METHODS MODIFIED="2014-02-11 10:09:13 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective, randomised, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-19 12:25:22 +0000" MODIFIED_BY="[Empty name]">
<P>Colorectal cancer (but also breast, lung, and other cancers) treated with taxanes (109), cisplatin (8), carboplatin (2), oxaliplatin (50) or combination (20); total 189 evaluable (of 207 enrolled)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-04 14:54:44 +0000" MODIFIED_BY="[Empty name]">
<P>Vitamin E 300 mg twice daily or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-19 12:25:24 +0000" MODIFIED_BY="[Empty name]">
<P>NCI-CTC NCI-CTC adverse event score for neuropathy 3.0</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-19 12:25:24 +0000" MODIFIED_BY="[Empty name]">
<P>Different types of malignancy were not of comparable distribution in intervention and control groups, although the chemotherapy treatments were similar. The inclusion of a large number of participants receiving taxanes was confounding</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-27 09:58:23 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Lin-2006">
<CHAR_METHODS MODIFIED="2014-02-11 10:09:06 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-19 12:25:25 +0000" MODIFIED_BY="[Empty name]">
<P>14 participants with colorectal cancer treated with oxaliplatin (85 mg/m² every 2 weeks for 12 cycles, plus weekly fluorouracil and leucovorin); 5 participants received N-acetylcysteine (NAC) and 9 served as placebo controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-08 23:58:52 +0000" MODIFIED_BY="[Empty name]">
<P>NAC 1200 mg one and one-half hours before each oxaliplatin treatment or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-19 12:25:26 +0000" MODIFIED_BY="Kate Jewitt">
<P>Sensory (sural SNAP) amplitude, distal latency, and conduction velocity, and motor (median compound muscle action potential (CMAP)) amplitude, distal latency, conduction velocity, and F wave latency were measured at baseline and after 4, 8, and 12 cycles of chemotherapy. Clincal neurotoxicity was assessed every 2 weeks using the NCI-CTC rating scale. After 12 cycles of treatment, the incidence of &#8805; Grade 1, 2, and 3 neurotoxicity was 80%, 20%, and 0% among the 5 participants in the NAC group, respectively, and 100%, 89%, and 33% in the control group (P = 0.01)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-19 15:19:30 +0000" MODIFIED_BY="Kate Jewitt">
<P>The nerve conduction data were reported only for the NAC group, indicating no significant deterioration over the full trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-12 14:24:55 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Lorusso-2003">
<CHAR_METHODS MODIFIED="2013-12-12 17:20:58 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-04 14:56:14 +0000" MODIFIED_BY="Kate Jewitt">
<P>187 participants with ovarian cancer treated with carboplatin and paclitaxel every 21 days for 6 cycles; 93 participants received amifostine and 94 participants served as controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-12 14:24:55 +0000" MODIFIED_BY="[Empty name]">
<P>Amifostine 910 mg/m² pretreatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-12 14:16:33 +0000" MODIFIED_BY="Kate Jewitt">
<P>Amifostine appeared to be protective against neurotoxicity (grade 3 to 4 neurotoxicity 3.7% vs 7.2%; P = 0.02)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-19 15:19:38 +0000" MODIFIED_BY="Kate Jewitt">
<P>The authors concluded that amifostine could exert some protection from the cumulative toxicity associated with carboplatin and paclitaxel</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-19 12:25:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lu-2008">
<CHAR_METHODS MODIFIED="2014-02-11 10:07:59 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective, randomised, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-19 12:25:30 +0000" MODIFIED_BY="[Empty name]">
<P>Patients (n = 92; 46 in each group) with digestive tract tumours (colorectal or gastric carcinoma) treated with an oxaliplatin regimen (FOLFOX 4): oxaliplatin 85 mg/m² every 2 weeks; 4-week cycle repeated for 6 cycles</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-19 12:25:30 +0000" MODIFIED_BY="[Empty name]">
<P>Amifostine, 500 mg/m² every 4 weeks for 6 cycles, or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-14 14:27:49 +0100" MODIFIED_BY="[Empty name]">
<P>NCI-CTC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-19 12:25:31 +0000" MODIFIED_BY="[Empty name]">
<P>More haematological toxicity in PC+A arm; however mean values were similar</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-27 10:02:35 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Milla-2009">
<CHAR_METHODS MODIFIED="2014-02-11 10:08:07 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-08 23:38:10 +0000" MODIFIED_BY="Kate Jewitt">
<P>27 participants with colorectal cancer treated with FOLFOX4, which includes oxaliplatin (85 mg/m² with each 2 week cycle up to 12 cycles) plus other drugs (none known to be neurotoxic); 14 participants received GSH and 13 participants received saline placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-08 23:38:11 +0000" MODIFIED_BY="[Empty name]">
<P>GSH; 1500 mg/m² or placebo before each oxaliplatin treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-19 12:25:33 +0000" MODIFIED_BY="Kate Jewitt">
<P>At the end of treatment, only moderate neurotoxicity reported in the GSH arm (50% grade 1 and 50% grade 2), whereas in the placebo arm the neurotoxicity was more severe (69% grade 2 and 31% grade 3). The difference was considered statistically significant (Mann-Whitney test; P = 0.0037)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-27 10:02:35 +0000" MODIFIED_BY="Ruth Brassington">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-19 12:25:36 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Pace-2003">
<CHAR_METHODS MODIFIED="2014-02-19 12:25:35 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised, placebo-controlled (control participants were untreated)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-19 12:25:35 +0000" MODIFIED_BY="Kate Jewitt">
<P>27 participants with various solid tumours (lung, ovarian, rhinopharyngeal, gastric, testicular, oesophagus, ethmoid, and tongue cancer) treated with cisplatin (cumulative dose &gt; 300 mg/m²); 13 participants treated with vitamin E (vit E) and 14 participants served as controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-11 09:47:15 +0000" MODIFIED_BY="Ruth Brassington">
<P>Vit E 300 mg/day starting before cisplatin and continuing up to 3 months after cisplatin treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-19 12:25:35 +0000" MODIFIED_BY="Kate Jewitt">
<P>The median SNAP amplitudes were reduced by a greater degree in those without vit E than those taking vit E (without vit E group: baseline 14.5 ± 8.5 µv; 6 months later 13.6 ± 9.2 µv; vit E group: baseline 15.5 ± 6.3 µv; 6 months later 13.7 ± 5.5 µv). The differences between sural SNAPs in the 2 groups were not significant</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-19 12:25:36 +0000" MODIFIED_BY="Kate Jewitt">
<P>Of 47 patients enrolled, 20 dropped out mainly for disease progression. Clinical impairment on neurological examination was measured by an non-validated scale. The trial authors concluded that supplemental vit E decreases the incidence and severity of neurotoxicity</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-19 12:25:37 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Planting-1999">
<CHAR_METHODS MODIFIED="2014-02-11 10:08:17 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-08 23:38:14 +0000" MODIFIED_BY="[Empty name]">
<P>74 participants with advanced head and neck cancer treated with cisplatin (70 mg/m² weekly); 37 participants received amifostine and 37 participants served as controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-08 23:38:15 +0000" MODIFIED_BY="[Empty name]">
<P>Amifostine 740 mg/m² immediately before cisplatin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-09 00:16:48 +0000" MODIFIED_BY="Ruth Brassington">
<P>Participants receiving amifostine showed significantly less subclinical neurotoxicity as measured by the VPT relative to controls</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-19 12:25:37 +0000" MODIFIED_BY="Ruth Brassington">
<P>The trial authors explained that the borderline significant group difference for the right hand VPT reflected an imbalance at baseline for the groups and limited data. The authors concluded that amifostine reduced the risk of subclinical neurotoxicity caused by cisplatin but did not result in a higher cisplatin dose intensity</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-11 10:08:23 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Roberts-1997">
<CHAR_METHODS MODIFIED="2014-02-11 10:08:23 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-08 23:38:18 +0000" MODIFIED_BY="[Empty name]">
<P>196 participants with epithelial ovarian cancer treated with cisplatin (75 to 100 mg/m²) and cyclophosphamide (600 to 1000 mg/m²); 129 participants treated with Org 2766 and 67 participants served as controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-08 23:38:20 +0000" MODIFIED_BY="[Empty name]">
<P>Org 2766 2 mg/m² or 4 mg/m²</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>VPT increased during the study, independent of receiving Org 2766, with no difference in the rate of change or the degree of neuropathy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-19 15:20:10 +0000" MODIFIED_BY="Kate Jewitt">
<P>No evidence of efficacy in preventing or slowing development of neuropathy. The authors concluded that no benefit could be demonstrated using Org 2766 and suggested that high Org 2766 dose might eventually increase the peripheral neurotoxicity of cisplatin</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-19 12:25:40 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Schmidinger-2000">
<CHAR_METHODS MODIFIED="2014-02-11 10:08:28 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-08 23:38:22 +0000" MODIFIED_BY="[Empty name]">
<P>20 participants with non-small cell lung cancer (NSCLC) and head and neck cancer treated with cisplatin (80 mg/m² x every 4 weeks); 11 participants treated with GSH and 9 participants served as controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-08 23:38:23 +0000" MODIFIED_BY="[Empty name]">
<P>GSH 5 g/m² before cisplatin or placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-09 00:21:12 +0000" MODIFIED_BY="Ruth Brassington">
<P>No difference in clinical or nerve conduction measurement between the 2 groups</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-19 12:25:40 +0000" MODIFIED_BY="Kate Jewitt">
<P>The trial authors concluded that the combination of GSH and cisplatin was safe and the antitumour efficacy of cisplatin not impaired. They identified no difference between GSH-treated and control groups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-19 12:25:46 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Smyth-1997">
<CHAR_METHODS MODIFIED="2014-02-11 10:08:33 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-08 23:38:24 +0000" MODIFIED_BY="[Empty name]">
<P>151 participants with ovarian cancer treated with cisplatin (100 mg/m² x every 3 weeks x 6 courses); 74 participants received GSH and 77 participants served as controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-08 23:38:26 +0000" MODIFIED_BY="[Empty name]">
<P>GSH 3 g/m² before cisplatin<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-19 12:25:44 +0000" MODIFIED_BY="Ruth Brassington">
<P>Mean increase in Hospital Anxiety and Depression score was 0.8 in the GSH group and 2.5 in the placebo group (depression score)<BR/>45 of 47 in Rotterdam had better scores in GSH</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-19 12:25:46 +0000" MODIFIED_BY="Kate Jewitt">
<P>Participants reported improvement in QOL if they received GSH<BR/>They had significantly less tingling in hands and feet<BR/>GSH allowed more cycles of cisplatin because of less toxicity. The authors concluded that participants receiving GSH had a clear improvement in quality of life with significantly less tingling in their hand and feet and received more cycles of cisplatin because of less toxicity<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-11 10:08:39 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-van-der-Hoop-1990">
<CHAR_METHODS MODIFIED="2014-02-11 10:08:39 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-08 23:38:29 +0000" MODIFIED_BY="Kate Jewitt">
<P>55 participants with epithelial ovarian cancer treated with cisplatin (75 mg/m²) and cyclophosphamide (750 mg/m²); 33 participants received Org 2766 and 22 participants served as controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-08 23:38:32 +0000" MODIFIED_BY="[Empty name]">
<P>Org 2766 low dose (0.25 mg/m²) and high dose (1 mg/m²), immediately before and after cisplatin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-10 10:03:43 +0000" MODIFIED_BY="Kate Jewitt">
<P>In the high dose Org 2766 group, the VPT increased about 2-fold, significantly less than the nearly 8-fold increase in the placebo group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-10 10:03:43 +0000" MODIFIED_BY="Kate Jewitt">
<P>The authors felt that Org 2766 prevented or attenuated cisplatin neuropathy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-19 12:25:51 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-van-Gerven-1994">
<CHAR_METHODS MODIFIED="2014-02-11 09:50:45 +0000" MODIFIED_BY="Kate Jewitt">
<P>Prospective, randomised, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-08 23:38:27 +0000" MODIFIED_BY="[Empty name]">
<P>42 participants with testicular and adenocarcinoma of unknown primary treated with cisplatin (100 mg/m² for at least 4 cycles) and with different combinations of etoposide, bleomicin and ifosphamide; 19 participants treated with Org 2766 and 23 participants served as controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Org 2766 2 mg/d x 5 days or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-19 12:25:51 +0000" MODIFIED_BY="Kate Jewitt">
<P>Borderline significant difference in degree of VPT favouring Org 2766 vs placebo. Symptom scores were not significantly different.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-19 12:25:51 +0000" MODIFIED_BY="Kate Jewitt">
<P>The trial authors indicated that Org 2766 cannot completely prevent cisplatin neuropathy but may ameliorate nerve damage</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AUC: area under the curve<BR/>DDTC: diethyldithiocarbamate<BR/>GSH: glutathione<BR/>NCI-CTC: National Cancer Institute Common Toxicity Criteria<BR/>NCS: nerve conduction study<BR/>NIS: Neuropathy Impairment Scale<BR/>NSS: Neuropathy Symptom Scale<BR/>NSCLC: non-small cell lung cancer<BR/>SCLC: small cell lung cancer<BR/>SNAP: sensory nerve action potential<BR/>VPT: vibration perception threshold<BR/>vs: versus<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-02-19 12:25:57 +0000" MODIFIED_BY="Kate Jewitt" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-02-19 12:25:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ali-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-19 12:25:54 +0000" MODIFIED_BY="[Empty name]">
<P>Review of existing studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-14 13:00:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ao-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-14 13:00:23 +0100" MODIFIED_BY="[Empty name]">
<P>Meta-analysis of existing data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-19 12:25:54 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Argyriou-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-19 12:25:54 +0000" MODIFIED_BY="Kate Jewitt">
<P>Unable to separate the effects of cisplatin from those of paclitaxel</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:20:40 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Block-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:20:40 +0000" MODIFIED_BY="Kate Jewitt">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:20:43 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Bogliun-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:20:43 +0000" MODIFIED_BY="Kate Jewitt">
<P>Neither the control group nor the intervention group developed neurotoxicity, so unable to assess efficacy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-14 13:00:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cancer-Care-Ontario-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-14 13:00:27 +0100" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:20:45 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Capizzi-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:20:45 +0000" MODIFIED_BY="Kate Jewitt">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-11 12:18:58 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Cassidy-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-11 12:18:58 +0000" MODIFIED_BY="Kate Jewitt">
<P>Randomised, placebo-controlled trial that was discontinued prematurely because of nausea and vomiting, limiting analyses. Nevertheless, the available data suggested that nimodipine exacerbated (not prevented) neurotoxicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:20:52 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Catalano-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:20:52 +0000" MODIFIED_BY="Kate Jewitt">
<P>Abstract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-11 12:18:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-11 12:18:54 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial; analyses based on retrospective data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:20:54 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Culy-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:20:54 +0000" MODIFIED_BY="Kate Jewitt">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:20:56 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-De-Grandis-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:20:56 +0000" MODIFIED_BY="Kate Jewitt">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-16 17:13:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Vos-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-16 17:13:38 +0100" MODIFIED_BY="[Empty name]">
<P>Unable to separate the effects of carboplatin from those of paclitaxel</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-16 17:13:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Durand-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-16 17:13:38 +0100" MODIFIED_BY="[Empty name]">
<P>Reports of treatment of acute sensory symptoms, not prevention of neuropathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-11 12:18:41 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Gamelin-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-11 12:18:41 +0000" MODIFIED_BY="Kate Jewitt">
<P>Retrospective, non-randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:04 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Gamelin-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:04 +0000" MODIFIED_BY="Kate Jewitt">
<P>Letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:06 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Gedlicka-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:06 +0000" MODIFIED_BY="Kate Jewitt">
<P>Letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:09 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Gispen-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:09 +0000" MODIFIED_BY="Kate Jewitt">
<P>No details of study provided</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:11 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Glover-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:11 +0000" MODIFIED_BY="Kate Jewitt">
<P>Phase I trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-14 13:50:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glover-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-14 13:50:57 +0100" MODIFIED_BY="[Empty name]">
<P>Phase I trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:15 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Glover-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:15 +0000" MODIFIED_BY="Kate Jewitt">
<P>Treatment schedule not comparable</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-11 12:18:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gradishar-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-11 12:18:37 +0000" MODIFIED_BY="[Empty name]">
<P>Phase II study, not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:16 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Grothey-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:16 +0000" MODIFIED_BY="Kate Jewitt">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:19 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Haigentz-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:19 +0000" MODIFIED_BY="Kate Jewitt">
<P>Phase I trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:21 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Heidenreich-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:21 +0000" MODIFIED_BY="Kate Jewitt">
<P>Limited information</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:25 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Hensley-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:25 +0000" MODIFIED_BY="Kate Jewitt">
<P>Description of practice guideline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:27 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Hilkens-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:27 +0000" MODIFIED_BY="Kate Jewitt">
<P>Study involved dosing of cisplatin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:31 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Hilpert-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:31 +0000" MODIFIED_BY="Kate Jewitt">
<P>Unable to separate the effects of carboplatin from those of paclitaxel</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:33 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Hochster-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:33 +0000" MODIFIED_BY="Kate Jewitt">
<P>Letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:37 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Kesari-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:37 +0000" MODIFIED_BY="Kate Jewitt">
<P>Letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:38 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Leong-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:38 +0000" MODIFIED_BY="Kate Jewitt">
<P>Only two doses of carboplatin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:42 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Lissoni-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:42 +0000" MODIFIED_BY="Kate Jewitt">
<P>Details of neuropathy not provided</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:44 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Lissoni-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:44 +0000" MODIFIED_BY="Kate Jewitt">
<P>Groups not comparable and previous therapy unknown</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-14 12:42:18 +0100" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Lissoni-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-14 12:42:18 +0100" MODIFIED_BY="Kate Jewitt">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-28 19:55:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miller-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-28 19:55:13 +0100" MODIFIED_BY="[Empty name]">
<P>Unable to separate the effects of cisplatin from those of docetaxel</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:52 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Mollman-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:52 +0000" MODIFIED_BY="Kate Jewitt">
<P>Study of risk factors associated with cisplatin neuropathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-19 12:25:55 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Moore-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-19 12:25:55 +0000" MODIFIED_BY="Ruth Brassington">
<P>Phase II, open label study without placebo or any comparison group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:54 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Pace-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:54 +0000" MODIFIED_BY="Kate Jewitt">
<P>Letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-19 13:53:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pace-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-19 13:53:45 +0100" MODIFIED_BY="[Empty name]">
<P>Substantial dropout rate, excluding intention-to-treat analyses</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:21:59 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Penz-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:21:59 +0000" MODIFIED_BY="Kate Jewitt">
<P>Pilot study, not controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:22:01 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Rick-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:22:01 +0000" MODIFIED_BY="Kate Jewitt">
<P>Open label, unblinded trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-19 12:25:55 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Wang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-19 12:25:55 +0000" MODIFIED_BY="Kate Jewitt">
<P>Randomised but neither blinded nor placebo-controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-19 12:25:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wen-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-19 12:25:57 +0000" MODIFIED_BY="[Empty name]">
<P>Meta-analysis of calcium/magnesium infusions for the prevention of oxaliplatin-related neurotoxicity in people with colorectal cancer</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-19 15:22:07 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Wilkes-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-19 15:22:07 +0000" MODIFIED_BY="Kate Jewitt">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-10-04 22:56:22 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2013-10-04 22:56:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dong-2010">
<CHAR_METHODS MODIFIED="2013-08-12 13:30:25 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-10-04 22:56:15 +0100" MODIFIED_BY="Ruth Brassington">
<P>Awaiting translation</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-10-04 22:56:19 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Pang-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-10-04 22:56:19 +0100" MODIFIED_BY="Ruth Brassington">
<P>Awaiting translation</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-10-04 22:56:22 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Romano-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-10-04 22:56:22 +0100" MODIFIED_BY="Ruth Brassington">
<P>Article not obtainable</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-02-27 10:01:05 +0000" MODIFIED_BY="Ruth Brassington">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-02-19 12:24:00 +0000" MODIFIED_BY="Kate Jewitt" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:23:53 +0000" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-Argyriou-2006">
<DESCRIPTION>
<P>Randomised but the "simple" randomisation method was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:24:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Argyriou-2006a">
<DESCRIPTION>
<P>Randomisation method not specifically described, other than that there was a 1:1 ratio</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:52:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arrieta-2011">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 17:25:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bogliun-1996">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 17:38:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cascinu-1995">
<DESCRIPTION>
<P>Random, computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 17:41:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cascinu-2002">
<DESCRIPTION>
<P>Used cards from a computer-generated list in sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-12 17:21:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chay-2010">
<DESCRIPTION>
<P>States that the trial is randomised but the method is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:53:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Colombo-1995">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:56:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeVos-2005">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:53:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gallardo-1999">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 17:45:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gandara-1995">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 17:23:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grothey-2011">
<DESCRIPTION>
<P>Randomised but not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 17:53:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hovestadt-1992">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 17:23:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ishibashi-2010">
<DESCRIPTION>
<P>Randomised but method not specifically described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 17:23:10 +0000" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-Kanat-2003">
<DESCRIPTION>
<P>Randomised but method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 17:19:32 +0000" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-Kemp-1996">
<DESCRIPTION>
<P>Randomised but method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 17:19:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Knijn-2011">
<DESCRIPTION>
<P>Not randomised; at discretion of treating physicians</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:55:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kottschade-2011">
<DESCRIPTION>
<P>Random number sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-07 20:05:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2006">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:12:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lorusso-2003">
<DESCRIPTION>
<P>Computer generated list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 17:20:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lu-2008">
<DESCRIPTION>
<P>Randomised using random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-07 20:13:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Milla-2009">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 17:23:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pace-2003">
<DESCRIPTION>
<P>Randomised but method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 17:23:10 +0000" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-Planting-1999">
<DESCRIPTION>
<P>Randomised but method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 17:23:10 +0000" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-Roberts-1997">
<DESCRIPTION>
<P>Randomised but method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 17:23:10 +0000" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-Schmidinger-2000">
<DESCRIPTION>
<P>Randomised but method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:36:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smyth-1997">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 17:23:11 +0000" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-van-Gerven-1994">
<DESCRIPTION>
<P>Randomised but method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-08 23:41:50 +0000" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Hoop-1990">
<DESCRIPTION>
<P>Randomised but method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-02-19 12:25:52 +0000" MODIFIED_BY="Kate Jewitt" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-10 10:03:41 +0000" MODIFIED_BY="Kate Jewitt" RESULT="YES" STUDY_ID="STD-Argyriou-2006">
<DESCRIPTION>
<P>Opaque, sealed envelopes containing random numbers (I or II)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:24:00 +0000" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-Argyriou-2006a">
<DESCRIPTION>
<P>Described as "concealed", known only to the randomisation co-ordinator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:52:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arrieta-2011">
<DESCRIPTION>
<P>None detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-25 19:52:02 +0100" MODIFIED_BY="Michael Lunn" RESULT="UNKNOWN" STUDY_ID="STD-Bogliun-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-25 19:52:09 +0100" MODIFIED_BY="Michael Lunn" RESULT="YES" STUDY_ID="STD-Cascinu-1995">
<DESCRIPTION>
<P>Adequate, concealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-08 22:43:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cascinu-2002">
<DESCRIPTION>
<P>Used cards from a computer-generated list in sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-05 17:02:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chay-2010">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:53:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Colombo-1995">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:56:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeVos-2005">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:53:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gallardo-1999">
<DESCRIPTION>
<P>Pilot</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-25 19:52:20 +0100" MODIFIED_BY="Michael Lunn" RESULT="UNKNOWN" STUDY_ID="STD-Gandara-1995">
<DESCRIPTION>
<P>Presumably, but not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:54:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grothey-2011">
<DESCRIPTION>
<P>Presumably, but not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:25:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hovestadt-1992">
<DESCRIPTION>
<P>Presumably done, but not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 17:23:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ishibashi-2010">
<DESCRIPTION>
<P>Centralised allocation via random number assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:01:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kanat-2003">
<DESCRIPTION>
<P>Unclear, as not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:04:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kemp-1996">
<DESCRIPTION>
<P>Presumably, but not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:55:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Knijn-2011">
<DESCRIPTION>
<P>As above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:55:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kottschade-2011">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-07 20:05:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2006">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 17:20:16 +0000" MODIFIED_BY="Kate Jewitt" RESULT="YES" STUDY_ID="STD-Lorusso-2003">
<DESCRIPTION>
<P>Randomisation performed centrally to avoid bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-06 23:17:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lu-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-07 20:13:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Milla-2009">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:19:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pace-2003">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:24:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Planting-1999">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:25:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roberts-1997">
<DESCRIPTION>
<P>Randomised but method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:25:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmidinger-2000">
<DESCRIPTION>
<P>Randomised but method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 17:23:11 +0000" MODIFIED_BY="Kate Jewitt" RESULT="YES" STUDY_ID="STD-Smyth-1997">
<DESCRIPTION>
<P>Central randomisations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:25:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Gerven-1994">
<DESCRIPTION>
<P>Randomised but method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-08 23:42:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Hoop-1990">
<DESCRIPTION>
<P>Done before study, and treatment codes were not revealed to clinicians</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-02-19 14:58:22 +0000" MODIFIED_BY="Kate Jewitt" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Participant</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Observer</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-11 09:57:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Argyriou-2006">
<DESCRIPTION>
<P>Not done, as participants received vit E or no vit E</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-07 20:37:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Argyriou-2006">
<DESCRIPTION>
<P>Both neurologists were blinded to group assignment until study completion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-07 19:53:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Argyriou-2006a">
<DESCRIPTION>
<P>"Open label" trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-01-17 15:49:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Argyriou-2006a">
<DESCRIPTION>
<P>The evaluators and the senior oncologist were blinded to participant group assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 14:52:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arrieta-2011">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-01-17 15:50:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arrieta-2011">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-11 10:06:44 +0000" MODIFIED_BY="Kate Jewitt" RESULT="NO" STUDY_ID="STD-Bogliun-1996">
<DESCRIPTION>
<P>Randomised but not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-02-19 12:24:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bogliun-1996">
<DESCRIPTION>
<P>Same. The analyses of data were performed without knowledge of treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-19 12:24:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cascinu-1995">
<DESCRIPTION>
<P>Placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-02-11 09:58:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cascinu-1995">
<DESCRIPTION>
<P>The same blinded evaluator examined all participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-08 22:44:11 +0000" MODIFIED_BY="Kate Jewitt" RESULT="YES" STUDY_ID="STD-Cascinu-2002">
<DESCRIPTION>
<P>Double-blinded RCT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-02-08 22:44:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cascinu-2002">
<DESCRIPTION>
<P>Double-blinded RCT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-08 23:13:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chay-2010">
<DESCRIPTION>
<P>No details, but participants said to be blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-08-05 16:12:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chay-2010">
<DESCRIPTION>
<P>Observer blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 14:53:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Colombo-1995">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-08-12 14:53:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Colombo-1995">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-04 14:51:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeVos-2005">
<DESCRIPTION>
<P>Not described. Unclear if participants were blinded, as control group did not receive placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-08-12 14:56:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-DeVos-2005">
<DESCRIPTION>
<P>Not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-08 23:35:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gallardo-1999">
<DESCRIPTION>
<P>Participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-08-12 14:53:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gallardo-1999">
<DESCRIPTION>
<P>Observer not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-11 10:00:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gandara-1995">
<DESCRIPTION>
<P>Placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-02-19 12:25:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gandara-1995">
<DESCRIPTION>
<P>Described as blinded, including a blinded interim safety analysis, Independent statistical analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-11 10:00:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grothey-2011">
<DESCRIPTION>
<P>Placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-02-19 12:25:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grothey-2011">
<DESCRIPTION>
<P>Not described. Independent statistical analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-19 12:25:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hovestadt-1992">
<DESCRIPTION>
<P>Placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-02-19 12:25:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hovestadt-1992">
<DESCRIPTION>
<P>Placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-07 20:02:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ishibashi-2010">
<DESCRIPTION>
<P>Described as "double-blind" study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-07 20:02:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ishibashi-2010">
<DESCRIPTION>
<P>Described as "double-blind" study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-17 17:23:10 +0000" MODIFIED_BY="Kate Jewitt" RESULT="NO" STUDY_ID="STD-Kanat-2003">
<DESCRIPTION>
<P>Randomised but no placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-11 18:00:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kanat-2003">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-19 12:25:20 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kemp-1996">
<DESCRIPTION>
<P>Randomised but not placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-11 18:06:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kemp-1996">
<DESCRIPTION>
<P>Evaluations performed by a third party blinded to treatment or adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 14:55:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Knijn-2011">
<DESCRIPTION>
<P>Not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-08-12 14:55:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Knijn-2011">
<DESCRIPTION>
<P>Not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 14:55:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kottschade-2011">
<DESCRIPTION>
<P>Subject blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-08-12 14:55:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kottschade-2011">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-19 12:25:27 +0000" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2006">
<DESCRIPTION>
<P>Described only as randomised and placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-02-08 23:59:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2006">
<DESCRIPTION>
<P>Presumably, but not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-09 00:02:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lorusso-2003">
<DESCRIPTION>
<P>Not placebo controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-11 18:14:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lorusso-2003">
<DESCRIPTION>
<P>Performed by "dedicated" physicians but unclear if blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-06 23:17:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lu-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-08-06 23:17:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lu-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-19 12:25:34 +0000" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-Milla-2009">
<DESCRIPTION>
<P>Described only as randomised and placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-07 20:13:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Milla-2009">
<DESCRIPTION>
<P>Presumably but not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-11 09:47:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pace-2003">
<DESCRIPTION>
<P>Participants were not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-11 18:23:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pace-2003">
<DESCRIPTION>
<P>Neurologists performing examinations were not blinded to treatment status</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-11 18:25:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Planting-1999">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-11 18:25:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Planting-1999">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-11 09:49:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberts-1997">
<DESCRIPTION>
<P>Decribed as blinded, placebo-controlled study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-11 18:33:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roberts-1997">
<DESCRIPTION>
<P>Presumably, but not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-11 18:33:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmidinger-2000">
<DESCRIPTION>
<P>Not specifically described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-02-19 12:25:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmidinger-2000">
<DESCRIPTION>
<P>Not specifically described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-19 12:25:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smyth-1997">
<DESCRIPTION>
<P>Presumably (placebo controlled), but not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-02-19 12:25:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smyth-1997">
<DESCRIPTION>
<P>Presumably (placebo controlled), but not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-11 18:42:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Gerven-1994">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-11 18:42:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Gerven-1994">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-19 12:25:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Hoop-1990">
<DESCRIPTION>
<P>Placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-02-19 12:25:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Hoop-1990">
<DESCRIPTION>
<P>Treatment codes were not revealed to clinicians</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-02-19 14:57:52 +0000" MODIFIED_BY="Ruth Brassington" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-02-19 14:57:52 +0000" MODIFIED_BY="Ruth Brassington" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-02-19 12:25:51 +0000" MODIFIED_BY="Kate Jewitt" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-19 12:23:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Argyriou-2006">
<DESCRIPTION>
<P>Evaluated neurotoxicity on all participants completing the trial and evaluated efficacy using intention-to-treat analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-19 12:24:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Argyriou-2006a">
<DESCRIPTION>
<P>Investigators evaluated neurotoxicity in all participants completing the trial and measured efficacy using intention-to-treat analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 14:52:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arrieta-2011">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-17 15:50:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bogliun-1996">
<DESCRIPTION>
<P>Few subjects lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-11 09:58:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cascinu-1995">
<DESCRIPTION>
<P>Based on assessable participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-11 09:58:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cascinu-2002">
<DESCRIPTION>
<P>Analyses based on evaluable participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-05 17:02:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chay-2010">
<DESCRIPTION>
<P>Trial terminated early</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 14:53:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Colombo-1995">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-04 15:13:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeVos-2005">
<DESCRIPTION>
<P>10 did not complete (5 each arm), 1 received low dose; information not clear on other 46</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-08 23:35:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gallardo-1999">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-19 12:25:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gandara-1995">
<DESCRIPTION>
<P>Based on evaluable participants but a small percentage were lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 14:54:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grothey-2011">
<DESCRIPTION>
<P>Based on evaluable subjects but small percentage lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-19 12:25:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hovestadt-1992">
<DESCRIPTION>
<P>Based on evaluable participants, but substantial dropout</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-01-10 10:03:41 +0000" MODIFIED_BY="Kate Jewitt" RESULT="YES" STUDY_ID="STD-Ishibashi-2010">
<DESCRIPTION>
<P>Early termination of enrolment because of relatively "poorer" performance in the Ca/Mg group at interim analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-11 18:00:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kanat-2003">
<DESCRIPTION>
<P>All data included</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-13 10:47:48 +0100" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-Kemp-1996">
<DESCRIPTION>
<P>Unclear if difference in dropouts between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-04 22:56:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Knijn-2011">
<DESCRIPTION>
<P>Unknown, but inadequate handling of unavailable data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-04 16:34:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kottschade-2011">
<DESCRIPTION>
<P>18 cancellations/withdrawals out of 207 participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-09 11:03:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2006">
<DESCRIPTION>
<P>Not described, but all data evaluated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-09 00:02:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lorusso-2003">
<DESCRIPTION>
<P>Based on evaluable participants but small proportion of missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-19 12:25:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lu-2008">
<DESCRIPTION>
<P>7 withdrawals in the AMIF group; 10 withdrawals in the placebo group; well described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-11 15:26:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Milla-2009">
<DESCRIPTION>
<P>No dropouts (all data included)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-11 09:47:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pace-2003">
<DESCRIPTION>
<P>Based on evaluable participants, although substantial drop out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-19 12:25:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Planting-1999">
<DESCRIPTION>
<P>Based on evaluable data, but there was limited drop out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-11 09:49:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberts-1997">
<DESCRIPTION>
<P>Based on evaluable participants, but limited drop out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-11 09:50:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmidinger-2000">
<DESCRIPTION>
<P>Based on evaluable participants but only 1 participant dropped out (in control group)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-11 09:50:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smyth-1997">
<DESCRIPTION>
<P>Based on evaluable participants but substantial drop out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-08 23:40:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Gerven-1994">
<DESCRIPTION>
<P>Based on participants completing 4 cycles of chemotherapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-19 12:25:51 +0000" MODIFIED_BY="Kate Jewitt" RESULT="YES" STUDY_ID="STD-van-der-Hoop-1990">
<DESCRIPTION>
<P>Intention-to-treat analyses based on all enrolled participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-02-27 10:01:02 +0000" MODIFIED_BY="Ruth Brassington" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-07 15:00:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Argyriou-2006">
<DESCRIPTION>
<P>Yes, as above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-07 19:58:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Argyriou-2006a">
<DESCRIPTION>
<P>Yes, as above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:52:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arrieta-2011">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 15:50:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bogliun-1996">
<DESCRIPTION>
<P>No formal statistical analysis presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:24:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cascinu-1995">
<DESCRIPTION>
<P>Based on assessable participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-11 09:59:00 +0000" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-Cascinu-2002">
<DESCRIPTION>
<P>Analyses based on evaluable participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-27 10:01:02 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Chay-2010">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-11 09:59:12 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Colombo-1995">
<DESCRIPTION>
<P>No details as to neurological assessment provided. No P values given for any significance (although calculable from the data provided). No objective data provided except mean sural amplitude without significance values</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 17:17:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DeVos-2005">
<DESCRIPTION>
<P>None detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:53:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gallardo-1999">
<DESCRIPTION>
<P>None detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 17:48:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gandara-1995">
<DESCRIPTION>
<P>Same</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:54:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grothey-2011">
<DESCRIPTION>
<P>None detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 17:56:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hovestadt-1992">
<DESCRIPTION>
<P>Same</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-07 20:03:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ishibashi-2010">
<DESCRIPTION>
<P>Yes, based on data to time of termination</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:01:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kanat-2003">
<DESCRIPTION>
<P>No subjects dropped out of study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:11:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kemp-1996">
<DESCRIPTION>
<P>Used intent to treat analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:55:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Knijn-2011">
<DESCRIPTION>
<P>Unknown</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:55:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kottschade-2011">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-27 09:58:17 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2006">
<DESCRIPTION>
<P>Reported nerve conduction results from the NAC group but not the control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-09 00:02:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lorusso-2003">
<DESCRIPTION>
<P>Based on evaluable participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-06 23:18:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lu-2008">
<DESCRIPTION>
<P>None detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-07 20:11:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Milla-2009">
<DESCRIPTION>
<P>Not described but data from all subjects included</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:25:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pace-2003">
<DESCRIPTION>
<P>Based on evaluable participants, although substantial drop out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:26:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Planting-1999">
<DESCRIPTION>
<P>Same</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:25:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberts-1997">
<DESCRIPTION>
<P>Based on evaluable participants, but limited drop out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:25:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmidinger-2000">
<DESCRIPTION>
<P>Based on evaluable participants but only 1 participant dropped out (in control group)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-11 09:50:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smyth-1997">
<DESCRIPTION>
<P>As above, analyses performed on relatively small subset of evaluable participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-08 23:40:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Gerven-1994">
<DESCRIPTION>
<P>As above, few eligible participants had missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-11 09:50:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Hoop-1990">
<DESCRIPTION>
<P>Intention-to-treat analyses based on all enrolled participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-02-27 10:01:05 +0000" MODIFIED_BY="Ruth Brassington" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-07 19:58:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Argyriou-2006">
<DESCRIPTION>
<P>No evidence of other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-07 19:58:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Argyriou-2006a">
<DESCRIPTION>
<P>No evidence of other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-17 15:50:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arrieta-2011">
<DESCRIPTION>
<P>Significant differences between study and control groups at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 17:28:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bogliun-1996">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 17:38:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cascinu-1995">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 17:42:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cascinu-2002">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-27 10:01:05 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Chay-2010">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:53:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colombo-1995">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 15:13:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DeVos-2005">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:53:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gallardo-1999">
<DESCRIPTION>
<P>Same</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 17:50:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gandara-1995">
<DESCRIPTION>
<P>None detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-11 10:01:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grothey-2011">
<DESCRIPTION>
<P>Study closed early for "Treatment interference"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 17:56:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hovestadt-1992">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-07 20:03:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ishibashi-2010">
<DESCRIPTION>
<P>No evidence of other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:01:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kanat-2003">
<DESCRIPTION>
<P>None detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:07:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kemp-1996">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:55:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Knijn-2011">
<DESCRIPTION>
<P>Not detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 14:55:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kottschade-2011">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-07 20:09:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2006">
<DESCRIPTION>
<P>No evidence of other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:16:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lorusso-2003">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:25:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lu-2008">
<DESCRIPTION>
<P>None detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-07 20:11:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Milla-2009">
<DESCRIPTION>
<P>No evidence of other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:23:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pace-2003">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:26:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Planting-1999">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:31:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberts-1997">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:34:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmidinger-2000">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:39:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smyth-1997">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:44:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Gerven-1994">
<DESCRIPTION>
<P>None identified </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 18:50:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Hoop-1990">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2010-10-12 17:27:12 +0100" MODIFIED_BY="Kate Jewitt"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-02-27 18:04:58 +0000" MODIFIED_BY="Ruth Brassington">
<COMPARISON ID="CMP-001" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="1">
<NAME>Amifostine - clinical impairment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.7460096161858143" CI_START="0.23306546205360892" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="100.0" ID="CMP-001.01" LOG_CI_END="0.4387020537489241" LOG_CI_START="-0.6325220797650368" LOG_EFFECT_SIZE="-0.09691001300805639" METHOD="MH" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.7228723553499613" Q="1.9456493636130436E-33" RANDOM="NO" SCALE="59.82" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="37" WEIGHT="100.0" Z="0.35462258419073095">
<NAME>Clinical impairment at 3 months</NAME>
<GROUP_LABEL_1>Amifostine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours amifostine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.7460096161858143" CI_START="0.23306546205360892" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4387020537489241" LOG_CI_START="-0.6325220797650368" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="3958" O_E="0.0" SE="0.6292423586710815" STUDY_ID="STD-Planting-1999" TOTAL_1="37" TOTAL_2="37" VAR="0.39594594594594595" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="2">
<NAME>Amifostine - functional activities of daily living</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8957513353152601" CI_START="0.055129938524738506" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.04781253574949701" LOG_CI_START="-1.2586124918011903" LOG_EFFECT_SIZE="-0.6532125137753437" METHOD="MH" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.03445078181549018" Q="0.0" RANDOM="NO" SCALE="42.46" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="2.114755612356313">
<NAME>Functonal activities of daily living as measured at 3 months</NAME>
<GROUP_LABEL_1>Amifostine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours amifostine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8957513353152604" CI_START="0.05512993852473846" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.04781253574949684" LOG_CI_START="-1.2586124918011907" LOG_EFFECT_SIZE="-0.6532125137753437" ORDER="3959" O_E="0.0" SE="0.7112298877412102" STUDY_ID="STD-Kanat-2003" TOTAL_1="19" TOTAL_2="19" VAR="0.5058479532163744" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-02-27 18:04:58 +0000" MODIFIED_BY="Ruth Brassington" NO="3">
<NAME>Amifostine - neurotoxicity rating</NAME>
<DICH_OUTCOME CHI2="37.26861447115681" CI_END="0.7616796055761922" CI_START="0.5735867838136778" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6609760625460794" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="178" I2="91.95033128392315" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.11822767274362266" LOG_CI_START="-0.24140086393529867" LOG_EFFECT_SIZE="-0.17981426833946065" METHOD="MH" MODIFIED="2014-02-04 14:29:11 +0000" MODIFIED_BY="[Empty name]" NO="1" NOTES="&lt;p&gt;Analysis 2.1 and 2.2 results are reported as RR in the text&lt;/p&gt;" NOTES_MODIFIED="2014-02-04 14:29:11 +0000" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="4.0369749432223045E-8" P_Q="1.0" P_Z="1.049658720610378E-8" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="230" TOTAL_2="227" WEIGHT="99.99999999999999" Z="5.722503191515603">
<NAME>Neurotoxicity rating &#8805; 1</NAME>
<GROUP_LABEL_1>Favours amifostine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours amifostine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0487951641966309" CI_START="0.780509037658871" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="42" LOG_CI_END="0.020690676233934325" LOG_CI_START="-0.10762206379611496" LOG_EFFECT_SIZE="-0.0434656937810903" MODIFIED="2013-08-07 16:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.07537153865195782" STUDY_ID="STD-DeVos-2005" TOTAL_1="45" TOTAL_2="45" VAR="0.005680868838763571" WEIGHT="23.451279086419884"/>
<DICH_DATA CI_END="0.7609963796039778" CI_START="0.2595687305376221" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.11861740935525482" LOG_CI_START="-0.5857476268674701" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2013-08-07 16:53:56 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.27439460209854477" STUDY_ID="STD-Kanat-2003" TOTAL_1="19" TOTAL_2="19" VAR="0.07529239766081872" WEIGHT="10.050548179894236"/>
<DICH_DATA CI_END="0.9968474261929077" CI_START="0.6640391829176988" EFFECT_SIZE="0.8136004857316332" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="81" LOG_CI_END="-0.0013713081207924517" LOG_CI_START="-0.17780629348910107" LOG_EFFECT_SIZE="-0.08958880080494673" ORDER="3973" O_E="0.0" SE="0.1036387837726075" STUDY_ID="STD-Kemp-1996" TOTAL_1="122" TOTAL_2="120" VAR="0.010740997501865293" WEIGHT="45.60124752695814"/>
<DICH_DATA CI_END="0.3365958570793696" CI_START="0.07461426144649588" EFFECT_SIZE="0.15847665847665848" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="37" LOG_CI_END="-0.47289123375128683" LOG_CI_START="-1.1271781554286178" LOG_EFFECT_SIZE="-0.8000346945899522" MODIFIED="2013-08-07 16:01:42 +0100" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.3843313765657608" STUDY_ID="STD-Lu-2008" TOTAL_1="44" TOTAL_2="43" VAR="0.1477106070129326" WEIGHT="20.896925206727733"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.980563915286986" CI_END="0.6146247849812471" CI_START="0.1071331473648525" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.25660609436154613" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="39" I2="32.89860386008771" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.21138993063421932" LOG_CI_START="-0.9700761361674625" LOG_EFFECT_SIZE="-0.5907330334008408" METHOD="MH" MODIFIED="2014-02-27 18:03:00 +0000" MODIFIED_BY="Ruth Brassington" NO="2" NOTES="&lt;p&gt;But this data was &amp;quot;during chemotherapy&amp;quot; - not after&lt;/p&gt;&lt;p&gt;Kemp - no data entered&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-02-27 18:03:00 +0000" NOTES_MODIFIED_BY="Ruth Brassington" P_CHI2="0.22530918263973232" P_Q="1.0" P_Z="0.002272017071655933" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.20962921191984754" TOTALS="YES" TOTAL_1="74" TOTAL_2="74" WEIGHT="100.0" Z="3.0521590125128837">
<NAME>Neurotoxicity rating &#8805; 2</NAME>
<GROUP_LABEL_1>Amifostine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours amifostine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8957282411977242" CI_START="0.18928751513256561" EFFECT_SIZE="0.4117647058823529" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" LOG_CI_END="-0.04782373280464885" LOG_CI_START="-0.7228780299233853" LOG_EFFECT_SIZE="-0.38535088136401713" MODIFIED="2013-08-07 15:54:41 +0100" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.3965302357002088" STUDY_ID="STD-DeVos-2005" TOTAL_1="45" TOTAL_2="45" VAR="0.15723622782446312" WEIGHT="54.13682455594508"/>
<DICH_DATA CI_END="1.8627820278251161" CI_START="0.03355196639564513" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2701620391951836" LOG_CI_START="-1.4742820218511086" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2013-08-13 18:57:50 +0100" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="1.0246950765959597" STUDY_ID="STD-Gallardo-1999" TOTAL_1="10" TOTAL_2="10" VAR="1.0499999999999998" WEIGHT="15.767282752046226"/>
<DICH_DATA CI_END="0.41394851176726283" CI_START="0.029824189872403442" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="18" LOG_CI_END="-0.3830536744490833" LOG_CI_START="-1.5254313444295666" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2013-08-07 16:55:29 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.6710382982072027" STUDY_ID="STD-Kanat-2003" TOTAL_1="19" TOTAL_2="19" VAR="0.4502923976608188" WEIGHT="30.09589269200869"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.789182748731737" CI_END="1.2934779890347825" CI_START="0.22464372504143473" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5390470422104898" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="27" I2="28.29440806955315" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.11175904277651344" LOG_CI_START="-0.6485057080210553" LOG_EFFECT_SIZE="-0.2683733326222709" METHOD="MH" MODIFIED="2014-02-27 18:04:58 +0000" MODIFIED_BY="Ruth Brassington" NO="3" NOTES="&lt;p&gt;Kanat data - delete or include in analysis&lt;/p&gt;" NOTES_MODIFIED="2014-02-27 18:04:58 +0000" NOTES_MODIFIED_BY="Ruth Brassington" P_CHI2="0.247934600385612" P_Q="1.0" P_Z="0.16643993967147844" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1856303013742977" TOTALS="YES" TOTAL_1="211" TOTAL_2="208" WEIGHT="100.0" Z="1.3837339316306012">
<NAME>Neurotoxicity rating &#8805; 3</NAME>
<GROUP_LABEL_1>Favours amifostine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours amifostine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.787165399728159" CI_START="0.2296239756931617" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4451627419669189" LOG_CI_START="-0.6389827679830317" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-08-07 15:55:54 +0100" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.6368324391514267" STUDY_ID="STD-DeVos-2005" TOTAL_1="45" TOTAL_2="45" VAR="0.4055555555555556" WEIGHT="33.73501274467945"/>
<DICH_DATA CI_END="1.2965172061803059" CI_START="0.26863775338821844" EFFECT_SIZE="0.5901639344262295" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.11277828469933623" LOG_CI_START="-0.5708329531862957" LOG_EFFECT_SIZE="-0.22902733424347976" ORDER="3974" O_E="0.0" SE="0.40155662506422307" STUDY_ID="STD-Kemp-1996" TOTAL_1="122" TOTAL_2="120" VAR="0.161247723132969" WEIGHT="57.49474169294069"/>
<DICH_DATA CI_END="1.1072375838093846" CI_START="0.003837575990699379" EFFECT_SIZE="0.06518518518518518" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.0442408189515545" LOG_CI_START="-2.4159430116412297" LOG_EFFECT_SIZE="-1.1858510963448374" MODIFIED="2013-08-07 13:24:34 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="1.4451241601965688" STUDY_ID="STD-Lu-2008" TOTAL_1="44" TOTAL_2="43" VAR="2.0883838383838382" WEIGHT="8.770245562379861"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="4">
<NAME>Calcium/magnesium - nerve conduction study (NCS) results</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="247.1876696289171" CI_START="1.0682672820873942" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="16.25" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="2.393026803206099" LOG_CI_START="0.02867992742368751" LOG_EFFECT_SIZE="1.2108533653148932" METHOD="MH" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.04469502807850676" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="9" WEIGHT="100.0" Z="2.007513373680384">
<NAME>Abnormal sensory nerve action potential</NAME>
<GROUP_LABEL_1>Ca/Mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ca/Mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="247.1876696289171" CI_START="1.0682672820873942" EFFECT_SIZE="16.25" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.393026803206099" LOG_CI_START="0.02867992742368751" LOG_EFFECT_SIZE="1.2108533653148932" MODIFIED="2013-08-05 18:28:35 +0100" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="1.3888290585403784" STUDY_ID="STD-Chay-2010" TOTAL_1="7" TOTAL_2="9" VAR="1.9288461538461537" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="5">
<NAME>Calcium/magnesium - sensory neuropathy (SNP)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9428724136261565" CI_START="0.33260067371569185" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.56" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.025547070578588932" LOG_CI_START="-0.47807687540901006" LOG_EFFECT_SIZE="-0.25181197299379954" METHOD="MH" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.02916425101897639" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="52" WEIGHT="100.0" Z="2.1812591907786825">
<NAME>Oxaliplatin specific sensory neurotoxicity &#8805; grade 2</NAME>
<GROUP_LABEL_1>Ca/Mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ca/Mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9428724136261565" CI_START="0.33260067371569185" EFFECT_SIZE="0.56" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="-0.025547070578588932" LOG_CI_START="-0.47807687540901006" LOG_EFFECT_SIZE="-0.25181197299379954" MODIFIED="2013-08-06 15:39:21 +0100" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.26581824741605053" STUDY_ID="STD-Grothey-2011" TOTAL_1="50" TOTAL_2="52" VAR="0.07065934065934065" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.857447988239456" CI_END="1.6016720954476833" CI_START="0.4398485289493394" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8393408813121577" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="29" I2="48.152249723195816" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.20457360930507448" LOG_CI_START="-0.35669685616620767" LOG_EFFECT_SIZE="-0.07606162343056658" METHOD="MH" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="2" P_CHI2="0.14533366477509946" P_Q="1.0" P_Z="0.5952688207208006" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.147810259106691" TOTALS="YES" TOTAL_1="76" TOTAL_2="77" WEIGHT="100.0" Z="0.5312164159729375">
<NAME>Chronic NCI-CTC &#8805; grade 2</NAME>
<GROUP_LABEL_1>Ca/Mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ca/Mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8978029597675818" CI_START="0.6505248054759919" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.2782511196150616" LOG_CI_START="-0.18673613849371135" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2013-08-06 16:20:12 +0100" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.2731358171371426" STUDY_ID="STD-Chay-2010" TOTAL_1="9" TOTAL_2="10" VAR="0.07460317460317459" WEIGHT="48.871826328710824"/>
<DICH_DATA CI_END="1.0102595793700466" CI_START="0.29375176334865194" EFFECT_SIZE="0.5447619047619048" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" LOG_CI_END="0.004432977152624074" LOG_CI_START="-0.5320195177064518" LOG_EFFECT_SIZE="-0.26379327027691385" MODIFIED="2013-08-06 02:35:32 +0100" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="0.3151148509628978" STUDY_ID="STD-Grothey-2011" TOTAL_1="50" TOTAL_2="52" VAR="0.09929736929736929" WEIGHT="43.98792046867536"/>
<DICH_DATA CI_END="17.56372717261354" CI_START="0.17730785844059951" EFFECT_SIZE="1.7647058823529411" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2446166823409863" LOG_CI_START="-0.7512720156582093" LOG_EFFECT_SIZE="0.2466723333413885" MODIFIED="2013-08-06 02:35:44 +0100" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="1.1723949010131223" STUDY_ID="STD-Ishibashi-2010" TOTAL_1="17" TOTAL_2="15" VAR="1.3745098039215686" WEIGHT="7.14025320261381"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="131.36277991464215" CI_START="0.45134550318230104" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="7.7" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="2.118472330463662" LOG_CI_START="-0.3454908801186981" LOG_EFFECT_SIZE="0.8864907251724818" METHOD="MH" MODIFIED="2014-02-12 00:14:58 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.15844483313716107" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0" Z="1.4103212957925637">
<NAME>SNP grade 3</NAME>
<GROUP_LABEL_1>Ca/Mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ca/Mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="131.36277991464203" CI_START="0.45134550318230127" EFFECT_SIZE="7.7" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1184723304636615" LOG_CI_START="-0.3454908801186979" LOG_EFFECT_SIZE="0.8864907251724818" MODIFIED="2013-08-05 18:03:08 +0100" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="1.4473441867106782" STUDY_ID="STD-Chay-2010" TOTAL_1="9" TOTAL_2="10" VAR="2.0948051948051947" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="6">
<NAME>Diethyldithiocarbamate - National Cancer Institute (NCI) neurotoxicity rating scale</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.32444460882921" CI_START="0.5369488717500153" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1171875" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.3663192014692266" LOG_CI_START="-0.27006706583483975" LOG_EFFECT_SIZE="0.048126067817193446" METHOD="MH" MODIFIED="2014-02-12 00:13:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.766893633115379" Q="0.0" RANDOM="NO" SCALE="106.73" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="96" TOTAL_2="99" WEIGHT="100.0" Z="0.2964405880058456">
<NAME>NCI toxicity for neuropathy</NAME>
<GROUP_LABEL_1>DDTC</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DDTC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3244446088292094" CI_START="0.5369488717500154" EFFECT_SIZE="1.1171875" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.3663192014692265" LOG_CI_START="-0.2700670658348397" LOG_EFFECT_SIZE="0.048126067817193446" ORDER="3960" O_E="0.0" SE="0.3738164435772368" STUDY_ID="STD-Gandara-1995" TOTAL_1="96" TOTAL_2="99" VAR="0.13973873348873347" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="7">
<NAME>Glutathione - nerve conduction study (NCS) results</NAME>
<CONT_OUTCOME CHI2="0.05589393857786615" CI_END="4.108928824180893" CI_START="-0.5334402837418362" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.7877442702195283" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.01" MODIFIED="2014-02-12 00:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="1" P_CHI2="0.8131075642379807" P_Q="1.0" P_Z="0.1311615616189877" Q="0.0" RANDOM="NO" SCALE="24.15" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="36" UNITS="" WEIGHT="100.0" Z="1.5095371788590835">
<NAME>SSC amplitude</NAME>
<GROUP_LABEL_1>GSH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GSH</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.7795072296097665" CI_START="-1.7595072296097651" EFFECT_SIZE="1.5100000000000007" ESTIMABLE="YES" MEAN_1="8.71" MEAN_2="7.2" MODIFIED="2013-10-31 20:17:45 +0000" MODIFIED_BY="Ruth Brassington" ORDER="51" SD_1="5.5" SD_2="5.05" SE="1.6681465860593467" STUDY_ID="STD-Cascinu-2002" TOTAL_1="21" TOTAL_2="19" WEIGHT="50.402808889370014"/>
<CONT_DATA CI_END="5.365953919865728" CI_START="-1.2259539198657268" EFFECT_SIZE="2.0700000000000003" ESTIMABLE="YES" MEAN_1="9.65" MEAN_2="7.58" MODIFIED="2013-10-31 19:36:49 +0000" MODIFIED_BY="Ruth Brassington" ORDER="52" SD_1="5.9" SD_2="3.33" SE="1.6816400433190564" STUDY_ID="STD-Colombo-1995" TOTAL_1="16" TOTAL_2="17" WEIGHT="49.59719111062998"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="8">
<NAME>Glutathione - clinical impairment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.291795383010979" CI_START="0.21443667773733885" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.11119372800366427" LOG_CI_START="-0.6687009299093222" LOG_EFFECT_SIZE="-0.278753600952829" METHOD="MH" MODIFIED="2014-02-12 00:13:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.16119044696623747" Q="0.0" RANDOM="YES" SCALE="23.88" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="16" WEIGHT="100.0" Z="1.4010790121076875">
<NAME>Impairment at 3 months</NAME>
<GROUP_LABEL_1>GSH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.291795383010979" CI_START="0.21443667773733885" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.11119372800366427" LOG_CI_START="-0.6687009299093222" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="3961" O_E="0.0" SE="0.4581139825989069" STUDY_ID="STD-Bogliun-1996" TOTAL_1="19" TOTAL_2="16" VAR="0.2098684210526316" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="9">
<NAME>Glutathione - Neuropathy Symptom Score (NSS)</NAME>
<DICH_OUTCOME CHI2="0.5031615869055099" CI_END="0.9727698737309376" CI_START="0.49607994935207983" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6946737577393237" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-0.011989887778381737" LOG_CI_START="-0.3044483260009569" LOG_EFFECT_SIZE="-0.1582191068896693" METHOD="MH" MODIFIED="2014-02-12 00:12:57 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.47811428730873007" P_Q="1.0" P_Z="0.03394967895602846" Q="0.0" RANDOM="NO" SCALE="4.71" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="31" WEIGHT="100.0" Z="2.1206688584847115">
<NAME>NSS symptoms of neuropathy at 3 months</NAME>
<GROUP_LABEL_1>GSH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9906303073837727" CI_START="0.5632411243954041" EFFECT_SIZE="0.746969696969697" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="-0.00408838932732922" LOG_CI_START="-0.24930564320194812" LOG_EFFECT_SIZE="-0.12669701626463867" ORDER="3965" O_E="0.0" SE="0.1440418287709345" STUDY_ID="STD-Bogliun-1996" TOTAL_1="19" TOTAL_2="16" VAR="0.02074804843567521" WEIGHT="81.20336561358945"/>
<DICH_DATA CI_END="2.1959797084726738" CI_START="0.10005855775999956" EFFECT_SIZE="0.46875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.34162832278212435" LOG_CI_START="-0.9997457613105738" LOG_EFFECT_SIZE="-0.32905871926422475" MODIFIED="2013-08-06 19:31:54 +0100" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.7879297769048542" STUDY_ID="STD-Colombo-1995" TOTAL_1="16" TOTAL_2="15" VAR="0.6208333333333333" WEIGHT="18.796634386410542"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="10">
<NAME>Glutathione - World Health Organization (WHO) evidence of neurotoxicity</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.46552399752651435" CI_START="0.07551973729989643" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-0.33205792644479615" LOG_CI_START="-1.1219395294277286" LOG_EFFECT_SIZE="-0.7269987279362623" METHOD="MH" MODIFIED="2014-02-12 00:12:44 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="3.087323824210081E-4" Q="0.0" RANDOM="NO" SCALE="41.1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="18" WEIGHT="100.0" Z="3.6078605152481225">
<NAME>WHO neurotoxicity during trial</NAME>
<GROUP_LABEL_1>GSH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4655239975265143" CI_START="0.07551973729989643" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.3320579264447962" LOG_CI_START="-1.1219395294277286" LOG_EFFECT_SIZE="-0.7269987279362623" ORDER="3963" O_E="0.0" SE="0.4639803635691685" STUDY_ID="STD-Cascinu-1995" TOTAL_1="24" TOTAL_2="18" VAR="0.21527777777777776" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="11">
<NAME>Glutathione - chronic National Cancer Institute (NCI) toxicity rating</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8931832097612562" CI_START="0.019903842328753245" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.13333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="-0.049059449479432186" LOG_CI_START="-1.7010630773039679" LOG_EFFECT_SIZE="-0.8750612633917001" METHOD="MH" MODIFIED="2014-02-12 00:12:24 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.0378593885394149" Q="0.0" RANDOM="NO" SCALE="105.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0" Z="2.0763738428012886">
<NAME>NCI toxicity at 12 weeks</NAME>
<GROUP_LABEL_1>GSH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8931832097612562" CI_START="0.019903842328753245" EFFECT_SIZE="0.13333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.049059449479432186" LOG_CI_START="-1.7010630773039679" LOG_EFFECT_SIZE="-0.8750612633917001" ORDER="3964" O_E="0.0" SE="0.9703951085339758" STUDY_ID="STD-Cascinu-2002" TOTAL_1="10" TOTAL_2="8" VAR="0.9416666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="12">
<NAME>Glutathione - National Cancer Institute (NCI) neurotoxicity rating 2-4 at treatment end</NAME>
<DICH_OUTCOME CHI2="7.41079894283452" CI_END="0.8524922775783722" CI_START="0.1004079634317064" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2925696727839393" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="34" I2="73.01235648912329" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="-0.06930954643551193" LOG_CI_START="-0.9982318416003982" LOG_EFFECT_SIZE="-0.5337706940179551" METHOD="MH" MODIFIED="2014-02-12 00:12:09 +0000" MODIFIED_BY="Kate Jewitt" NO="1" P_CHI2="0.02459047474733822" P_Q="1.0" P_Z="0.02429441660597094" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.6039222382607944" TOTALS="YES" TOTAL_1="48" TOTAL_2="39" WEIGHT="100.0" Z="2.2524410098100685">
<NAME>Chronic NCI &#8805; grade 2</NAME>
<GROUP_LABEL_1>GSH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.40145403645139754" CI_START="0.008290867856965393" EFFECT_SIZE="0.057692307692307696" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="13" LOG_CI_END="-0.3963641710782474" LOG_CI_START="-2.081400006752026" LOG_EFFECT_SIZE="-1.2388820889151366" MODIFIED="2013-08-11 23:07:09 +0100" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.989798390936687" STUDY_ID="STD-Cascinu-1995" TOTAL_1="24" TOTAL_2="18" VAR="0.9797008547008546" WEIGHT="18.80105201634035"/>
<DICH_DATA CI_END="0.8117869045376966" CI_START="0.13981566887266325" EFFECT_SIZE="0.33689839572192515" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="-0.0905579588488501" LOG_CI_START="-0.8544441553169844" LOG_EFFECT_SIZE="-0.47250105708291723" MODIFIED="2010-09-09 14:00:46 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.4487105331030386" STUDY_ID="STD-Cascinu-2002" TOTAL_1="10" TOTAL_2="8" VAR="0.2013411425176131" WEIGHT="36.97396510973705"/>
<DICH_DATA CI_END="0.8686840389133279" CI_START="0.3095043099709405" EFFECT_SIZE="0.5185185185185185" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="-0.061138158083592804" LOG_CI_START="-0.5093332988779058" LOG_EFFECT_SIZE="-0.2852357284807493" MODIFIED="2010-09-09 14:01:24 +0100" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.26327204430430756" STUDY_ID="STD-Milla-2009" TOTAL_1="14" TOTAL_2="13" VAR="0.0693121693121693" WEIGHT="44.2249828739226"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="13">
<NAME>Glutathione - other outcomes</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8102509601833163" CI_START="0.2798606613970682" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.47619047619047616" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="-0.09138044563722875" LOG_CI_START="-0.5530581438306097" LOG_EFFECT_SIZE="-0.3222192947339193" METHOD="MH" MODIFIED="2014-02-04 14:29:11 +0000" MODIFIED_BY="Ruth Brassington" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.006222122545784662" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="2.7358402421156103">
<NAME>Oliguria</NAME>
<GROUP_LABEL_1>GSH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8102509601833163" CI_START="0.2798606613970682" EFFECT_SIZE="0.47619047619047616" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" LOG_CI_END="-0.09138044563722875" LOG_CI_START="-0.5530581438306097" LOG_EFFECT_SIZE="-0.3222192947339193" ORDER="3962" O_E="0.0" SE="0.27119176526025557" STUDY_ID="STD-Bogliun-1996" TOTAL_1="27" TOTAL_2="27" VAR="0.07354497354497355" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="14">
<NAME>Org 2766 - qualitative vibration position testing (VPT)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4342213021968178" CI_START="0.3098855412087956" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="0.15661616870106737" LOG_CI_START="-0.5087986868124299" LOG_EFFECT_SIZE="-0.17609125905568127" METHOD="MH" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2995749208709626" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="12" WEIGHT="100.0" Z="1.0373454180703883">
<NAME>Abnormal VPT at 3 to 5 months</NAME>
<GROUP_LABEL_1>ORG 2766</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ORG 2766</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.434221302196818" CI_START="0.3098855412087955" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.15661616870106745" LOG_CI_START="-0.50879868681243" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="3966" O_E="0.0" SE="0.39086797998528583" STUDY_ID="STD-van-Gerven-1994" TOTAL_1="8" TOTAL_2="12" VAR="0.1527777777777778" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="15">
<NAME>Org 2766 (1 or 2 mg)- vibration perception testing (VPT) finger or hand</NAME>
<CONT_OUTCOME CHI2="8.01814237475396" CI_END="1.2324382849725546" CI_START="-4.780559948762148" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.7740608318947966" ESTIMABLE="YES" I2="75.05656663945966" I2_Q="0.0" ID="CMP-015.01" MODIFIED="2014-02-12 00:11:32 +0000" MODIFIED_BY="Michael Lunn" NO="1" P_CHI2="0.018150298987119062" P_Q="1.0" P_Z="0.24746596311531388" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="5.134114578603813" TOTALS="YES" TOTAL_1="82" TOTAL_2="93" UNITS="" WEIGHT="100.0" Z="1.1565263124108147">
<NAME>VPT hand 3 to 5 months post treatment</NAME>
<GROUP_LABEL_1>ORG 2766</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ORG 2766</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8550849908408583" CI_START="-0.3550849908408583" EFFECT_SIZE="0.25" ESTIMABLE="YES" MEAN_1="2.81" MEAN_2="2.56" ORDER="3968" SD_1="1.42" SD_2="1.89" SE="0.30872250491013686" STUDY_ID="STD-Roberts-1997" TOTAL_1="58" TOTAL_2="59" WEIGHT="44.99581369135916"/>
<CONT_DATA CI_END="-0.8397328753307463" CI_START="-9.140267124669254" EFFECT_SIZE="-4.99" ESTIMABLE="YES" MEAN_1="0.88" MEAN_2="5.87" ORDER="3969" SD_1="0.68" SD_2="9.9" SE="2.1175221368382435" STUDY_ID="STD-van-der-Hoop-1990" TOTAL_1="16" TOTAL_2="22" WEIGHT="24.464736818321143"/>
<CONT_DATA CI_END="0.9625171848728216" CI_START="-5.322517184872822" EFFECT_SIZE="-2.18" ESTIMABLE="YES" MEAN_1="1.85" MEAN_2="4.03" ORDER="3967" SD_1="1.87" SD_2="5.06" SE="1.603354556339094" STUDY_ID="STD-van-Gerven-1994" TOTAL_1="8" TOTAL_2="12" WEIGHT="30.53944949031969"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="16">
<NAME>Oxcarbazepine - sensory nerve action potential (SNAP) amplitude</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.786587932965659" CI_START="-1.3865879329656607" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.1999999999999993" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.01" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.17148736709635692" Q="0.0" RANDOM="NO" SCALE="11.04" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.3674402065748272">
<NAME>SNAP amplitude: sural</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.786587932965659" CI_START="-1.3865879329656607" EFFECT_SIZE="3.1999999999999993" ESTIMABLE="YES" MEAN_1="11.5" MEAN_2="8.3" MODIFIED="2010-09-08 20:41:49 +0100" MODIFIED_BY="[Empty name]" ORDER="20" SD_1="7.1" SD_2="6.1" SE="2.3401388847673124" STUDY_ID="STD-Argyriou-2006a" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.190590207914429" CI_START="-1.1905902079144277" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.000000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.02" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.21922550223296178" Q="0.0" RANDOM="NO" SCALE="11.04" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="99.99999999999999" Z="1.2285902336679029">
<NAME>SNAP amplitude: superficial peroneal</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.190590207914429" CI_START="-1.1905902079144277" EFFECT_SIZE="2.000000000000001" ESTIMABLE="YES" MEAN_1="8.8" MEAN_2="6.8" MODIFIED="2013-11-11 20:47:34 +0000" MODIFIED_BY="[Empty name]" ORDER="21" SD_1="4.4" SD_2="4.8" SE="1.6278820596099708" STUDY_ID="STD-Argyriou-2006a" TOTAL_1="16" TOTAL_2="16" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.179693222351807" CI_START="-1.779693222351808" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.1999999999999993" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.03" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.4299200403968081" Q="0.0" RANDOM="NO" SCALE="10.94" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.7893284999291689">
<NAME>SNAP amplitude: ulnar</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.179693222351807" CI_START="-1.779693222351808" EFFECT_SIZE="1.1999999999999993" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="7.0" MODIFIED="2010-09-08 20:45:55 +0100" MODIFIED_BY="[Empty name]" ORDER="22" SD_1="4.3" SD_2="4.3" SE="1.520279579551077" STUDY_ID="STD-Argyriou-2006a" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="17">
<NAME>Oxcarbazepine - neurotoxicity rating</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9088482948653233" CI_START="0.19102320166297668" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-017.01" LOG_CI_END="-0.04150860324811429" LOG_CI_START="-0.7189138801750977" LOG_EFFECT_SIZE="-0.38021124171160603" METHOD="MH" MODIFIED="2014-02-12 00:09:34 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.02779547328303117" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="2.200161013367261">
<NAME>Neuropathy after 12 cycles</NAME>
<GROUP_LABEL_1>OXC</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OXC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9088482948653233" CI_START="0.19102320166297668" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.04150860324811429" LOG_CI_START="-0.7189138801750977" LOG_EFFECT_SIZE="-0.38021124171160603" MODIFIED="2010-12-16 21:30:28 +0000" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.39791121287711073" STUDY_ID="STD-Argyriou-2006a" TOTAL_1="16" TOTAL_2="16" VAR="0.15833333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-2.2167289843987374" CI_START="-11.983271015601261" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.02" MODIFIED="2014-02-12 00:09:45 +0000" MODIFIED_BY="Kate Jewitt" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.004376367036692491" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="99.99999999999999" Z="2.8496768346003796">
<NAME>Severity of neuropathy (TNS)</NAME>
<GROUP_LABEL_1>OXC</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OXC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.2167289843987374" CI_START="-11.983271015601261" EFFECT_SIZE="-7.1" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="11.2" MODIFIED="2010-09-08 20:36:41 +0100" MODIFIED_BY="[Empty name]" ORDER="19" SD_1="6.5" SD_2="9.05" SE="2.4915105859698854" STUDY_ID="STD-Argyriou-2006a" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="18">
<NAME>Retinoic acid - National Cancer Institute (NCI) neurotoxicity rating</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0175116644377011" CI_START="0.5469847526462948" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.746031746031746" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-018.01" LOG_CI_END="0.007539396542851369" LOG_CI_START="-0.26202477957857984" LOG_EFFECT_SIZE="-0.12724269151786424" METHOD="MH" MODIFIED="2014-02-04 14:29:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.06426626668386584" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="47" WEIGHT="100.0" Z="1.850328157541308">
<NAME>NCI-CTC grade &#8805; 2</NAME>
<GROUP_LABEL_1>ATRA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ATRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0175116644377011" CI_START="0.5469847526462948" EFFECT_SIZE="0.746031746031746" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="35" LOG_CI_END="0.007539396542851369" LOG_CI_START="-0.26202477957857984" LOG_EFFECT_SIZE="-0.12724269151786424" MODIFIED="2013-08-06 18:07:20 +0100" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.15834333141792079" STUDY_ID="STD-Arrieta-2011" TOTAL_1="45" TOTAL_2="47" VAR="0.025072610604525498" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="19">
<NAME>Vitamin E - qualitative sensory nerve conduction study (NCS) amplitudes</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9254881620293082" CI_START="0.16570404535682753" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3916083916083916" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-019.01" LOG_CI_END="-0.03362913196048682" LOG_CI_START="-0.7806668889572359" LOG_EFFECT_SIZE="-0.4071480104588614" METHOD="MH" MODIFIED="2014-02-12 00:09:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.0326447081407776" Q="0.0" RANDOM="NO" SCALE="22.22" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="14" WEIGHT="100.0" Z="2.136425982227772">
<NAME>Abnormal median or sural sensory amplitude</NAME>
<GROUP_LABEL_1>Vitamin E</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin E</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9254881620293083" CI_START="0.16570404535682748" EFFECT_SIZE="0.3916083916083916" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.03362913196048677" LOG_CI_START="-0.780666888957236" LOG_EFFECT_SIZE="-0.4071480104588614" ORDER="3971" O_E="0.0" SE="0.4388136763564265" STUDY_ID="STD-Pace-2003" TOTAL_1="13" TOTAL_2="14" VAR="0.1925574425574426" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="20">
<NAME>Vitamin E - sensory nerve action potential amplitude</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.550216642425623" CI_START="-0.35021664242562345" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.5999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-020.01" MODIFIED="2014-02-12 00:19:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.07406715244606753" Q="0.0" RANDOM="NO" SCALE="11.044521081175382" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.7861983235460095">
<NAME>Superficial peroneal amp 3 mos s/p treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.550216642425623" CI_START="-0.35021664242562345" EFFECT_SIZE="3.5999999999999996" ESTIMABLE="YES" MEAN_1="8.5" MEAN_2="4.9" MODIFIED="2010-09-08 21:24:15 +0100" MODIFIED_BY="[Empty name]" ORDER="24" SD_1="6.6" SD_2="3.9" SE="2.0154536887332766" STUDY_ID="STD-Argyriou-2006" TOTAL_1="14" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0693312038239894E-32" CI_END="5.708547143915292" CI_START="-2.7085471439152924" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.5000000000000002" ESTIMABLE="YES" I2="100.00000000000001" I2_Q="0.0" ID="CMP-020.02" MODIFIED="2014-02-12 00:20:40 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.48482359517284124" Q="0.0" RANDOM="NO" SCALE="11.452308100542089" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.6985655325402851">
<NAME>Ulnar SNAP amp 3 mos s/p treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.708547143915292" CI_START="-2.7085471439152924" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="8.4" MEAN_2="6.9" MODIFIED="2010-09-08 21:26:19 +0100" MODIFIED_BY="[Empty name]" ORDER="25" SD_1="6.9" SD_2="4.4" SE="2.1472573869274" STUDY_ID="STD-Argyriou-2006" TOTAL_1="14" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7289157716212797" CI_END="5.6119179406475475" CI_START="-1.5975758008400676" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="2.00717106990374" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-020.03" MODIFIED="2014-02-12 00:20:40 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3932348816553348" P_Q="1.0" P_Z="0.27512593643528827" Q="0.0" RANDOM="NO" SCALE="11.874283346710302" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="1.0913340517056378">
<NAME>Sural amplitude uv after 6 cycles</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.969333969550914" CI_START="-1.3693339695509161" EFFECT_SIZE="3.299999999999999" ESTIMABLE="YES" MEAN_1="10.7" MEAN_2="7.4" MODIFIED="2010-09-08 21:20:59 +0100" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="7.0" SD_2="5.9" SE="2.382357026140289" STUDY_ID="STD-Argyriou-2006" TOTAL_1="14" TOTAL_2="16" WEIGHT="59.59909593449191"/>
<CONT_DATA CI_END="5.771255738297867" CI_START="-5.571255738297868" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="13.7" MEAN_2="13.6" ORDER="3970" SD_1="5.5" SD_2="9.2" SE="2.8935509953407355" STUDY_ID="STD-Pace-2003" TOTAL_1="13" TOTAL_2="14" WEIGHT="40.40090406550809"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="21">
<NAME>Vitamin E - incidence of neuropathy</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8960960300773418" CI_START="0.1084142774683704" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3116883116883117" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-021.01" LOG_CI_END="-0.04764544670179027" LOG_CI_START="-0.9649135202199615" LOG_EFFECT_SIZE="-0.5062794834608758" METHOD="MH" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.030496911987994674" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="16" WEIGHT="100.0" Z="2.1635759105600254">
<NAME>Incidence of peripheral neuropathy (completed trial)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8960960300773418" CI_START="0.1084142774683704" EFFECT_SIZE="0.3116883116883117" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.04764544670179027" LOG_CI_START="-0.9649135202199615" LOG_EFFECT_SIZE="-0.5062794834608758" MODIFIED="2010-09-08 21:35:51 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.5388078069347667" STUDY_ID="STD-Argyriou-2006" TOTAL_1="14" TOTAL_2="16" VAR="0.2903138528138528" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0047123457439586" CI_START="0.20762459667763522" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4567307692307692" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-021.02" LOG_CI_END="0.002041738833167496" LOG_CI_START="-0.682721198180995" LOG_EFFECT_SIZE="-0.3403397296739138" METHOD="MH" MODIFIED="2014-02-27 10:13:41 +0000" MODIFIED_BY="Ruth Brassington" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.05138194212699794" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="19" WEIGHT="100.0" Z="1.9482760430276407">
<NAME>Incidence of peripheral neuropathy (intention to treat)</NAME>
<GROUP_LABEL_1>Vitamin E</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin E</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0047123457439586" CI_START="0.20762459667763522" EFFECT_SIZE="0.4567307692307692" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.002041738833167496" LOG_CI_START="-0.682721198180995" LOG_EFFECT_SIZE="-0.3403397296739138" MODIFIED="2010-09-08 21:31:46 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.4022331388333245" STUDY_ID="STD-Argyriou-2006" TOTAL_1="16" TOTAL_2="19" VAR="0.16179149797570852" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" MODIFIED="2014-02-12 00:08:00 +0000" MODIFIED_BY="[Empty name]" NO="22">
<NAME>Vitamin E - modified peripheral neuropathy (PNP) score</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.22986594594594134" CI_START="-10.730134054054059" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.48" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-022.01" MODIFIED="2014-02-04 14:29:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.040778332034754956" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="2.0457768363049316">
<NAME>Modified peripheral neuropathy (PNP) score</NAME>
<GROUP_LABEL_1>Vitamin E</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin E</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.22986594594594134" CI_START="-10.730134054054059" EFFECT_SIZE="-5.48" ESTIMABLE="YES" MEAN_1="4.99" MEAN_2="10.47" MODIFIED="2010-09-08 21:44:04 +0100" MODIFIED_BY="[Empty name]" ORDER="28" SD_1="1.33" SD_2="10.62" SE="2.6786890450367693" STUDY_ID="STD-Argyriou-2006" TOTAL_1="14" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-023" MODIFIED="2014-02-12 00:08:23 +0000" MODIFIED_BY="[Empty name]" NO="23">
<NAME>Vitamin E - clinical impairment</NAME>
<DICH_OUTCOME CHI2="0.16728061168103742" CI_END="0.7258661936318568" CI_START="0.2299400930748863" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.40854098952690493" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-023.01" LOG_CI_END="-0.13914342988273207" LOG_CI_START="-0.6383852971818977" LOG_EFFECT_SIZE="-0.38876436353231486" METHOD="MH" MODIFIED="2014-02-12 00:08:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6825402620654565" P_Q="1.0" P_Z="0.0022695508786129545" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="33" WEIGHT="99.99999999999999" Z="3.0524849813502306">
<NAME>Total neuropathy score after 6 cycles</NAME>
<GROUP_LABEL_1>Vitamin E</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitaminin E</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0047123457439586" CI_START="0.20762459667763522" EFFECT_SIZE="0.4567307692307692" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.002041738833167496" LOG_CI_START="-0.682721198180995" LOG_EFFECT_SIZE="-0.3403397296739138" MODIFIED="2010-09-08 23:07:12 +0100" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.4022331388333245" STUDY_ID="STD-Argyriou-2006" TOTAL_1="16" TOTAL_2="19" VAR="0.16179149797570852" WEIGHT="50.70422535211267"/>
<DICH_DATA CI_END="0.8339901715818113" CI_START="0.15451332017095715" EFFECT_SIZE="0.358974358974359" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.07883906741134569" LOG_CI_START="-0.8110340752851768" LOG_EFFECT_SIZE="-0.4449365713482612" ORDER="3972" O_E="0.0" SE="0.4300949720488313" STUDY_ID="STD-Pace-2003" TOTAL_1="13" TOTAL_2="14" VAR="0.18498168498168496" WEIGHT="49.29577464788731"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-02-27 10:13:42 +0000" MODIFIED_BY="Ruth Brassington">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-02-27 10:01:06 +0000" MODIFIED_BY="Ruth Brassington" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Red (-) = high risk of bias; yellow (?) = unclear risk of bias; green (+) = low risk of bias.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVMAAATACAIAAADC4zNpAAA+mUlEQVR42u3dv24dxxnGYQIBghQs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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-02-04 14:29:12 +0000" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-003.02" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Amifostine - neurotoxicity rating, outcome: 2.2 Neurotoxicity rating &#8805; 2.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsIAAACwCAMAAAAyufgIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-02-04 14:29:12 +0000" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-003.03" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Amifostine - neurotoxicity rating, outcome: 2.3 Neurotoxicity rating &#8805; 3.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuoAAACwCAMAAABuM7ssAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-02-27 10:13:42 +0000" MODIFIED_BY="Ruth Brassington" NO="4" REF_ID="CMP-005.02" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Ca/Mg - sensory neuropathy (SNP), outcome: 5.1 Chronic NCI-CTC &#8805; grade 2.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArcAAACwCAMAAAAi2bbUAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2014-02-12 00:12:10 +0000" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-012.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 11 GSH - NCI NT rating 2-4 at treatment end, outcome: 11.1 Chronic NCI &#8805; grade 2.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArcAAACwCAMAAAAi2bbUAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2014-02-12 00:20:41 +0000" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-020.03" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 20 Vitamin E - SNAP amplitude, outcome: 20.1 Sural amplitude uv after 6 cycles.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAssAAACQCAMAAADJANb0AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2014-02-12 00:08:24 +0000" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-023.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 24 Vitamin E - Clinical impairment, outcome: 24.1 Total neuropathy score after 6 cycles.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArEAAACgCAMAAAAsEcQIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-02-12 10:18:57 +0000" MODIFIED_BY="Kate Jewitt">
<APPENDIX ID="APP-01" MODIFIED="2014-02-12 10:18:57 +0000" MODIFIED_BY="Kate Jewitt" NO="1">
<TITLE MODIFIED="2012-10-22 17:06:41 +0100" MODIFIED_BY="Kate Jewitt">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-11-26 16:08:39 +0000" MODIFIED_BY="[Empty name]">
<P>#1 (cisplatin OR cis-diaminedichloroplatinum OR platinum OR organoplatinum OR oxaliplatin OR carboplatin)<BR/>#2 (therap* OR adverse OR toxic* OR neurotoxic*)<BR/>#3 (#1 AND #2)<BR/>#4 (neuroprotect* OR chemoprotect* OR protect* OR org2766 OR corticotrop* OR glutathione OR amifostine OR (growth NEXT factor*) OR neurotrophin3 OR neurotropin3 OR antidote* OR (vitamin NEXT E))<BR/>#5 MeSH descriptor Acetylcarnitine, this term only<BR/>#6 (acetyl l carnitine) or alc<BR/>#7 (#4 OR #5 OR #6)<BR/>#8 (neuropath* OR nerv* OR neurotox* OR neurol*)<BR/>#9 MeSH descriptor Peripheral Nervous System Diseases, this term only<BR/>#10 MeSH descriptor Peripheral Nerves, this term only<BR/>#11 (#8 OR #9 OR #10)<BR/>#12 (#3 AND #7 AND #11)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-02-12 10:18:57 +0000" MODIFIED_BY="Kate Jewitt" NO="2">
<TITLE MODIFIED="2010-10-05 20:24:35 +0100" MODIFIED_BY="Kate Jewitt">MEDLINE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-05 14:12:39 +0000" MODIFIED_BY="Kate Jewitt">
<P>Database: Ovid MEDLINE(R) &lt;1946 to February Week 3 2013&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 randomized controlled trial.pt. (340611)<BR/>2 controlled clinical trial.pt. (85213)<BR/>3 randomized.ab. (243875)<BR/>4 placebo.ab. (135354)<BR/>5 drug therapy.fs. (1580528)<BR/>6 randomly.ab. (174990)<BR/>7 trial.ab. (250886)<BR/>8 groups.ab. (1141737)<BR/>9 or/1-8 (2946306)<BR/>10 exp animals/ not humans.sh. (3765892)<BR/>11 9 not 10 (2502948)<BR/>12 cisplatin/ae, tu, to (14735)<BR/>13 cisplatin.tw. (35823)<BR/>14 cis-diamminedichloroplatinum.tw. (1989)<BR/>15 platinum compounds.tw. or platinum compounds/ae, to, tu (1366)<BR/>16 exp organoplatinum compounds/ae, to, tu (6449)<BR/>17 (oxaliplatin or carboplatin).tw. (13012)<BR/>18 or/12-17 (51975)<BR/>19 exp peripheral nervous system diseases/ci, pc (6830)<BR/>20 exp central nervous system diseases/ci, pc (89001)<BR/>21 (neuropath$ or neuro$ or nerv$).tw. (1392830)<BR/>22 or/19-21 (1457786)<BR/>23 18 and 22 (5142)<BR/>24 exp neuroprotective agents/ (57571)<BR/>25 chemoprotect$.mp. (1147)<BR/>26 Protective Agents/ (3135)<BR/>27 neuroprotective agents/ (19938)<BR/>28 (protect$ or neuroprotect$).tw. (464836)<BR/>29 (ORG2766 or ORG 2766).tw. (216)<BR/>30 Adrenocorticotropic Hormone/ (43262)<BR/>31 (acth or corticotropin or corticotrophin or adrenocorticotropin or adrenocorticotrophin).tw. (42979)<BR/>32 glutathione/ or glutathione.tw. (90417)<BR/>33 amifostine.tw. or amifostine/ (1591)<BR/>34 exp nerve growth factors/ (35075)<BR/>35 (nerve adj3 growth adj3 factor$).tw. (14391)<BR/>36 neurotrophin 3.tw. (2014)<BR/>37 exp antidotes/ (47996)<BR/>38 antidote$.tw. (3477)<BR/>39 vitamin E.tw. or vitamin E/ (29477)<BR/>40 (alc or acetyl l carnitine).tw. (1658)<BR/>41 Acetylcarnitine/ (993)<BR/>42 or/24-41 (741678)<BR/>43 11 and 18 and 22 and 42 (268)<BR/>44 remove duplicates from 43 (263)<BR/>45 44 and 20100801:20130304.(ed). (34)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-02-12 10:18:54 +0000" MODIFIED_BY="Kate Jewitt" NO="3">
<TITLE MODIFIED="2010-10-05 20:24:20 +0100" MODIFIED_BY="Kate Jewitt">EMBASE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-05 14:11:28 +0000" MODIFIED_BY="Kate Jewitt">
<P>Database: Embase &lt;1980 to 2013 Week 09&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 crossover-procedure.sh. (36349)<BR/>2 double-blind procedure.sh. (113402)<BR/>3 single-blind procedure.sh. (17075)<BR/>4 randomized controlled trial.sh. (338076)<BR/>5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (935629)<BR/>6 trial.ti. (141499)<BR/>7 or/1-6 (1066673)<BR/>8 (animal/ or nonhuman/ or animal experiment/) and human/ (1243614)<BR/>9 animal/ or nonanimal/ or animal experiment/ (3363752)<BR/>10 9 not 8 (2783529)<BR/>11 7 not 10 (978201)<BR/>12 limit 11 to embase (763556)<BR/>13 CISPLATIN/ae, to [Adverse Drug Reaction, Drug Toxicity] (25725)<BR/>14 cisplatin.tw. (48796)<BR/>15 cis-diamminedichloroplatinum.mp. (2168)<BR/>16 Platinum Derivative/ae, to [Adverse Drug Reaction, Drug Toxicity] (1122)<BR/>17 (platinum compound or platinum derivative).mp. (6528)<BR/>18 Platinum Complex/ae, to [Adverse Drug Reaction, Drug Toxicity] (836)<BR/>19 oxaliplatin.tw. or OXALIPLATIN/ (17733)<BR/>20 carboplatin.tw. or CARBOPLATIN/ (40774)<BR/>21 or/13-20 (108555)<BR/>22 exp Peripheral Neuropathy/ (46553)<BR/>23 (neuropath$ or neuro$ or nerv$).mp. (2599138)<BR/>24 22 or 23 (2599437)<BR/>25 21 and 24 (20122)<BR/>26 Neuroprotective Agent/ (8475)<BR/>27 Neuroprotection/ (41483)<BR/>28 (chemoprotect$ or neuroprotect$ or protect$).mp. (704538)<BR/>29 (ORG 2766 or ORG2766).mp. (442)<BR/>30 CORTICOTROPIN/ (52750)<BR/>31 (acth or corticotropin or corticotrophin or adrenocorticotropin or adrenocorticotrophin).mp. (74650)<BR/>32 GLUTATHIONE/ or Glutathione.tw. (109305)<BR/>33 amifostine.tw. or AMIFOSTINE/ (3366)<BR/>34 Nerve Growth Factor/ (20503)<BR/>35 (nerve adj growth adj factor).tw. (16261)<BR/>36 neurotrophin 3.tw. or Neurotrophin 3/ (3856)<BR/>37 antidote$.tw. or Antidote/ (7719)<BR/>38 vitamin E.tw. or Alpha Tocopherol/ (57279)<BR/>39 (ALC or acetly l carnitine).tw. (1870)<BR/>40 or/26-39 (938266)<BR/>41 12 and 25 and 40 (194)<BR/>42 remove duplicates from 41 (193)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-02-12 10:06:07 +0000" MODIFIED_BY="Kate Jewitt" NO="4">
<TITLE MODIFIED="2010-10-05 20:23:46 +0100" MODIFIED_BY="Kate Jewitt">CINAHL (EBSCOhost) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-05 13:50:02 +0000" MODIFIED_BY="[Empty name]">
<P>Tuesday, March 05, 2013 8:30:37 AM<BR/>
<BR/>S46 S44 AND S45 14<BR/>S45 EM 20100801-20130305 949,875<BR/>S44 S18 and S26 and S30 and S43 50<BR/>S43 S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 78,095<BR/>S42 (MH "Carnitine") or acetyl l carnitine or alc 0<BR/>S41 ("vitamin e") or (MH "Vitamin E") 4,118<BR/>S40 ("antidotes") or (MH "Antidotes") 806<BR/>S39 neurotrophin 3 46<BR/>S38 growth and factor 11,765<BR/>S37 ("amifostine") or (MH "Amifostine") 167<BR/>S36 (glutathione) or (MH "Glutathione") 2,778<BR/>S35 acth or corticotropin or corticotrophin or adrenocorticotropin or adrenocorticotrophin 799<BR/>S34 (MH "Corticotropin-Releasing Hormone") or (MH "Adrenocorticotropic Hormone") 932<BR/>S33 ORG 2766 or ORG2766 2<BR/>S32 chemoprotect* or neuroprotect* or protect* 59,269<BR/>S31 (MH "Neuroprotective Agents+") 1,741<BR/>S30 S27 or S28 or S29 181,864<BR/>S29 (MH "Peripheral Nervous System Diseases/CI/PC") 499<BR/>S28 (MH "Central Nervous System Diseases+/CI/PC") 16,400<BR/>S27 neuropath* or neuro* or nerv* 168,132<BR/>S26 S19 or S20 or S22 or S23 or S24 or S25 5,202<BR/>S25 (MH "Carboplatin") 1,158<BR/>S24 oxaliplatin or carboplatin 2,449<BR/>S23 ((platinum or organoplatunum) and compound*) 307<BR/>S22 (MH "Platinum/AE/TU") 146<BR/>S21 cis-diaminedichloroplatinum 0<BR/>S20 TI cisplatin or AB cisplatin 2,355<BR/>S19 (MH "Cisplatin/AE/PO/TU") 1,348<BR/>S18 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 593,468<BR/>S17 ABAB design* 79<BR/>S16 TI random* or AB random* 119,989<BR/>S15 ( TI (cross?over or placebo* or control* or factorial or sham? or dummy) ) or ( AB (cross?over or placebo* or control* or factorial or sham? or dummy) ) 245,939<BR/>S14 ( TI (clin* or intervention* or compar* or experiment* or preventive or therapeutic) or AB (clin* or intervention* or compar* or experiment* or preventive or therapeutic) ) and ( TI (trial*) or AB (trial*) ) 83,802<BR/>S13 ( TI (meta?analys* or systematic review*) ) or ( AB (meta?analys* or systematic review*) ) 25,697<BR/>S12 ( TI (single* or doubl* or tripl* or trebl*) or AB (single* or doubl* or tripl* or trebl*) ) and ( TI (blind* or mask*) or AB (blind* or mask*) ) 19,319<BR/>S11 PT ("clinical trial" or "systematic review") 106,730<BR/>S10 (MH "Factorial Design") 860<BR/>S9 (MH "Concurrent Prospective Studies") or (MH "Prospective Studies") 199,928<BR/>S8 (MH "Meta Analysis") 15,806<BR/>S7 (MH "Solomon Four-Group Design") or (MH "Static Group Comparison") 32<BR/>S6 (MH "Quasi-Experimental Studies") 5,858<BR/>S5 (MH "Placebos") 8,083<BR/>S4 (MH "Double-Blind Studies") or (MH "Triple-Blind Studies") 26,197<BR/>S3 (MH "Clinical Trials+") 156,771<BR/>S2 (MH "Crossover Design") 10,227<BR/>S1 (MH "Random Assignment") or (MH "Random Sample") or (MH "Simple Random Sample") or (MH "Stratified Random Sample") or (MH "Systematic Random Sample") 60,15</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2014-02-12 10:06:01 +0000" MODIFIED_BY="Kate Jewitt" NO="5">
<TITLE MODIFIED="2012-10-22 17:06:19 +0100" MODIFIED_BY="Kate Jewitt">LILACS (IAHx) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-10-22 17:09:54 +0100" MODIFIED_BY="Kate Jewitt">
<P>(MH:cisplatin/ae or MH:cisplatin/tu or MH:cisplatin/to or TW:cisplatin or TW:cisplatino or TW:cis-diamminedichloroplatinum or MH:platinum compounds/ae or MH: platinum compounds/tu or MH:platinum compoounds/to or TW:platinum compounds or MH:D02.691.800$/ae or MH:D02.691.800$/tu or MH:D02.691.800$/to or TW:oxaliplatin or TW:carboplatin) and (MH:A08.800$ or MH:A08.186$ or neuropath$ or nerv$) and (neuroprotective agents or chemoprotect$ or protective or org2766 or org 2766 or Adrenocorticotropic Hormone or acth or corticotropin or corticotrophin or adrenocorticotropin or adrenocorticotrophin or amifostine or antidote$ or MH:D23.529.850$ or neurotrophin or "vitamin E" or alc or acetyl or carnitine or acetylcarnitine or "nerve growth factor") AND ((PT:"Randomized Controlled Trial" or "Randomized Controlled trial" or "Ensayo Clínico Controlado Aleatorio" or "Ensaio Clínico Controlado Aleatório" or PT:"Controlled Clinical Trial" or "Ensayo Clínico Controlado" or "Ensaio Clínico Controlado" or "Random allocation" or "Distribución Aleatoria" or "Distribuição Aleatória" or randon$ or Randomized or randomly or "double blind" or "duplo-cego" or "duplo-cego" or "single blind" or "simples-cego" or "simples cego" or placebo$ or trial or groups) AND NOT (B01.050$ AND NOT (humans or humanos or humanos)))</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>